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Organization of the thesis 
 
This thesis comprises eight chapters, each of them including a brief introduction.  
Chapters 1 and 2 present (a) the longstanding debate on nosology of psychotic 
disorders; (b) current understanding of biological and environmental risk factors for 
non-affective and affective psychoses, focusing on common genetic variants and 
cannabis use; (c) the integration of these risk determinants into a developmental risk 
factor model of psychosis; and (d) the symptom dimension based approach toward 
conducting transdiagnostic research into this model. Chapter 3 illustrates general 
aims and hypotheses of this thesis, introducing the European Network of National 
Schizophrenia Networks studying Gene-Environment Interactions’ (EU-GEI) study. 
In chapters 4, 5 and 6, the experimental part of this thesis is presented, in the form of 
two published and a submitted paper. A general discussion is presented in Chapter 
7, and conclusions and future directions in Chapter 8. A diagram summarising the 



























Epidemiological and biological evidence show no boundaries between diagnostic 
categories of non-affective and affective psychoses, thus challenging the current 
nosological model developed from Kraepelin’s paradigm. My thesis aimed to address 
this limitation by 1) examining the transdiagnostic dimensional structure of i) 
psychotic symptoms in first episode psychosis (FEP) patients and ii) psychotic 
experiences in the general population; 2) investigating the relationship between 
these dimensions and a set of external factors, such as the use of cannabis and 
genetic common variant liability for psychotic disorders. Overall, I expected that 
differences in symptom profiles at FEP reflected gradients of neurodevelopmental 
impairment in psychosis. 
 
Methods 
This thesis uses data from a multisite incidence and case-control study, which I 
worked on, conducted across six countries [i.e. the ‘European Network of National 
Schizophrenia Networks studying Gene-Environment Interactions’ (EU-GEI) study]. 
To examine the latent structure of psychopathology, I analysed ratings of psychotic 
symptoms and experiences using multidimensional item response modelling in 
Mplus, and I estimated different theory-based models of psychosis, including 
unidimensional, multidimensional, bifactor, and hierarchical solutions. To examine 
the common variant liability to psychosis, I examined the population structure in the 
EU-GEI sample and computed ancestry-specific schizophrenia (SZ), bipolar disorder 
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(BP), and combined schizophrenia-bipolar disorder (SZ-BP) Polygenic Risk Scores 
(PRSs) in PRSice.  
To examine the relationship between the latent structure of psychopathology and 
demographic and context determinants, detailed patterns of cannabis consumption, 
and PRSs, I used multiple linear regression models fitted in STATA14. 
 
Results 
The associations among ratings of both psychotic symptoms in FEP patients and 
psychotic experiences in population-based controls were best represented by a 
bifactor model, composed of one general psychosis factor and multiple specific 
dimensions. In FEP patients, the examination of general and specific dimensions 
with external factors showed that 1) higher scores on the negative symptom 
dimension were associated with being a male, and having never used cannabis; 2) 
higher scores on the positive symptom dimension were associated with exposure to 
socioenvironmental risk factors in psychosis, such as being part of an ethnic 
minority, and having had exposure to cannabis in a dose-response fashion, with 
those having used high potency varieties on a daily basis having the highest score; 
3) both higher scores on the positive and negative symptom dimensions were 
associated with a higher SZ-PRS. 
In population-based controls, the examination of general and specific dimensions 
with external factors showed that 1) higher scores on the positive psychotic 
experience dimension were associated with current use of cannabis but not with the 
extent of lifetime exposure to cannabis; 2) higher scores on the general and all the 




My thesis shows that symptom dimensions are useful psychosis phenotypes, that 
are validated by psychometric data and socioenvironmental and genetic factors. 
Specifically, the bifactor model of psychopathology holds across diagnostic 
categories of non-affective and affective psychosis at FEP and in the general 
population. Furthermore, my findings indicate that use of cannabis is associated with 
more positive and less negative symptoms at FEP, consistently with the hypothesis 
that cannabis users who develop psychosis have less early neurodevelopmental 
impairment than their non-user counterparts. Overall, these findings indicate that it is 
appropriate to conduct research using enhanced phenotypes, and they have 
translational relevance, they are important for developing secondary prevention 
strategies in psychosis. Currently, symptom dimensions at FEP could be used for 
formulating clinical impressions regardless of diagnostic categories according to a 
developmental-symptom approach, and for guiding tailored treatments.  
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Cardiff (UK). Overall, I contributed to the WP2 EU-GEI study by: 1) data cleaning for 
all the study sites; 2) recovering missing data through access to clinical records 
where possible; 3) rating psychopathology through clinical records for most cases 
 9 
recruited in London; 4) collecting additional biological samples in London as 
substitutes for those which failed initial quality control; 5) building and through the 
management of the central database integrating biological data with phenotype 
information; 6) computing principal ancestry components and polygenic risk scores 
(PRSs) as shown in the papers; 7) leading the follow-up study on the London sub-
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Chapter 1. History of nosology of psychotic disorders and psychiatric genetics  
 
In this chapter, I present the key milestones in the history of nosology for psychotic 
disorders and for psychiatric genetics. In the first part of the chapter, I illustrate the 
methodological caveats and dissatisfaction on the categorical distinction between 
non-affective and affective psychoses which were expressed since the inception of 
this dichotomy, and that ended up driving research and clinical practice. The second 
part of the chapter covers a brief history of psychiatric genetics. I explain how recent 
collaborative efforts provide an improved insight into the genetics of psychotic 
disorders and allow individuals to be indexed according to their genetic susceptibility 
to these disorders. 
 
1.1 Historical evolution of the concept of psychosis 
 
The concept of psychosis was introduced in psychiatric literature in the 19th century, 
initially as a synonym for ‘insanity’ or ‘mental illness’ (Canstatt, 1843), which was 
linked to a hypothetic neuro-biological basis (Friedreich, 1836). Since then, three 
main theoretical distinctions have refined the concept of psychosis.  
 
1.1.1 Exogenous and endogenous psychosis 
 
The first main conceptual distinction was made between endogenous and 
exogenous psychosis, as proposed by the French and German schools of thought. 
For example, Jacques-Joseph Moreau de Tours, who may be considered an early 
pioneer of current experimental studies on cannabis, used the intoxication states at 
the Club des Haschischins in Paris as an exogenous model for studying psychosis 
(Moreau de Tours, 1845); Paul Julius Möbius later distinguished endogenous from 
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exogenous psychosis based on possible etiological factors, attributing endogenous 
forms to hereditary-degenerative causes (Möbius, 1892). Shortly after, Karl 
Bonhoeffer established the fundamental framework of exogenous psychosis, 
introducing the concept of exogenous reaction types. Bonhoeffer hypothesised that 
different physical conditions could result in similar psychotic syndromes, so that the 
symptoms that we observe would be nosologically unspecific (Bonhoeffer, 1908, 
1917).  
 
1.1.2 Kraepelin’s paradigm of non-affective and affective psychotic disorders 
 
A second fundamental distinction in psychiatric nosology was made by Emil 
Kraepelin, who subdivided the endogenous psychosis into dementia praecox and 
manic-depressive insanity (Kraepelin, 1899). This dichotomy was extremely 
influential, to the point that current diagnostic distinction between non-affective and 
affective psychotic disorders is often referred as the Kraepelin’s paradigm, since it is 
mostly based on the differences between dementia praecox and manic-depressive 
insanity. Moreover, coherently with the German phenomenological tradition, 
Kraepelin postulated that psychosis had a causal explanation. More specifically, he 
assumed that dementia praecox and manic-depressive insanity were precise ‘natural 
disease entities’ (‘natürliche Krankheitseinheit’), on which several external validators 
should have converged. This theory was by and large consistent with Karl 
Kahlbaum’s original notion of a strict correspondence between hebephrenia and 
aetiological factors, symptomatology and outcome (Kalhbaum, 1863). However, 
according to Kraepelin, there was a gradient of importance of these ‘validators’ in 
distinguishing dementia praecox from manic-depressive insanity, with the highest 
importance attributed to the course and outcome of the disease (Kraepelin, 1899). 
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Unfortunately, Kraepelin went on to attribute a pessimistic connotation to dementia 
praecox: “The common outcome of all severe forms of dementia praecox is 
dementia. . .The prognosis of manic-depressive insanity is favourable for the 
individual attack. . .even after very long duration of excitement or depression, one 
may still hope with great probability for complete restoration.” (Kraepelin, 1899).  
Notably, psychiatrists often ignore that Kraepelin amended several times his 
nosology (e.g., his textbook had nine editions, from 1899 to 1927), as he was 
receptive to new empirical data and contemporary criticisms. For example, he 
accepted Bonhoeffer’s theory that psychopathology may be nosological unspecific, 
and, in 1921, Kraepelin even came to doubt his own paradigm, acknowledging the 
existence of a group of patients with prominent affective and psychotic symptoms, 
who were not classifiable (Kraepelin, 1921). Indeed, the term schizoaffective 
psychosis, introduced by Jacob Kasanin in 1933, served to categorise these patients 
(Kasanin, 1933) and it reflected the absence of a neat distinction between affective 
and psychosis spectra in clinical practice. Throughout his career Kraepelin continued 
to believe in natural disease entities, despite many psychiatrists strongly argued that 
their existence could not be proven using the resources available at the time (Hoche, 
1912). 
The term schizophrenia was first mentioned by Eugen Bleuler in 1908, and published 
in the chapter “Dementia praecox and the group of schizophrenias” (Bleuler, 1911). 
Bleuler was concerned to understand the common characteristics across 
schizophrenias, eventually conceptualising the core of the disease as being 
composed of “four As” (i.e., Association (lack of), Affectivity, Ambivalence, and 
Autism). Enlarging the concept of schizophrenia into a heterogenous group of 
schizophrenias was coherent with Bleuler’s strong therapeutic attitude, to the point 
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that, in contrast with Kraepelin’s fatalistic concept of dementia praecox, Bleuler 
reported individuals with a full recovery from schizophrenias (Maatz et al., 2015). 
Unfortunately, it was Kraepelin’s nihilistic attitude towards dementia praecox which 
survived across time and was applied to the term schizophrenia, despite the fact 
that, currently, some maintain that only a small proportion of patients do not recover 
if they are properly treated (Guloksuz and van Os, 2018). 
 
1.1.3 Psychosis and neurosis 
 
The evolution of the concept of psychosis and the introduction of psychoanalysis at 
the end of the 19th century led to a third main conceptual distinction in the modern 
nosology, which was made between ‘neurosis’ and ‘psychosis’ (Burgy, 2008). Karl 
Jaspers and the Heidelberg phenomenological school enforced this diagnostic 
distinction, highlighting that neurosis was a psychological development process, 
which allowed psychological comprehension, whereas psychosis was the result of a 
somatic illness, which required a causal explanation and was not otherwise 
comprehensible (Jaspers, 1913). The work of the Heidelberg school, as extended by 
Kurt Schneider and later continued by Walter Ritter von Baeyer, resulted in a 
progressive hierarchization of diagnoses, so that ‘psychopathic-neurotic’ and 
‘depressive-manic’  were considered to be less biologically driven than 
‘schizophrenic’ and ‘psycho-organic’ (Schneider, 1931). Thus, according to the 
Heidelberg school, psychotic symptoms were indicative of biological aetiology, while 
the speculative and ideological character of psychoanalytic theory was gradually 
criticised (Burgy, 2008).  
 
 16 
1.2 The operational revolution 
 
Currently, the two main classification systems in psychiatry (i.e., International 
Classification of Diseases (ICD) and Diagnostic and Statistical Manual of Mental 
Disorders (DSM)) define diseases based on the presence of specific diagnostic 
criteria. The introduction of these criteria was considered a revolution in psychiatry 
that occurred in the context of the ‘operationalism’, a methodological framework used 
for defining phenomena that are not directly observable. This approach was first 
adopted in physics by Percy Bridgman, and it served as a pragmatic way to reduce 
metaphysical assumptions over the scientific progress (Bridgman, 1927). The 
operationalism was widely discussed among psychologists since the 1930s 
(Stevens, 1935, Waters and Pennington, 1938, Bergmann and Spence, 1941); and it 
was comprehensively presented to psychiatrists in 1959 at the introductory lecture of 
the American Psychopathological Association conference, which was given by Carl 
Hempel, a logical positivist not involved in mental health research (Zubin, 1961). 
Shortly after, Erwin Stengel, an expert in classification systems who served as the 
discussant at the Hempel’s lecture and had been already concerned with the 
application of operationalism (Stengel, 1958), proposed the introduction of 
operational definitions to the World Health Organization (WHO) for revising the 
psychiatric section of the ICD (Stengel, 1959). Although Hempel was not involved in 
the subsequent construction of modern psychiatry nosology, some authors point out 
that Hempel's lecture had an important and direct effect on the construction of DSM-
III (Bolton, 2008, Parnas and Bovet, 2015), whereas others claim that the new 
classification followed an ongoing operationalism revolution and was largely 
independent from Hempel’s contribution (Aragona, 2013a, b, Cooper and Blashfield, 
2018). Moreover, other experts acknowledge that Hempel’s paper ‘Introduction to the 
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Problems of Taxonomy’, published in the conference proceeding (Zubin, 1961), 
impacted American nosology through the work of British psychiatrists such as Sir 
Aubrey Lewis at the Institute of Psychiatry (Sartorius and Norman, 2009, Cooper and 
Blashfield, 2018). Indeed, Lewis had been concerned with differences in the 
definition of schizophrenia and in evaluating treatments across Europe since 1937 
(Lewis, 2003, Cooper and Blashfield, 2018). The transcripts of the discussion during 
Hempel’s lecture at the conference indicate that Lewis strongly sustained that any 
psychiatry theory at that time would have not been solid enough and therefore: 
(LEWIS) “…for the purpose of public classification we should eschew categories 
based on theoretical concepts and restrict ourselves to the operational, descriptive 
classification…” (Zubin, 1961). 
Based on these principles and on a descriptive symptom-based approach, Lewis and 
colleagues generated “A Glossary of Mental Disorder” (Registrar General's Advisory 
Committee on Medical Nomenclature Statistics Sub-Committee on Classification of 
Mental Disorders, 1968). Moreover, most of these principles were reiterated in the 
subsequent “Glossary of Mental Health Disorders and Guide to their Classification of 
Mental Disorder”, which was written by a WHO committee directed by Lewis (World 
Health Organization, 1974).  
It is noteworthy that, following the conference, a group of American and British 
psychiatrists (e.g. Aubrey Lewis, Paul Hoch, Morton Kramer, Benjamin Pasamanick, 
Joseph Zubin, J.K. Wing, Robert Spitzer and Robert Kendell) joined the ‘US-UK 
Diagnostic Project’ from 1966 to 1971, to examine the differences in diagnostic 
frequencies across these two countries. They found major discrepancies in the 
schizophrenia, which was, for example, diagnosed at higher frequency in New York 
than in London, mainly due to different diagnostic practices of psychiatrists (Cooper 
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and et al., 1972). It became clear that the American concept of schizophrenia was 
broader than the British one. Interestingly, both American (Spitzer et al., 1964) and 
British (Wing et al., 1967) symptom rating scales were used for this project, and J.K. 
Wing and Robert Spitzer went on to develop computer software to turn a list of 
symptoms into a specific diagnosis, such as CATEGO (Wing et al., 1974) and 
DIAGNO (Spitzer and Endicott, 1969). Finally, the contribution of Robert Kendell to 
the US-UK project was highly relevant, given his expertise in statistical approaches 
(e.g. factor analysis) and his Popperian identification of the essential characteristics 
for each diagnosis (Cooper and Blashfield, 2018). Indeed, Spitzer had a high regard 
for Kendell’s ‘The Role of Diagnosis in Psychiatry’ (Kendell, 1975, Spitzer, 1977), 
which may be considered a milestone in the nosology development process. 
 
Furthermore, American psychiatry was radically changing at the time of 
operationalism, as evident by the different scenarios met by Michael Shepherd in 
1957 and Robin Murray in 1979 during their respective travel fellowships in US. 
These differences included a progressive decline of psychoanalysis in favour of 
behavioural psychotherapy, and an increased focus on neuropsychopharmacology 
and biological psychiatry (Murray, 1979). Indeed, in the 1970s, a group of 
psychiatrists at the Washington University School of Medicine in St. Louis, self-called 
neo-Kraepelinians, were challenging the psychosocial model of psychiatry common 
in the US, with the aim to identify biological substrates of psychiatric diseases and 
“carving the nature at his joints”. These efforts culminated with the publication of 
Feigner’s criteria (Feighner et al., 1972).  
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Feigner’s criteria were subsequently modified by Spitzer as Research Diagnostic 
Criteria (RDC) (Spitzer et al., 1978); indeed, both these criteria were designed for 
research purposes (e.g. by prioritising the exclusion of false negatives over the 
inclusion of false positives). 
 
Since Spitzer became the head of the Task Force on nomenclature and Statistics at 
the APA, the development of DSM-III (American Psychiatric Association, 1980) was 
due to the fusion of the neo-Kraepelinian conceptualization with the operationalized 
project. Moreover, this process was highly influenced by British psychiatrists and 
possibly by the WHO Glossary, as Spitzer had reviewed it for publication in the 
American Journal of Psychiatry (Cooper and Blashfield, 2018). Also, having actively 
participated to the US-UK project, Spitzer had a strong knowledge of psychiatry in 
the UK.  
Finally, after the publication of the ICD-10 (World Health Organization, 1992), the 
use of operationalised criteria became popular in clinical practice in Europe and in 
the rest of the world, as well as in US.  
 
In summary, the operationalised principles that guided the US-UK ‘operationalised’ 
task force required that: 1) aetiology should be excluded as a classificatory principle 
since unknown; 2) diagnostic criteria should be based upon easily observable 
features; 3) diagnoses should reflect narrow, rather than broad, disorders; 4) 
‘psychosis’ and ‘neurosis’ should not be included as classificatory principles. 
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1.2.1 Some unforeseen consequences of operationalism: the decline of 
phenomenology 
 
The two major exclusions from the DSM-III pragmatic principles were aetiology 
(since unknown), and phenomenology (e.g., the examination of the individual’s 
subjective experience). Excluding phenomenology aimed to make the rating of signs 
and symptoms as easy as objective. This was due to the fact that operationalised 
criteria were originally thought to be a pragmatic supplement to the narrative 
definitions of diagnostic criteria: that is, clinicians were free to ignore them and 
formulate diagnosis based on their clinical judgement (Spitzer et al., 1978), including 
any identification of phenomenal Gestalts of the psychopathology experience. 
However, this precaution did not survive to the DSM-III publication, despite the fact 
that the logical empiricism used for operationalised classifications was too 
reductionist to disentangle complex psychopathology phenomena (Faust and Miner, 
1986).  
 
Forty years after the introduction of the DSM-III and its updates (DSM-IV and DSM-
5), and in the context of the approval of the updated ICD-11 by the World Health 
Assembly in May 2019, many scholars became worried about a serious crisis of 
confidence in psychiatry nosology (Zachar and Kendler, 2017).   
Nancy Andreasen, an eminent member of the Task Force on the DSM-III, went to 
claim that DSM led to the ‘death of phenomenology’ and dehumanised the practice 
of psychiatry (Andreasen, 2007). Of note, Robin Murray had cautiously warned about 
these risks as early as in 1979, “…these [DSM-III] criteria may not be employed to 
the fullest advantage because many American psychiatrists are not familiar with 
systematic examination and recording of the mental state. German 
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phenomenological psychiatry, so influential elsewhere, never took root in North 
America. Consequently, even in the most research-oriented centres, the attempt to 
diagnose according to strictly defined conventions founders at times on an inability to 
elicit mental phenomena accurately” (Murray, 1979). Moreover, post-operationalised 
psychiatric trainees began to ignore descriptive psychopathology and 
phenomenology (Andreasen, 2007), whilst formulating somewhat dogmatic 
diagnoses.  
Indeed, DSM is sometimes referred to as the ‘bible of psychiatry’ (Paris and Phillips, 
2013) and often considered unshakably valid. After its introduction, symptoms began 
to be identified as an isolated entity, existing independently from the patient’s 
Gestalts of altered experience; and diagnoses began to have an independent 
existence of their own. Steven Hyman defined this effect as ‘reification’ of psychiatric 
disorders, due to the widespread acceptance of DSM, despite the fact that DSM was 
supposed to be only a heuristic and provisional proposal (Hyman, 2010). 
 
1.3 Psychotic disorders in DSM-5 and ICD-11 
 
Currently, psychotic disorders are generally divided into organic and functional 
psychosis. Organic psychosis is due to a specific medical condition (for example, 
neurological disorders or structural brain abnormalities), whereas functional 
psychosis is thought to be caused by multiple genetic and socioenvironmental 
factors. 
 
Moreover, functional psychosis is commonly subdivided into non-affective and 
affective psychotic disorders. DSM-5 includes non-affective disorders in the chapter 
‘Schizophrenia spectrum and other psychotic disorders’ (American Psychiatric 
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Association, 2013), defining eight types of discrete functional conditions (codes in 
brackets), such as: Delusional Disorder (297.1); Brief Psychotic Disorder (298.8); 
Schizophreniform Disorder (295.40); Schizophrenia (295.90); Schizoaffective 
disorder (295.70); Substance/Medication induced psychotic disorder (291.xx or 
292.xx based on the substance of abuse); catatonia (293.89). In addition, DSM-5 
considers schizotypal personality as part of the schizophrenia spectrum, although it 
is described in the chapter “Personality Disorders”. 
On the other hand, affective psychotic disorders are included in the chapter of 
‘Bipolar and Related Disorder’, and in the chapter of ‘Depressive Disorder’, with a 
specifier indicating psychotic features (i.e., Bipolar disorder / Major Depression with 
mood-congruent psychotic features (); and Bipolar disorder / Major Depression with 
mood-incongruent psychotic features).  
ICD-11 was approved by the World Health Assembly in May 2019 and it will be used 
by the WHO member states from 2022. ICD-11 “Schizophrenia and other primary 
psychotic disorders” include all conditions where psychotic symptoms are a core 
aspect, as opposed to conditions (e.g., mood disorders) where psychotic symptoms 
may be secondary to other forms of psychopathology. Similarly to the transition from 
DSM-IV to DSM-5, also in the transition from ICD-10 to ICD-11 symptoms of 
schizophrenia have remained largely unchanged, however first-rank symptoms have 
been de-emphasised and subtypes of schizophrenia have been replaced by 
dimensional descriptors [e.g., positive symptoms (delusions, hallucinations, 
disorganized thinking and behaviour, experiences of passivity and control); negative 
symptoms (constricted, blunted or flat affect, alogia or paucity of speech, avolition, 
anhedonia); depressive mood symptoms; manic mood symptoms; psychomotor 
symptoms (psychomotor agitation, psychomotor retardation, catatonic symptoms); 
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and cognitive symptoms (deficits in speed of processing, attention/concentration, 
orientation, judgment, abstraction, verbal or visual learning, and working memory)] 
(Reed et al., 2019).  
The main difference between DSM-5 and ICD-11 is related to the diagnosis of 
Schizoaffective Disorder, which in DSM-5 relies on the longitudinal course of the 
disease, whereas in ICD-11 schizoaffective disorder is diagnosed based on 
schizophrenia symptoms in concurrence or within a few days of a manic or 
depressive episode (psychotic and mood symptoms should last > 4 weeks) (Gaebel 
et al., 2012). Although this approach aimed to improve the diagnostic agreement, 
which is known to be low for schizoaffective disorder, first trials showed that these 
modifications in ICD-11 resulted only in a tiny improvement compared with previous 
ICD-10 (Peterson et al., 2019).   
 
1.3.1 Psychotic disorders’ main features 
 
Briefly, according to DSM-5 and ICD-11, in order to make a diagnosis of psychotic 
disorders, five main features should be taken into consideration: delusions; 
hallucinations; disorganized thinking (speech); grossly disorganised or abnormal 
motor behaviour (including catatonia); negative symptoms. 
 
Delusions  
Delusions are fixed beliefs which are not modifiable by convergent contradicting 
evidence regarding their veracity (American Psychiatric Association, 2013). Their 
content may refer to several themes, for example ranging from persecutory and 
referential delusions to somatic, religious, nihilistic, and grandiose delusions. 
Delusions are considered bizarre when their content is not understandable in the 
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same peer cultural context, and they do not therefore derive from ordinary life 
experience. Delusions of control or passivity phenomena are also considered 
bizarre, and they are commonly considered particularly pathognomonic of 
schizophrenia, i.e. first-rank symptoms of schizophrenia (Schneider, 1959). 
 
Hallucinations  
The first medical understanding of hallucinations was of a ‘percept without an object’, 
which was more linked to the conviction of the truth of their experience rather than to 
sensory disturbance (Esquirol, 1838). To exclude from this definition physiological 
conditions such as dreams, Jaspers considered these false perceptions should occur 
at the same time as the real perception (Jaspers, 1913). This phenomenological 
concept of hallucinations has persisted into the modern diagnostic criteria and has 
served as the basis for contemporary research. For example, within the National 
Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) conceptual 
framework, hallucinations are considered as conscious sensory experiences 
occurring without corresponding external stimulation of the sense organ and 
resembling a veridical perception (Ford et al., 2014b). Empirical studies have shown 
that hallucinations involve at a neural level the circuits from cochlear neurons to the 
superior temporal gyrus, and at a cognitive level the whole perceptual system 
including integration of different perceptions and cross-modal integration (Aleman 
and Larøi, 2008, Ford et al., 2014a, Parnas and Kendler, 2017). 
Hallucinations are central to the psychopathology of psychotic disorders (American 
Psychiatric Association, 2013), and certain types were for many years regarded as 
first rank symptoms of schizophrenia (Schneider, 1959).  
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Disorganised thinking or speech 
A formal thought disturbance in the form of disorganised thinking can be evident, for 
example, when the answers provided are unrelated to the questions (tangentiality), 
or when there is a sudden switching from one topic to another (derailment) 
(American Psychiatric Association, 2013). Disorganization may also relate to the 
language domain (Goldberg and Weinberger, 2010), for example speech may be 
incomprehensible, due to incoherence or “word salad”. 
Grossly disorganised or abnormal behaviour 
Although a wide range of abnormal behaviours is observed in psychosis, one 
common characteristic could be often summarised as a deficit of goal-directed 
behaviour, e.g., resulting in a reduced ability to plan or perform activities (American 
Psychiatric Association, 2013). 
Moreover, DSM-5 indicates catatonia as an abnormal behaviour, which may present 
in different forms, such as resistance to instruction (negativism), maintaining a rigid 
or bizarre posture (catalepsy), or lack of verbal (mutism) and motor (stupor) 
responses (American Psychiatric Association, 2013). 
Negative symptoms 
“Negative” symptoms signify a function that is dysfunctional as diminished or lost 
(American Psychiatric Association, 2013), as opposed to “positive” symptoms such 
as delusions or hallucinations, where a thought or perception function is 
dysfunctional as increased. Negative symptoms have been considered a core 
component of schizophrenia since Bleuler’s work (Bleuler, 1911), and they may 
concern the individual’s personal experience [e.g., decreased expression of emotion 
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and reactivity to events (blunted affect); decreased ability to experience pleasant 
emotions related to previous, current or future positive events (anhedonia), reduced 
speech output (alogia)], or the relation between the individual and the external world 
[(e.g., lack of interest in social interaction (asociality); lack of initiative in goal-directed 
activity (avolition) (Kimhy et al., 2006)]. 
 
1.4 Genetics in psychiatry 
 
 
1.4.1 Brief history of Psychiatric Genetics 
 
Early thoughts on inheritance of psychiatric disorders can be tracked back to the 
ancient Greeks. For example, Euripides described ‘morality’ as a hereditary trait; and 
during the medical revolution of the Renaissance, Paracelsus hypothesised that the 
disorder affecting the ‘insani’ was transmitted from parents to offspring (Schulze et 
al., 2004). However, the question whether or not mental health conditions were 
triggered by inherited elements became of research interest only towards the end of 
the nineteenth century, following the introduction of the theories of Darwin and 
Mendel, on evolution and inheritance. 
Indeed, initial ideas concerning psychiatric inheritance were incorporated in pseudo-
sciences such as physiognomy and phrenology, and they were subsequently 
integrated in Morel’s theory of ‘degeneration’ (Morel, 1860). This was the first 
conceptualization of psychiatric genetics; hence, as described above, many 
taxonomists based their classifications of psychotic disorders on a hereditary 
concept of degeneration. The introduction of a scientific approach in this field is 
attributed to Sir Francis Galton, who systematically examined complex hereditary 
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traits such as intelligence (Galton, 1869, 1883), paving the way towards the 
development of behavioural genetics. At that time, there was a lengthy debate 
between Galton’s ‘biometric’ scholars headed by Walter Franck Raphael Weldon, 
who supported the theory of quantitative variations in phenotypes (Weldon, 1902), 
and the Mendelists headed by William Bateson, who claimed that specific events 
caused substantial qualitative phenotypic variations across generations (Bateson 
and Mendel, 1913). 
Ernst Rüdin conducted the first systematic family study in psychiatry, reporting a 
higher lifetime risk of 7.7% for broadly defined schizophrenia in relatives of patients 
with schizophrenia compared with the general population. However, Rüdin and some 
other contemporary colleagues were firm supporters of ‘eugenics’, and their study 
interpretation was contaminated by racial ideology (Gottesman and Bertelsen, 1996, 
Schulze et al., 2004).  
After World War II, Franz Josef Kallmann completed his controversial study on the 
existence of a gene predisposing to schizophrenia in US (Kallmann, 1946).  
However, the UK kept psychiatric genetics alive. Eliot Slater and Valerie Cowie re-
considered genetics as a potential link between psychiatry and other medical 
sciences (Slater and Cowie, 1971); and Slater’s pupils, Irving Gottesman and Jerry 
Shields introduced the concept of polygenicity in schizophrenia (Gottesman and 
Shields, 1967). These studies were also important as they challenged the 
contemporary psychoanalytic explanations of schizophrenogenic rearing. 
Subsequent evidence from family studies, including twin, sibling, and adoption 
studies, confirmed the early observations that psychiatric conditions were in part 
heritable, had a non-Mendelian and polygenic architecture, and could not be entirely 
explained without considering other factors such as environmental exposure 
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(Polderman et al., 2015). Specifically, family studies in schizophrenia demonstrated 
that its heritability was around 80% (Cardno and Gottesman, 2000, Sullivan et al., 
2003). The application of genetic epidemiology to major psychiatric disorders gained 
further interest in the 1990s, when molecular genetic techniques allowed the 
examination of susceptibility genes in psychiatric disorders. Early molecular studies 
were based on linkage analyses aiming to identify co-segregation of genetic traits. 
Although linkage studies would better suit Mendelian diseases than psychiatric 
complex traits (Bush and Haines, 2010), this approach in the field of schizophrenia 
proposed some genomic regions of interest (Ng et al., 2009). Subsequently, finer 
hypothesis-driven approaches were applied to test the association between ‘best 
guess’ functional variants within plausible biological pathways and psychiatric 
expression. These studies led to the identification of several single nucleotide 
polymorphisms (SNPs) associated with schizophrenia (Farrell et al., 2015). Further 
studies reported interaction between some of these candidate SNPs and 
environmental risk factors in conferring synergistic risk towards psychotic disorders 
(Caspi and Moffitt, 2006). However, most of candidate gene associations and 
interactions were not consistently replicated (Keller, 2014), and a meta-analysis 
highlighted their lack of statistical power (Farrell et al., 2015). For example, in the 
field of depression, Border and colleagues showed no association between any 
candidate SNPs or G x E interaction with depression phenotypes in a very large 
population-based and case-control sample (Border et al., 2019). In summary, 
candidate gene studies were not better than chances for identifying risk variants at 
least when applied to complex traits, since they carried same limitations as linkage 
studies. Moreover, meta-analysis results of candidate gene studies should be 
cautiously interpreted due to the risks of sampling and sampling and publication bias 
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(e.g. negative results less likely to be published). For example, the largest meta-
analysis to date of candidate gene studies in schizophrenia reported 14 Bonferroni-
corrected independent loci associated, three of them never reported in Genome 
Wide Associated Studies (GWAS) (Liu et al., 2019). Nevertheless, candidate gene 
studies have been highly relevant in the history of psychiatric genetics as they set 
the grounds for the subsequent GWAS era. 
 
1.4.2 The GWAS era 
 
During the past decade, further advances in molecular biology, reduction in 
genotyping costs (van Dijk et al., 2014), and strong research collaborations have 
contributed to a shift towards GWAS, which apply high-throughput methods to 
examine millions of genetic variants (Lewis and Knight, 2012). Specifically, GWAS 
are designed to compare the frequencies of common genetic variants (i.e., SNPs 
with a frequency >1% in the general population) in large samples without having a-
priori hypotheses. Availability of large samples has been achieved through consortia 
such as the Psychiatric Genomic Consortium (PGC); and a high statistical threshold 
for multiple testing is applied in these studies (p=5x10-8) to minimise the risk of false 
positives (Sullivan, 2009). The first GWAS in the field of schizophrenia lacked power 
to identify risk loci. However, the progressive increase in sample size reflected an 
increasing number of identified loci, moving from one locus identified in 479 cases 
(O'Donovan et al., 2008) to 108 independent loci in 37,000 cases as part of the 
second wave of schizophrenia PGC mega-analysis (Schizophrenia Working Group 
of the Psychiatric Genomics Consortium, 2014), and up to 145 independent loci 
identified in more than 40,000 cases in the largest published mega-analysis to date 
(Pardinas et al., 2018, Dennison et al., 2019). More specifically, the relationship 
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between increase in sample size and number of discovered loci in schizophrenia 
became linear after having reached an inflection point at about 9,000 cases 
(Levinson et al., 2014). 
The GWAS approach has provided four main contributions so far towards our 
understanding of psychiatric disorders.  
First, it has clarified that the architectural structure of most psychiatric diseases is 
polygenic, identifying many genetic loci of biological relevance (Collins and Sullivan, 
2013, Dennison et al., 2019). 
Second, it has demonstrated that the effect size associated with a single common 
variant is usually minimal, in contrast to what was hypothesised in early candidate 
gene studies. For example, in current mega-analyses, there is approximately 100% 
power to find common genetic variants with odds ratio >1.35 (Farrell et al., 2015), 
which disproves the existence of a single ‘gene for schizophrenia’. Rather, 
psychiatric phenotypes are associated with numerous variants, each having small 
effect size and conferring a cumulative risk towards developing the condition. 
Third, it has showed that there is a partial biological overlap between major 
psychiatric disorders (e.g., schizophrenia and bipolar disorder) (International 
Schizophrenia Consortium et al., 2009, Bipolar Disorder Schizophrenia Working 
Group of the Psychiatric Genomics Consortium and Schizophrenia Working Group of 
the Psychiatric Genomics Consortium, 2018). This has expanded the scope of 
GWAS to cross disorder examinations of domains of psychopathology as well as to 
seek ‘modifier genes’ associated with specific clinical features (Fanous et al., 2012, 
Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013, Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2019). 
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Fourth, it has opened the way to the application of new study designs and statistical 
approaches, such as Polygenic Risk Score (PRS) analyses and precision medicine 
(Lewis and Knight, 2012, Bogdan et al., 2018).  
 
1.4.3 Polygenic Risk Score analyses 
 
Information from SNPs identified in GWAS studies can be used to explore the extent 
to which the genetic liability for a specific disorder is expressed in an independent 
sample (International Schizophrenia Consortium et al., 2009). Using this approach, 
the risk conferred by several million common genetic variants is summarised in an 
individual Polygenic Risk Score (PRS). This is computed by summing the number of 
SNP risk alleles carried, weighted by the effect size from the summary statistics from 
a large GWAS (International Schizophrenia Consortium et al., 2009). 
The application of PRS in the second wave of PGC schizophrenia GWAS, which 
included 36,989 patients and 113,075 controls, showed that common genetic 
variants accounted for 18% of the variance in the case-control status (corresponding 
to 7% of the variation on the liability scale, assuming a lifetime risk of schizophrenia 
of 1%) (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 
2014). Moreover, the public availability of summary statistic allows PRS for 
schizophrenia to be constructed in any independent genotyped sample, so 
researchers can test the extent to which the genetic liability for schizophrenia is 
correlated with the risk of developing schizophrenia or other phenotypes. For 
example, PRS for schizophrenia have been associated with a chronic course of the 
disorder (Meier et al., 2016) and response to treatment (Li et al., 2018). Recently, it 
has been shown that cognitive deficit in schizophrenia cases was associated with 
PRS that indexed cognitive traits in the general population rather than PRS for 
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schizophrenia (Richards et al., 2019). This body of evidence suggests that cognitive 
variation in schizophrenia depends on the same genetic factors that determine 
cognition variation in the general population (Mallet et al., 2020). 
 
1.4.4 Translating Polygenic Risk score to everyday clinical practice 
 
PRS can be used to identify individuals who have increased genetic risk for disease.  
In medical conditions, PRS could be used to identify high-risk subgroups of the 
population, for early intervention or screening.  For example, it has been proposed 
that mammogram screening programme could start earlier in women with high 
breast cancer PRS (Mavaddat et al., 2015). The potential value of a PRS clinical 
approach has been further proposed for coronary disease, where it could identify 8% 
of the population at a threefold increased risk (Khera et al., 2018). However, 
currently two main limitations make it difficult to apply this approach in psychiatric 
clinical practice. 
First, PRS does not have a strong predictive value in psychiatry. For example, 
although schizophrenia PRS is strongly associated with case status, it usually 
explains less than 10% of the variance in a typical first episode psychosis (FEP) - 
control study (Vassos et al., 2017), which may increase to 20% in the largest 
combined chronic samples (Pardinas et al., 2018). This raises the question of 
missing heritability and suggests that other factors must to be considered for 
implementing care algorithms in addition to common variants, for example rare 
variants with higher penetrance and environmental risk factors (Lewis and Vassos, 
2017). 
Second, largest GWAS samples are mainly composed of individuals of European 
ethnicity. As a consequence, PRSs have poor predictive value in people of non-
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European ancestry, for example of African ancestry (International Schizophrenia 
Consortium et al., 2009, Vassos et al., 2017). There are concerns that this may 
increase disparities in the availability of care, thus large GWAS should involve 
different ethnic groups (Martin et al., 2019). Further, restricting analysis to one 
population may limit the overall understanding of the genetics of schizophrenia; 
hence, some authors highlighted the importance of performing trans-ancestral 
analyses (Dennison et al., 2019). Indeed, some causal variants may differ in allele 
frequency and linkage disequilibrium (LD) patterns across populations, so that they 
may be too rare to be identified in one specific population, but they may come out in 
trans-ancestral examinations. 
Hence, schizophrenia GWAS should be expanded beyond European-ancestry 
populations to cover Asian, African, and Latino populations. Results from a recent 
East Asian schizophrenia GWAS indicated that the common variant structure of 
schizophrenia is similar across East Asian and European populations (Lam et al., 
2019), with the notable exception of long-range LD regions such as the MHC (Lam et 
al., 2019). Interestingly, trans-ancestral analyses of Asian and European GWAS 
identified risk variants that would be too rare in European only samples and filtered 
out due the low MAF, for example a variant within the GABBR1 gene, coding for a 
component of the GABA receptor, discovered in Asian GWAS (Yu et al., 2017).  
A recent trans-ancestral analysis of admixed African and Latino schizophrenia 
GWAS showed that in people of African ancestry, PRS constructed using African 
GWAS explained more variance than the one constructed using European GWAS; 
and that European and Latino cases carried more African-derived risk alleles than 
their ancestry matched controls (Bigdeli et al., 2019).  
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These findings suggest that generalizability of research findings and application of 
polygenic risk scoring in clinical practice depend on future availability of risk allele 




Chapter 2: Genetic and environmental risk factors in non-affective and 
affective psychosis, and the symptom dimension approach 
 
In the first part of this chapter, I illustrate the similarities and dissimilarities between 
non-affective and affective psychoses that, as a whole, challenge their 
conceptualization as discrete entities. Hence, I introduce the neurodevelopmental 
hypothesis of schizophrenia, which may explain differences in the expression of 
psychosis. In the second part of this chapter, I describe the extensive body of 
evidence indicating that cannabis use is a component cause of psychotic disorders, 
concluding that cannabis-associated psychosis may be integrated into a 
developmental risk factor model of psychosis. Finally, I explain that individual 
differences in psychosis may be best examined using a transdiagnostic approach 
based on symptom dimensions, that may reflect the continuous distribution of 
biological and environmental risk determinants across the psychosis spectrum. 
 
2.1 Diagnostic validity of non-affective and affective psychotic disorders 
 
The utility of psychiatric diagnostic categories should be distinguished from their 
validity (Kendell and Jablensky, 2003). From a utility perspective, the introduction of 
ICD-10 and of DSM-III and their successors led to a worldwide use of a common 
language, including reporting on psychiatric history, treatments, and outcomes 
(Kendell and Jablensky, 2003). However, from a validity perspective, research failed 
to find convergent validators of operationalised ‘disease entities’, at least under the 
original assumption that psychiatric diagnoses should be mutually exclusive 
(Stengel, 1959, Zubin, 1961). Robins and Guze, and later Kendler, identified different 
classes of validators based on their applicability to schizophrenia (Robins and Guze, 
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1970, Kendler, 1980). For example, Kendler distinguished between antecedent 
validators (e.g., familial aggregation, premorbid personality, and precipitating 
factors), concurrent validators (e.g., psychological scales), and predictive validators 
(e.g., diagnostic consistency, relapse and recovery, and treatment response) 
(Kendler, 1980). However, dissatisfaction with the distinction between schizophrenia, 
schizoaffective, and affective psychoses was evident due to the failure to 
discriminate these entities based on psychiatric history, mental state and even 
follow-up data (Brockington et al., 1979). Moreover, epidemiological data clearly 
emphasised these difficulties. For example, the Camberwell Register study showed 
that at FEP, two out of three patients had a diagnosis of schizophrenia according to 
RDC criteria, but only one out of three patients had the same diagnosis when using 
DSM-III or Feighner criteria (Castle et al., 1991). In addition, it became clear that 
classifying patients presenting both prominent mood and psychotic symptoms into 
the category of schizoaffective disorders had created further nosological challenges 
(Abrams et al., 2008). For example, a recent meta-analysis of 49 studies showed 
that the mean test-retest reliability of schizoaffective disorder (κ=0.57) was lower 
compared with schizophrenia (κ=0.69), bipolar disorder (κ=0.77) and unipolar 
depression (κ=0.73) (Santelmann et al., 2016). 
 
2.1.1 Validity of alternative categorical subtyping 
Hence, in the 1980s there were several efforts to operate a clear-cut division of 
schizophrenia into discrete sub-categories. That is, subtypes accounting for the 
predominance of positive or negative symptoms were proposed to identify positive, 
negative and mixed schizophrenia (Andreasen and Olsen, 1982); subtypes accounting 
for family history were proposed to differentiate familial from sporadic schizophrenia 
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(Murray et al., 1985); and subtypes based on primary enduring or transient negative 
symptoms were proposed to differentiate a ‘deficit syndrome’ from a non-deficit 
schizophrenia (Carpenter et al., 1988). Tim Crow split schizophrenia into two-
syndromes, of which type I would have been similar to Bleuler’s schizophrenia and 
type II to Pinel-Haslam’s schizophrenia (postulating a neurodegenerative process) 
(Crow, 1985). Later, Murray and colleagues proposed to discriminate 
neurodevelopmental forms from adult-onset schizophrenia (Murray et al., 1992), and 
indeed this was well supported by latent class analyses. However, this 
subclassification maintained the difficulty on how to interpret the intermediate 
schizoaffective subtype (Castle et al., 1994, Sham et al., 1996). 
Overall, there is evidence supporting the utility of sub-classifications (Fenton and 
McGlashan, 1994), especially when comparing the two extremes of opposed 
subtypes. However, all sub-categories carry the same methodological limitation as 
traditional diagnostic categories, i.e. poor validity of these constructs and the necessity 
to introduce intermediate phenotypes.  
 
2.1.2 Recent epidemiological studies on affective and non-affective psychosis 
 
The Kraepelinian paradigm has been consistently challenged by the large 
comorbidity indices between schizophrenia, schizoaffective, bipolar, and major 
depressive disorders (Laursen et al., 2009, Upthegrove et al., 2017). In addition, 
mounting evidence has been suggesting that the incidence of psychotic disorder is 
extremely heterogenous in time and place (McGrath et al., 2004). In South London, 
the examination of the Camberwell register showed that the incidence of psychosis 
has been increasing over a 30 year time (Boydell et al., 2003). Findings from the 
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Aetiology and Ethnicity in Schizophrenia and Other Psychoses (ÆSOP) incidence 
and outcome studies of psychosis suggests that the increase may be in part due to 
the massive migration phenomenon (Fearon et al., 2006). The ÆSOP study also 
showed that incidence varied across place, being higher in Southeast London than in 
Nottingham and Bristol (Kirkbride et al., 2006). In addition, the ten-year outcomes of 
the study (ÆSOP-10) suggested that diagnoses within psychosis spectrum other 
than schizophrenia at baseline tended to be unstable over time (Heslin et al., 2015). 
Further evidence that the incidence of psychosis is unstable comes from a recent 
comprehensive systematic review and meta-analysis, indicating a pooled incidence 
of all psychotic disorders of 26.6 per 100 000 person-years. The pooled incidence 
was 18.7 per 100 000 person-years for non-affective psychotic disorder and 4.6 per 
100 000 person-years for affective psychotic disorders, however there was a large 
geographical variation in part explained by differences in case ascertainment 
methods (Jongsma et al., 2019). The ‘European Network of National Schizophrenia 
Networks studying Gene-Environment Interactions’ (EU-GEI) study addressed this 
bias by examining the incidence of psychotic disorders using same ascertainment 
methodology and standardised research-based diagnoses from the Operational 
Criteria checklist (OPCRIT) across six different countries. The study showed a 
marked heterogeneity in the risk of developing a psychotic disorder, by person and 
place, with an global incidence rate of psychotic disorders of 21.4 per 100,000 per 
year (non-affective psychosis: 16.9 per 100 000 person-years; affective psychosis: 
4.3 per 100 000 person-years) with an eight fold variation of the incidence rates 
across the study sites (Jongsma et al., 2018).  
It is plausible that socioenvironmental and biological factors account for such a large 
variation in the incidence of psychosis. Di Forti and colleagues examined this 
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hypothesis, showing that daily cannabis use and use of high potency cannabis were 
two important contributors accounting for variation in the incidence rates of 
psychosis across the EU-GEI study sites, even accounting for age, gender, and 
ethnic minority status (Di Forti et al., 2019a). 
In summary, epidemiological research into psychotic disorders has clearly 
challenged the old idea of the existence of discrete natural disease entities with a 
homogenous and unchanging distribution.  
Further epidemiological evidence challenging a categorical definition of psychosis 
concerns the continuous distribution of delusions and hallucinations, as well as of 
negative psychotic experiences, in the general population (van Os et al., 2009). Data 
indicate that there are no discrete breaks in the distribution of symptoms, hence the 
threshold between subclinical and clinical psychosis would be dictated by social or 
contextual norms, reflecting qualitative or quantitative differences in 
symptomatology. For example, the presence of hallucinations extends trans-
diagnostically beyond schizophrenia to other psychotic and non-psychotic disorders 
(de Leede-Smith and Barkus, 2013) and to the general population (Linscott and van 
Os, 2013). Despite methodological differences among studies, a median prevalence 
of hallucinations of 13.2% was reported in the adult population (Beavan et al., 2011). 
In a recent quantitative review and meta-analysis, Maijer et al. (2018) aimed to 
calculate an accurate mean lifetime prevalence of auditory hallucinations in the 
general population, reporting a pooled estimated prevalence of 9.6% across 25 
studies (Maijer et al., 2018). Hence, hallucinations may be regarded as a continuous, 
or extended, phenotype ranging from symptoms of a clinical disorder to a transient 
phenomenon in the general population. Similarly, a proportion of 10% to 15% of the 
general population regularly experience delusional ideas of various degrees, 
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reaching in 1 to 3% of individuals a severity comparable to clinical cases of 
psychosis (Freeman, 2006).  
 
2.1.3 Pharmacology and clinical practice in affective and non-affective 
psychosis 
 
Two different pharmacology trajectories between schizophrenia and bipolar disorder 
(e.g., involving the use of lithium and other mood stabilisers) have been traditionally 
considered as a key element supporting a neat distinction between schizophrenia 
and bipolar disorder. However, several studies showed the efficacy of agents which 
impact on dopamine signalling in treatment of both non-affective and affective 
symptoms. For example, antipsychotics antagonise D2 dopamine receptor 
functioning and are used in bipolar disorder and schizophrenia (Post, 1999, Taylor et 
al., 2015), and clozapine is indicated for both treatment resistant schizophrenia and 
treatment resistant mania (Li et al., 2015, Howes et al., 2016, Fountoulakis et al., 
2019). These findings suggest that dopamine dysregulation may contribute to both 
positive and manic symptoms, as supported by positron emission tomographic 
findings (Jauhar et al., 2017). Moreover, mood stabilisers are used as add-on 
treatment in schizophrenia as they may contribute to reduce the severity of positive 
symptomatology (Casey et al., 2009). Altogether, these findings are in line with the 
original Brockington’s consideration that lithium and chlorpromazine would be 
equally effective in the treatment of the intermediate group composed of 




2.2 An alternative developmental perspective in psychotic disorders 
 
 
2.2.1 Pre- and peri-natal factors in non-affective and affective psychosis 
 
The post-modern conceptualization of schizophrenia as a neurodevelopmental 
disorder (Murray and Lewis, 1987, Weinberger, 1987) has emerged in the 1980s 
from studies showing that monozygotic twins with schizophrenia had larger cerebral 
ventricles than their healthy counterpart, particularly if they were exposed to perinatal 
hazards (Reveley et al., 1982, Reveley et al., 1984). Subsequent studies have 
confirmed that obstetric complications, e.g. pregnancy complications, fetal 
growth/development abnormalities, and delivery complications, were risk factor for 
schizophrenia (Lewis and Murray, 1987, Cannon et al., 2002b); however, no robust 
evidence has indicated an association between these complications and bipolar 
disorder (Scott et al., 2006). Moreover, perinatal hypoxia or asphyxia has been 
consistently associated with reduced volume of the amygdala and hippocampus 
(Murray et al., 2004), which is a brain structural pattern more common in 
schizophrenia than bipolar disorder (see paragraph 2.2.4). Similarly, fetal growth 
indicators such as low birth weight or small birth length well correlated with 
schizophrenia but not with bipolar disorder (Ogendahl et al., 2006). Moreover, 
maternal viral infections, especially influenza, have been associated with 
schizophrenia (Brown, 2006, Boksa, 2008, Benros et al., 2011, Kępińska et al., 
2020). On the other hand, evidence on the association between these infections and 




2.2.1 Early neurodevelopmental impairment in non-affective and affective 
psychosis 
 
In 2000s, the Dunedin study showed that an impairment in cognitive and neuromotor 
development during childhood was associated with developing schizophrenia but not 
bipolar disorder later in life (Cannon et al., 2002a). Indeed, cognitive deficit is a well-
established component of schizophrenia and it has been integrated into the 
developmental risk model of schizophrenia (Howes and Murray, 2014). However, it 
has been debated whether cognitive deficit follows a neurodevelopmental or 
neurodegenerative pattern. There is evidence that cognitive dysfunction is already 
present before the onset of psychosis (Bora and Pantelis, 2015), and even before 
the prodromal stage (Bora and Murray, 2014); however, it is difficult to ascertain the 
natural course of such a dysfunction after psychosis onset, given the confounding 
effect of several factors, for example the use of antipsychotics and hospitalizations. 
Longitudinal studies have found no clear evidence of cognitive decline, and it has 
been showed that such a decline would be restricted to some cognitive domain such 
as verbal knowledge and memory, whereas executive functions would remain stable 
over time (Zanelli et al., 2019). Noteworthy, cognitive deficit appears to be less 
common and less severe in bipolar disorder, and this difference may index two 
different neurodevelopment trajectories towards developing schizophrenia and 
bipolar disorder (Trotta et al., 2015). Consistent with these findings, a relationship 
has been found between cognitive deficit and negative symptoms (Kravariti et al., 
2012), which are often considered being a marker suggestive of early 
neurodevelopment impairment in schizophrenia. Of note, a large register-based 
cohort study showed that children achieving excellent performance were more at risk 
of developing bipolar disorder than schizophrenia (MacCabe et al., 2010).  
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2.2.3 Brain structure in non-affective and affective psychosis 
 
Neuroimaging studies have shown that schizophrenia and bipolar disorder carry 
different brain structural abnormalities. From this perspective, findings from the 
Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium, 
integrating data from 70 different institutions, are particularly relevant. Specifically, 
the ENIGMA study indicated that patients suffering schizophrenia have a thinner 
cortex and smaller surface area, especially in frontal and temporal lobe regions (van 
Erp et al., 2018); whereas patients suffering bipolar disorder have a thinner cortical 
grey matter in frontal, temporal and parietal lobe regions (Hibar et al., 2018); 
moreover, antipsychotics and mood stabilisers may be both associated with cortical 
thickness. In the largest examination of first-degree relatives of patients with 
schizophrenia or bipolar disorder, the ENIGMA study also concluded that family 
aggregation of brain abnormalities is disease specific. That is, in comparison with 
healthy individuals, relatives of patients suffering bipolar disorder patients had a 
larger intracranial volume, whereas relatives of patients suffering schizophrenia had 
smaller cortical grey matter, cerebellar grey and white matters, cerebral white matter, 
and thalamus, with a thinner cortex and enlarged lateral and third ventricles (de 
Zwarte et al., 2019). Given that intracranial volume is considered a proxy of early 
brain development, the authors suggested that two different neurodevelopment 
trajectories may underpin brain structural differences between schizophrenia and 
bipolar disorder (de Zwarte et al., 2019). 
Interestingly, the ENIGMA study further showed that common genetic variation may 
account to some extent for variation in subcortical volumes (Satizabal et al., 2019), 
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involving SNPs within genes operating in brain development and neuronal signalling, 
and in part overlapping with schizophrenia or autism spectrum disorders. 
 
2.2.3 Genetic studies in non-affective and affective psychosis 
 
From a genetic perspective, the Kraepelin’s paradigm is not consistent with the 
accumulated evidence that genetic risk is in part shared by schizophrenia and 
bipolar disorder (International Schizophrenia Consortium et al., 2009, Demjaha et al., 
2011, Cardno and Owen, 2014, O'Donovan and Owen, 2016, Power et al., 2017). 
Family studies showed familial co-aggregation of non-affective and affective 
psychosis (Cardno et al., 2002, Lichtenstein et al., 2009, Chou et al., 2017). 
Moreover, similar concordance rates were found for schizophrenia, schizoaffective, 
and mania in both monozygotic (47-57%) and dizygotic (14%) twins (Cardno et al., 
1999). Interestingly, GWAS identified SNPs associated with both bipolar disorder 
and schizophrenia in CACNA1C, ANK3, ITIH3-ITIH4, ZNF804A and NCAN but also 
SNPs (e.g., in MHC, ODZ4, TCF4) specific for either disorder separately (Hamshere 
et al., 2013, Bipolar Disorder Schizophrenia Working Group of the Psychiatric 
Genomics Consortium and Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2018, Cross-Disorder Group of the Psychiatric Genomics 
Consortium, 2019). The latest cross-disorder PGC metanalysis showed that 
schizophrenia and bipolar disorder had a SNP-based genetic correlation of 0.7, and 
several SNPs (N=109) had a pleiotropic effect across different psychiatric disorders, 
of which 83% and 72% involved schizophrenia and bipolar disorder respectively 
(Cross-Disorder Group of the Psychiatric Genomics Consortium, 2019). Moreover, 
the latest Psychiatric Genomic Consortium Bipolar and Schizophrenia Working 
Groups GWAS showed that four genomic regions contributed to differences between 
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schizophrenia and bipolar disorder, including disorder-independent causal variants 
and potassium ion channel genes (Bipolar Disorder Schizophrenia Working Group of 
the Psychiatric Genomics Consortium and Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2018). Furthermore, in this study schizophrenia 
PRS was associated with psychotic features in bipolar disorder (Bipolar Disorder 
Schizophrenia Working Group of the Psychiatric Genomics Consortium and 
Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2018).  
On the other hand, genetic elements consistently supporting dissimilarities between 
diagnostic categories of psychosis involve the contribution of rare variants (minor 
allele frequency <1%). For example, an enrichment of large copy number variants 
(CNVs) was reported in schizophrenia (Gulsuner and McClellan, 2015, Marshall et 
al., 2017), while whether CNVs contribute to bipolar disorder is not clear (Green et 
al., 2016). More specifically, an enrichment in pathways associated with the 
postsynaptic density has been reported in schizophrenia but not in bipolar disorder 
(Fromer et al., 2014, Kataoka et al., 2016). However, consistent with the difficulties in 
operating a neat Kraepelin’s distinction, it has been shown that CNVs exert their 
contribution in those patients with a diagnosis of ‘schizoaffective disorder bipolar 
type’ but not of bipolar disorder (Charney et al., 2019). Moreover, investigations of 
neurodevelopmental conditions have revealed that recurrent structural variants in 
schizophrenia, such as 1q21.1, 15q11.2, 15q13.3, 16p13.3, and 22q11.2, have a 
raised frequency in more than one conditions, including developmental delay, 
intellectual disabilities, autism spectrum disorders, and multiple congenital 
abnormalities (Grozeva et al., 2012, Rosenfeld et al., 2013, Watson et al., 2014). 
Further support to the hypothesis that ‘neurosusceptibilty’ variants confer 
susceptibility to a range of neurodevelopment conditions, is provided by a recent UK 
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Biobank study, showing that CNVs involved in neurodevelopmental disorders are 
associated with a subtle cognitive deficit even in unaffected individuals with a 
disadvantage in educational attainment (Kendall et al., 2019).  
 
2.2.4 Non-affective and affective psychosis according to a neurodevelopment 
model 
 
In summary, altogether the above evidence is consistent with the conclusions of 
Murray and colleagues (2004) that: ‘A plausible model to explain both the overlap 
and the distinctions between schizophrenia and bipolar disorder needs to invoke 
both common and unique risk factors: certain susceptibility genes, shared between 
schizophrenia and bipolar illness, can be thought of as predisposing individuals to 
psychosis in general. However, other genes (for example, genes involved in 
neurodevelopment) and/or environmental factors (pre- and perinatal complications, 
winter/spring birth, city birth) may then act, or interact, upon this background to 
launch an individual on a trajectory towards schizophrenia.’ (Murray et al., 2004). 
 
 
2.3 Cannabis use and psychosis 
 
2.3.1 Case series on cannabis and psychopathology 
There has been a long history of interest in the association between cannabis and 
psychopathology. Early concerns on cannabis use were focused on the risks of 
committing crimes whilst intoxicated. For example, Peebles reviewed admission data 
at the Agra Lunatyc Asylum in India over ten years, concluding that 25% of the 
admitted patients had used cannabis; and 25% of those who were in the Asylum as 
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a consequence of having committed a crime (including serious crimes such as 
murder, arson, or felonious assault) had done it due to the use of cannabis (Peebles, 
1914). The association between cannabis use and psychosis has also been 
extensively reported in the form of case series. For simplicity, I summarise here five 
reports (Bromberg, 1934, Talbott and Teague, 1969, Spencer, 1971, Bernhardson 
and Gunne, 1972, Chopra and Smith, 1974), although the evident value of several 
similar reports is weakened by the study design limitations.  
In the case series of marijuana intoxication described by Bromberg (1934) in the 
USA, different psychopathology outcomes are described, including (1) the acute 
intoxication, (2) a mania, 'which is an acute intoxication with manic-like features, (3) 
the toxic psychoses with delusional and hallucinatory experiences, (4) the toxic 
admixture of cannabis to other psychoses and (5) a so-called "dementia" (an end-
state of years of cannabis usage with ethical, intellectual and volitional deterioration). 
Fifty per cent of the cases with intoxication had a symptom pattern characterised by 
delusions and 36% by auditory hallucinations. These particular cases were 
described as having ‘toxic psychoses’ that ‘are long-lasting and may go on to an 
atypical manic or depressive or schizophrenic psychosis’.  
Later, Spencer (1971) reported that people with cannabis associated psychosis were 
very florid in their positive symptomatology. Talbott and Teague (1969) observed, in 
Vietnam, acute psychosis following cannabis use in soldiers, with delusions or 
hallucinations being a general part of the presentation in 10 out of 12 cases. 
Interestingly, at that time, Vietnamese marijuana was as twice as potent as American 
marijuana, which may have contributed to a more severe symptom profile observed 
in Vietnam. Consistent with Talbott and Teague, Gunne (1972) described a 
symptomatology characterised by auditory hallucinations in about half of 46 habitual 
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users of cannabis in Sweden; and Chopra and Smith (1974) reported the worst 
symptomatology (which included mostly visual hallucinations) in the group of people 
using ganja or charas, the two most potent varieties of cannabis available at the time 
in India. 
 
2.3.2 Epidemiological studies: cannabis use as a ‘causal’ factor for psychosis 
 
‘Causality’ implies that exposure to a noxa is a necessary, sufficient or contributory 
cause to develop a certain condition (Rothman and Greenland, 2005). 
Epidemiological methods for making causal inferences include ascertaining the 
strength of the association, its temporal direction, and the existence of a dose-
response effect (Rothman and Greenland, 2005), although broader criteria may 
apply when findings across different studies are convergent (Hill, 1965). 
 
Strength of the association 
The first systematic study which prospectively suggested an association between 
cannabis and psychosis was carried out in Sweden among conscripts, showing that 
those who had used cannabis more than fifty times in their life were six times more 
at risk to develop schizophrenia than those who had not used cannabis (Andreasson 
et al., 1987).  
The Dunedin study further clarified that the risk was higher if starting to use cannabis 
during adolescence (Arseneault et al., 2002); and in the NEMESIS longitudinal 
study, van Os and colleagues went to show that use of cannabis was associated 
with subclinical psychotic symptoms in the general population (van Os et al., 2002a). 
Subsequently, a large body of epidemiological evidence demonstrated an 
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association between the cumulative exposure to cannabis and non-affective 
psychotic outcomes (Di Forti and Murray, 2005, Moore et al., 2007, Murray et al., 
2007, Murray and Di Forti, 2016). Moreover, experiencing psychotic symptoms has 
been reported in over half of a sample of polysubstance abusers who used cannabis, 
either while using or withdrawing cannabis (Smith et al., 2009).  
Di Forti and colleagues (2015) took further into account the potency of cannabis, 
identifying as high-potency the varieties, in London, containing high concentration of 
Delta-9 Tetrahydrocannabinol (Δ9-THC) and low concentration of cannabidiol (CBD), 
such as ‘skunk’ (Di Forti et al., 2015). Indeed, in the Genetic And Psychosis (GAP) 
study, they showed that the highest risk of developing a psychotic disorder was 
carried by subjects using skunk on a daily basis (Di Forti et al., 2015).  
Moreover, many studies showed that the association between exposure to cannabis 
and later onset of psychosis held after controlling for any currently known socio-
environmental factor associated with psychotic disorders. For example, in the EU-
GEI study, daily use of high potency cannabis increased the risk of psychotic 
disorder of 5 fold compared to never use independently of co-exposure to eight 
different types of other drugs (including tobacco), IQ, level of education, employment 
and relationship status, gender, age, urban or rural context, and ethnic group (Di 
Forti et al., 2019a). 
Evidence that cannabis use increases the risk of bipolar disorder is less consistent 
(Moore et al., 2007). Of note, a systematic review of three prospective studies 
showed that individuals who used cannabis weekly would have an increase in the 
risk ranging from 2.5 to 9 times to develop bipolar disorder than those not using 





It is widely recognised that prospective population-based studies are gold-standard 
for establishing chronological relationship between exposure to a factor and 
subsequent outcome. These studies have consistently shown that use of cannabis 
precedes the development of schizophrenia. For example, in the previously 
mentioned Dunedin birth cohort study, 96% of 1,037 new-born individuals were 
followed up until the age of 26 (Arseneault et al., 2002). Findings showed the 
existence of a relationship between the use of cannabis at age 15 and a diagnosis of 
schizophrenia at the age of 26 (Arseneault et al., 2002). Moreover, convergent 
findings were reported in other high-quality population-based studies, including the 
previously mentioned pioneer study on conscripts in Sweden (Andreasson et al., 




Finally, there is consistent evidence that cannabis exposure and onset of psychosis 
follows a dose-response relation risk. A metanalysis confirmed that individuals with 
heavy cannabis use had an odds ratio (OR) of 3.90 (95% CI 2.84 to 5.34) for the risk 
of schizophrenia and other psychosis-related outcomes compared to nonusers, 
which indicates a moderate to large effect (Marconi et al., 2016). 
Furthermore, potent cannabis varieties have become available worldwide (Freeman 
et al., 2019) and importantly, as presented above, increasing availability of high 
potency cannabis may impact on the incidence rates of psychotic disorders across 
Europe (Di Forti et al., 2019a), to the point that not only the frequency of use but also 
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the potency of cannabis are now recognised as vital information for conducting high-
quality research into this field (Di Forti et al., 2019a, Freeman and Lorenzetti, 2019).  
 
Conclusions based on the above evidence 
 
1) Is cannabis use a sufficient cause of the disorder?  
Longitudinal cohort studies show that only a minor proportion of the adolescents who 
use cannabis develop a psychotic disorder later in life, hence the conclusion is that 
cannabis is not a sufficient cause of schizophrenia. 
 
2) Is cannabis use a necessary cause of the disorder?  
Individuals may develop schizophrenia without having had any lifetime exposure to 
cannabis, hence, the conclusion is that cannabis use is not a necessary cause of 
schizophrenia. However, I also argue that this is not entirely falsifiable due to the use 
of current diagnostic system. Indeed, as widely discussed in this thesis, diagnostic 
categories are useful constructs for clinical practice, but they are arbitrary as 
nosological constructs. In a hypothetical scenario where Bonhoeffer was more 
influential than Kraepelin and an exogenous cannabis-associated psychosis would 
exist as an official diagnosis, cannabis use would be a necessary (though not 
sufficient) cause of that disorder. 
 
3) Is cannabis use a contributory cause of the disorder? 
Altogether, the above evidence clearly demonstrate that cannabis use is a 
contributory cause of the disorder. This conclusion is consistent with what is 
currently known about complex multifactorial disorders, where both genes and socio-
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environmental factors are neither sufficient nor necessary causes to the disorder, but 
they interact with each other to confer risk. 
 
2.3.3 Experimental studies on cannabis and psychotic symptoms 
 
Experimental studies have shown that Δ9-THC administration results in short-lived 
psychotic symptoms (Morrison et al., 2009, Winton-Brown et al., 2011) and brief 
negative symptoms (Morrison and Stone, 2011) in healthy volunteers, and in a 
worsening of psychotic symptoms in individuals with schizophrenia (D'Souza et al., 
2005). On the other hand, psychoactive effects of Δ9-THC could be contained by the 
co-administration of CBD (Englund et al., 2013). However, a recent meta-analysis of 
15 studies confirmed that acute administration of Δ9-THC in healthy volunteers 
induces positive symptoms with large effect size to a greater extent than negative 
symptoms, whereas the evidence for the counterbalancing effect of CBD on these 
symptoms remains inconclusive (Hindley et al., 2020). In addition, the use of 
synthetic cannabinoid receptor agonists, commonly known as ‘spice’, has increased 
over recent years. These substances are more potent than the Δ9-THC contained in 
traditional cannabis (van Amsterdam et al., 2015), and their use can induce florid 
psychotic symptoms and hallucinations (Papanti et al., 2013).  
 
2.3.4 Biological plausibility of the association between cannabis use and 
experiencing psychotic symptoms 
 
Δ9-THC elicits its acute psychoactive effects firstly interacting with the 
endocannabinoid system, a lipid signalling neuromodulatory pathway (Piomelli et al., 
2000, Piomelli, 2003, Fakhoury, 2017) which plays a primary role in synapse 
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formation and neurogenesis (Harkany et al., 2008), and in modulating synaptic 
strength mostly through retrograde signalling (Kano et al., 2009) especially during 
adolescence (Viveros et al., 2012, Meyer et al., 2018). The endocannabinoid system 
includes (1) at least two endocannabinoid receptors (CB1R and CB2R), (2) the 
endocannabinoid ligands, such as anandamide and 2-arachidonoylglycerol, and (3) 
their synthetic and degradative enzymes. Δ9-THC is an exogenous partial agonist of 
the CB1R (Pertwee, 2008), which is located pre-synaptically on GABAergic and 
glutamatergic neurons inhibiting neurotransmitter release. The distribution of CB1 
receptor is most abundant in key areas involved in psychosis, for example pre-frontal 
cortex, basal ganglia, and hippocampus (Mackie, 2005). THC psychotropic effect 
can be perhaps attenuated by CBD, which may act as an antagonist for CB1R even 
though it is said to lack affinity for this receptor (Thomas et al., 2004, Thomas et al., 
2007). Synthetic cannabinoid receptor agonists, like ‘spice’, mimic the action of Δ9-
THC, but they are full agonists of CB1R, for which they have high affinity. Thus, 
consumption of synthetic cannabinoids results in stronger effects compared with the 
Δ9-THC derived from the plant cannabis, and there are reports showing severe 
perceptual disturbances including hallucinations in people using spice (Hurst et al., 
2011, Lerner A et al., 2014, Besli et al., 2015). 
Some suggest that Δ9-THC’s effects are mediated by the dopaminergic system 
(Murray et al., 2014, Bloomfield et al., 2016). Disruption in dopaminergic system is 
thought to be the final mechanism underpinning psychotic disorders, and especially 
positive symptoms (Di Forti et al., 2007, Howes and Murray, 2014). Certainly, as 
previously mentioned, the endocannabinoid system modulates dopaminergic 
neurons through retrograde signalling. Animal research suggests that endogenous 
cannabinoids, anandamide and 2-arachidonoylglycerol stimulate dopamine release 
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in the nucleus accumbens after binding CB1R (Oleson and Cheer, 2012); and 
exogenous cannabinoids, such as Δ9-THC, enhance dopaminergic cell firing as well 
as dopamine synthesis and release in different brain regions (Bloomfield et al., 
2016). However, the interaction between endocannabinoids and dopamine system is 
complex and requires more research. Studies of the effects of Δ9-THC on striatal 
dopamine in humans have been inconsistent. 
Studies on candidate genes involved in the dopamine system have raised the 
question of gene x cannabis exposure interaction in psychotic outcomes, in both 
people with psychosis and population controls (Murray et al., 2016). Specifically, the 
most reported SNPs in interaction with cannabis are rs4680 in COMT; rs2494732 in 
AKT1; and rs1076560 in DRD2. 
First, the COMT polymorphism Val158Met was tested for interaction with the use of 
cannabis during adolescence. The authors reported increased risk of hallucinatory 
experiences in adulthood among Val/Val individuals (OR = 5.3, 95% CI: 2.2–12.7) 
and, to a lesser extent, among Val/Met individuals (OR = 2.6, 95% CI: 1.4–4.9), but 
not among Met/Met individuals (OR = 1.2, 95% CI: .50–3.0) for those exposed to 
cannabis compared with the not-exposed counterpart (Caspi et al., 2005).  This is 
the only interaction that has been studied enough to allow a small meta-analysis, 
which showed that the initial findings were not confirmed (Vaessen et al., 2018). 
Three studies which used continuous outcomes found no interaction between this 
COMT polymorphism and cannabis use on the severity of positive symptoms 
(Vaessen et al., 2018), which is consistent with an experimental study reporting no 
effect on THC-induced psychotic symptoms (Tunbridge et al., 2015).  
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Second, two studies suggested that the AKT1 polymorphism increases risk of 
psychotic illness among cannabis users (van Winkel et al., 2011, Di Forti et al., 
2012). In addition, van Winkel (2011) showed that this interaction was associated 
with scoring higher at positive schizotypy (van Winkel et al., 2011). Consistently with 
these findings, another study has shown that this polymorphism is associated with a 
more severe psychotogenic response to cannabis (Morgan et al., 2016).  
 
Third, it has been reported that the DRD2 polymorphism increases psychosis risk in 
people using cannabis more than in those not using cannabis (Colizzi et al., 2015b). 
It has been finally reported that cannabis users carrying the risk variants in both 
DRD2 and AKT1 genes are at an even higher risk of developing psychosis (Colizzi et 
al., 2015a).  
 
All of the above reports concerning candidate genes should be treated with caution 
pending further replication. Current research is focusing on whether the genetic 
liability to schizophrenia, summarised by PRS may modify the association between 
cannabis use and psychosis. Indeed, Di Forti and colleagues reported that both 
schizophrenia PRS and cannabis use, independently from each other, increase the 
risk of experiencing a FEP (Di Forti et al., 2019b). 
 
 
2.3.5 Cannabis-associated psychosis and neurodevelopmental trajectories 
 
It is crucial to ascertain if the psychopathology profile of cannabis-associated 
psychosis is different from schizophrenia and other psychotic disorders in people not 
using cannabis. Certainly, psychotic symptoms elicited by cannabis improve rapidly 
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in most people, however it is noteworthy, the continued use of cannabis can shape a 
clinical picture which is in the long run undistinguishable from schizophrenia-like 
psychosis (Manrique-Garcia et al., 2012). Schoeler et al. (2016) suggested that 
cannabis-associated psychosis is characterised by worse outcome when the use of 
cannabis is protracted over the course of the disorder; specifically, they reported, in 
the GAP sample, that patients who continued to use cannabis on a daily basis after 
FEP were at a higher risk of a subsequent psychosis relapse (OR 3.28; 95% CI 
1.22–9.18) and involved in more intense psychiatric care (OR 3.16; 95% CI 1.26–
8.09) (Schoeler et al., 2016b). These results are in line with a comprehensive review 
of literature and meta-analysis (Schoeler et al., 2016a). 
 
The developmental risk factor model of psychosis has expanded to account for 
environmental factors, including adverse life events and social contexts, and use of 
drugs such as cannabis (Murray et al., 2017a). Neurodevelopmental aberrancies 
may occur during different pre/peri-natal, childhood or adolescence stages. 
Regardless of diagnostic categories of non-affective or affective psychotic disorders, 
cannabis-associated psychosis may not involve early neurodevelopment impairment 
but disruptions occurring in adolescence, when cannabis is mostly used. For 
example, compared with those not using cannabis, patients with psychosis who use 
cannabis have higher IQ and premorbid IQ (Ferraro et al., 2013, Loberg et al., 2014), 
better premorbid social functioning (Ferraro et al., 2019), and less neurological soft 




2.4 The transdiagnostic approach based on symptom dimensions in 
psychoses 
 
As previously described, according to the developmental risk model of psychosis, 
children carrying early abnormalities in neural networks (due to genetics and/or 
medical events) may experience a deficit in neuro- and social cognition and take on 
a trajectory of scholastic and social difficulties, resulting often in social isolation and 
deficits in emotional expression (Murray et al., 2017a). These difficulties, which may 
unfortunately attract further risk events for psychosis such as bullying, often result in 
prominent primary negative symptoms at first episode of psychosis (FEP) (Murray et 
al., 2017a). Other socioenvironmental risk factors, including cannabis use, may elicit 
neurodevelopmental aberrancies later in adolescence, contributing to a phenotype 
that would be than characterised by less negative symptoms (Murray et al., 2017b). 
However, current diagnostic categories may obscure the actual distribution of 
psychotic symptoms (Dikeos et al., 2006), whereas a transdiagnostic approach 
based on symptom dimensions may be more appropriate to evaluate the extent of 
developmental risk across the psychosis spectrum [i.e. the ‘neurodevelopmental 
continuum’ (Owen and O'Donovan, 2017)]. The symptom dimension approach is 
based on the assumption that psychotic symptoms follow a continuous distribution 
(van Os and Tamminga, 2007, Tesli et al., 2014), and on the possibility to statistically 
identify groups of symptoms that occur together more often than by chance alone, 
which may also coexist in the same individual (Allardyce et al., 2007a, Demjaha et 
al., 2009, Russo et al., 2014a). 
In social science, this approach is used for measuring constructs that cannot be 
directly measured due to their latent structure. In recent years, studying psychosis 
using symptom dimensions has become popular, due to the crisis of confidence in 
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traditional nosology (Jablensky, 2005, Zachar and Kendler, 2017). However, it may 
be surprising that the symptom dimension approach is not novel in psychosis. In 
1933, a first relevant factor analysis on psychotic symptoms was computed by hand 
by Thomas Moore on 367 patients from two mental health institutions, in Baltimore 
and Anacostia (Moore, 1933). Moore identified symptom dimensions of 1) cognitive 
defect 2) catatonic syndrome; 3) uninhibited or kinetic syndrome; 4) non-euphoric 
manic syndrome; 5) euphoric manic syndrome; 6) delusional hallucinatory syndrome; 
7) syndrome of constitutional hereditary depression; and 8) syndrome of retarded 
depression (Moore, 1933). One year later, Thurstone, an expert in factor analysis, 
re-analysed Moore’s data, identifying a latent structure composed of five groups of 
symptoms, i.e. 1) catatonic, cognitive, manic, hallucinatory (which included both 
delusions and hallucinations), and depressive symptoms (Thurstone, 1934). In 1952, 
these data were re-analysed once again by Degan, who conveyed on a nine-factor 
solution, with higher-order domains that were interpreted as mania, hebephrenic 
schizophrenia, depression, and catatonic schizophrenia (Degan, 1952). More 
recently, Blashfield identified a five-factor structure in line with Thurstone’s work 
(Blashfield, 1984). 
Interestingly, even if different factor analysis identified a very similar latent structure, 
symptom dimensions were differently interpreted. For example, Degan proposed that 
the syndromes identified through his work reflected different psychological defence 
mechanisms, which was consistent with the psychoanalytic approach common in 
America after World War II (Fenichel, 1945). Indeed, it could be observed that 
‘Factor A’ of Degan’s analysis was mainly composed of items indicating paranoid 
delusions, hallucinations and lack of insight, which would currently correspond to a 
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positive symptom dimension, but it was interpreted at the time as a ‘hyper-projection’ 
syndrome. 
 
After operationalization, the first studies investigating symptom dimensions in 
schizophrenia produced different models, initially including three schizophrenia 
factors (Liddle, 1987), such as reality distortion, psychomotor poverty, and 
disorganization. Overall, this factor analysis added the disorganization dimension to 
the classic Andreasen’s subtyping of positive and negative schizophrenia. This 
structure was widely replicated, and a meta-analysis of ten studies confirmed the 
three-factors structure (Grube et al., 1998). On the other hand, other studies 
privileged a structure with four or five schizophrenia factors (Lindenmayer et al., 
1994, Peralta et al., 1994, Wickham et al., 2001).  
Nevertheless, it was observed that these factors could not accommodate the whole 
symptom diversity in schizophrenia (Kay and Sevy, 1990). Thus, psychopathology 
models including also depressive and manic factors were proposed and replicated in 
schizophrenia (Lindenmayer et al., 1994, Salokangas, 1997, Wickham et al., 2001, 
Wallwork et al., 2012). However, the use of schizophrenia samples was a limitation 
because, as McGorry has pointed out, the heterogeneity of psychosis would have 
been better studied at FEP (McGorry et al., 1998). Further, this approach allowed to 
set a common time point for all the patients. Hence the five-factor structure was 
confirmed in psychotic disorders (Salokangas, 2003, Dikeos et al., 2006, Demjaha et 
al., 2009), and in first-episode psychosis sample (McGorry et al., 1998). Finally, it 
was confirmed in a sample of bipolar patients only (Lindenmayer et al., 2008). 
Hence, its validity across the spectrum of non-affective and affective psychosis has 
been consistently supported. 
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Collectively, such evidence has demonstrated the validity of the dimensional 
representation of psychosis, and that schizophrenia factors extend beyond 
schizophrenia, encompassing all forms of psychosis independently from the 
diagnosis. Moreover, it has been shown that such symptom dimensions explain 
more clinical characteristics than diagnostic categories alone (Dikeos et al., 2006, 
Russo et al., 2014b), thus allowing us to consider the utility of a hybrid of a 
categorical-dimensional system (Adam, 2013). 
An unsolved theoretical question in psychosis is whether symptom data distribution 
is unidimensional or multidimensional. The statistical model that applies to solve this 
dimensionality issue is the bifactor solution (Holzinger and Swineford, 1937). After 
disappearing for many decades, bifactor measurement modelling has been recently 
rediscovered in psychometrics, including a general factor representing shared 
variance among all symptoms and a set of specific factors where the remainder of 
the variance is shared among subsets of symptoms (Reise et al., 2007, Reise, 
2012). In psychosis, this resulted in the identification of a more fundamental general, 
transdiagnostic dimension in addition to the traditional five specific symptom 
dimensions (Reininghaus et al., 2013, Reininghaus et al., 2016, Shevlin et al., 2017, 









Chapter 3: Methodology 
 
3.1 Summary  
 
The main objective of this PhD project is the investigation of the dimensional 
structure of psychopathology at FEP and its relationship with genetic and 
socioenvironmental determinants, focusing on common risk variants and cannabis 
use. In this chapter, I present overall aims, sample, and methods. In the following 
chapters (Chapters 4, 5, and 6), each study is illustrated in detail in the form of 
published or submitted manuscripts. 
 
3.1.1 Aims and hypothesis 
 
1) Examine the transdiagnostic dimensional structure at FEP. I hypothesised 
that a bifactor model composed of one general psychosis factor and five 
specific dimensions of positive, negative, disorganization, manic, and 
depressive symptoms best fitted the covariance among the observed 
symptoms (Study 1; Chapter 4).  
2) Examine the dimensional structure of psychotic experiences in controls 
representative of the population living in the same areas of the patients with 
psychosis. I hypothesised that one general psychosis experience factor and 
three specific dimensions of positive, negative, and depressive psychotic 
experiences best fitted the covariance among the reported experiences 
(Study 2; Chapter 5).  
3) Examine whether socioenvironmental and context factors explain differences 
in symptom dimensions regardless of the categorical diagnoses. I 
hypothesised that being male and not using cannabis, as marker suggestive 
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of a more early neurodevelopmental impairment in psychosis, would be 
associated with more negative symptoms (Study 1 and Study 2; Chapters 4 
and 5); being part of an ethnic minority and using cannabis, as marker 
suggestive of more socioenvironmental risk for psychosis, would be instead 
associated with more positive symptoms (Study 1 and Study 2; Chapters 4 
and 5). 
4) Examine whether the genetic liability to schizophrenia and bipolar disorder 
explains differences in symptom dimensions. Regardless of categorical 
diagnoses, I hypothesised that common variants liability to developing 
schizophrenia would be associated with more negative symptomatology; and, 
furthermore, with more positive symptomatology independently from the use 
of cannabis. Moreover, I hypothesised that, regardless of categorical 
diagnoses, common variants liability to bipolar disorder would be associated 
with more manic symptomatology (Study 3; Chapter 6). 
 
3.2 Study design 
 
A multi-site population-based incidence and case-control study [The EUropean 
Network of National Schizophrenia Networks Studying Gene- 
Environment Interactions (EU-GEI) study], was used for this thesis, which comprises 
cases with a first episode of psychosis (International Classification of Diseases 
[ICD]-10 diagnoses F20-29 and F30-33) and controls recruited from 17 sites in six 
countries (England, the Netherlands, France, Spain, Italy, and Brazil). The 
catchment areas were intentionally selected to include a mix of urban and rural 





Recruitment and data collection were conducted over a five-year period between 
2010 and 2015 in all sites except the Veneto region in Italy. The Veneto sample was 
part of an earlier study (the Psychosis Incident Cohort Outcome Study [PICOS]; 
2005-2007), which used similar methodology as the EU-GEI study, allowing it to be 
pooled with the main sample. 
The incidence sample consisted of 2,774 individuals with a first episode of 
psychosis. Of the 1,519 individuals that were approached, 1,130 were consented 
and assessed (41% of the total incidence sample). Main reasons for non-
participation were: refusal to participate, language barriers, and exclusion after 
consenting as they did not meet the age inclusion criteria. In addition, 1,497 
population controls were recruited and assessed.  
The incidence sample was used for the study 1 (Chapter 4) of this thesis, whereas 
the case-control sample was used for study 2 and study 3 (Chapters 5 and 6). 
 
3.2.2 Case ascertainment and recruitment 
 
All cases presenting to mental health services in any of the 17 catchment areas with 
a suspected first episode of psychosis were potentially eligible for inclusion in the 
study. The inclusion criteria for cases were: a) presence of at least one positive 
psychotic symptom for at least one day or two negative psychotic symptoms (for at 
least six months duration) within the time-frame of the study; b) aged between 18 
and 64 years; and c) resident within a clearly defined catchment area at the time of 
their initial presentation. Residence was defined as a minimum of a one 
night stay at a residential address within the catchment areas. Exclusion criteria 
were: a) previous contact with specialist mental health services for psychotic 
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symptoms outside of the study period at each site; b) evidence of psychotic 
symptoms precipitated by an organic cause (ICD-10: F09); c) transient psychotic 
symptoms resulting from acute intoxication (F1X.5); d) severe learning disabilities, 
defined by an IQ less than 50 or diagnosis of intellectual disability (F70 to F79); and, 
for the case-control study, e) lack of fluency of the primary language at each study 
site. 
Teams of centrally trained researchers regularly screened general adult and 
specialist mental health services to identity study participants. Only cases that met 
the criteria based on the symptoms reported in the clinical notes were included in the 
study. Potential cases were approached when considered appropriate by clinical 
staff and sought informed consent. 
 
3.2.3 Control recruitment 
 
Inclusion criteria for controls were a) aged between 18 and 64 years; b) resident 
within a clearly defined catchment area at the time of consent into the study; c) 
sufficient fluency of the primary language at each study site; and d) no current or 
past psychotic disorder. A mixture of random and quota sampling was used to select 
a population-based sample of controls representative of local populations in relation 
to age, gender, and ethnicity. Quotas for control recruitment were based on the most 
accurate local demographic data available, and achieved using varying recruitment 
methods, including: 1) random sampling from lists of all postal addresses; 2) 
stratified random sampling via GP lists from randomly selected surgeries; and 3) ad 
hoc approaches (e.g., internet and newspaper adverts, leaflets at local stations, 
shops, and job centers). Individuals who agreed to participate in the study were 
screened for a history of psychosis and excluded if reported previous or current 
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treatment for psychotic symptoms. Those who indicated a possible psychotic 
symptom in the screening survey, were interviewed further with standardised 
interviews to establish presence of a psychotic disorder. 
 
3.2.4 Data content 
 
Demographic, clinical, social, psychological, cognitive, and biological data were 
collected in the EU-GEI study using previously validated questionnaires, tasks, and 
procedures.  
For the purpose of this thesis, environmental exposures and psychopathology were 
measured using previously validated instruments, and a detailed description is 
presented in the methods of the subsequent study chapters. 
Genetic risk was measured indirectly, using a familial liability score for psychosis, 
and directly, using DNA extracted from two 9ml non-fasting venous blood samples 
and/or via saliva samples (Oragene). Samples were genotyped using custom 
Illumina HumanCoreExome-24 BeadChip genotyping arrays containing probes for 
570,038 genetic variants (Illumina Inc., San Diego, CA). Genotype data were called 
using the GenomeStudio package, transferred into PLINK format for 
further analysis and underwent quality control based on genotype variants and 
samples. 
 
3.2.5 Quality assurance and control 
 
Study meetings were regularly arranged prior to and during the study annually, 
including both principal investigators and core researchers to: 1) guarantee 
standardised procedures were being implemented; 2) provide instruction; 3) discuss 
any issues with recruitment; and 4) conduct inter-rater reliability training. The study 
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was designed to ensure comparable procedures and methods across different sites, 
with some local adaptation to allow for variations in healthcare provision and health 
service contact points. The main deviation from protocol was in the Veneto region, 
Italy, where data were derived from a previous study which used comparable 
methods, however had a lower upper-age limit of 54. 
A technical working committee of the overall EU-GEI study (Work Package 11) 
trained researchers who were performing the assessments at the outset and 
throughout the study. Furthermore, an online resource was made available with 
taped interviews, samples of recordings, and written summaries for staff training 
purposes. Inter-rater reliability was assessed annually. Researchers were required to 
attain and maintain a minimum threshold of correct ratings before being allowed to 
administer the core assessments. Satisfactory levels of inter-rater reliability for the 
core measurements, ranging from 0.70-0.91, were achieved. 
 
3.2.6 Data management 
 
Data used for the current thesis was collected on paper, stored at each of the 
participating study centres, and entered locally using an encrypted web-based 
system, based on a commercial software (4D), which was adapted for the EU-GEI 
study. In order to minimise data entry errors, information was entered using field 
codes, restricted to logical values where possible. Blood and/or saliva samples were 
taken at site-specific clinical research facilities by trained staff and were pseudo-
anonymized using a bar code and sent to the Institute of Psychological Medicine and 
Clinical Neurology at Cardiff University for genotyping. The data resource has 
undergone a rigorous period of validation checks and cleaning by a small number of 
experienced researchers. This includes but is not limited to manual checks of 
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missing data and corroboration of these against the paper files at each of the 17 
sites. 
 
3.2.7 Ethical approval 
 
All participants who agreed to take part to the study provided informed, written 
consent following full explanation of the study. Ethical approval was provided by 



















Chapter 4: Study 1 
 
The core of this paper is the investigation of the structure of psychopathology at 
FEP, based on the notion that affective and non-affective psychoses are not entirely 
separate entities and they partly overlap. Thus, in order to identify latent factors that 
account for the variation and covariation among observed symptoms (i.e. symptom 
dimensions), I needed to estimate a model where the shared elements (i.e. a unique 
general factor) and the specific elements (i.e. multiple specific dimensions) may co-
exist across the psychosis spectrum. As explained in the introduction, the bifactor 
structure is a hybrid uni- and multi- dimensional solution which scales general and 
specific dimensions simultaneously, by modelling in parallel the variance-covariance 
of the whole symptomatology (general factor) and of subset of symptoms (specific 
dimensions). The second part of this paper focuses on the examination of clinical 
and demographic characteristics associated with symptom dimensions in order to 
confer external validity to the bifactor model and inform research and clinical 
practice. Table 1 reports the summary of aims and hypotheses for study 1. 
 
Table 1. Summary of aims and hypothesis for study 1  
Aims Hypothesis Grounds of the hypothesis Analytic approach 




A bifactor solution 
accounts for the 
variance-covariance 





and biological studies 
indicated lack of neat 
boundaries between 
categories of psychotic 
disorders (Owen and 
O'Donovan, 2017, Cross-
Disorder Group of the 
Psychiatric Genomics 






The bifactor solution is 
appropriate for modelling 
psychosis symptoms (Reise 
et al., 2007, Reininghaus et 
al., 2016) 








are more common 
in minority ethnic 
groups 
A disadvantageous social 
context may exacerbate 
positive symptoms 










Early deficits in neuro- and 
social cognition may 
contribute to exacerbation 
of primary negative 

















4.1 Transdiagnostic dimensions of psychopathology at first episode psychosis: 
findings from the multinational EU-GEI study 
 




















4.2 Study 1, supplementary material  
 
Supplementary Table S1 

















Persecutory Delusions 54 POS 71.1% (1,551) 71.6% (794) 71% (757) 
Well organised delusions 55 POS 35.1% (765) 41.6% (458) 28.8% (307) 
Delusions of influence 58 POS 33.3% (726) 24.1% (267) 15.4% (165) 
Bizarre Delusions 59 POS 30.7% (669) 23.3% (259) 11.3% (121) 
Widespread Delusions 60 POS 34.4% (751) 42.4% (437) 29.6% (314) 
Delusions of passivity 61 POS 12.2% (264) 15.2% (168) 9% (96) 
Primary delusional perception 62 POS 20.5% (440) 26.2% (286) 14.6% (154) 
Other primary delusions 63 POS 17% (370) 19.4% (213) 14.9% (157) 
Delusions & hallucinations last for one week 64 POS 51.4% (1076) 47.9% (495) 54.8% (581) 
Persecutory delusions & hallucinations 65 POS 28.1% (591) 30.1% (311) 26.2% (280) 
Thought insertion 66 POS 11.2% (241) 16.4% (180) 5.8% (61) 
Thought broadcast 68 POS 10.2% (221) 15.5% (171) 4.7% (50) 
Third person auditory hallucinations 73 POS 24.5% (531) 29.3% (322) 19.7% (209) 
Running commentary voices 74 POS 19.5% (422) 24.1% (266) 14.7% (156) 
Abusive/accusatory/persecutory voices 75 POS 35% (732) 31.8% (329) 38.1% (403) 
Other (non-affective) auditory hallucinations 76 POS 20.6% (446) 23.3% (264) 17.2% (182) 
Non-affective hallucination in any modality 77 POS 24.8% (537) 26.7% (294) 23% (243) 
Negative formal thought disorder 29 NEG 17.5% (378) 19% (209) 16%(169) 
Restricted affect 32 NEG 31.3% (679) 36.4% (404) 25.9% (275) 
Blunted affect 33 NEG 17.7% (374) 21.9% (243) 12.3% (131) 
Bizarre behaviour 17 DIS 53.1% (1,147) 44.9% (496) 61.7% (651) 
Speech difficult to understand 26 DIS 24% (520) 20.9% (230) 27.2% (290) 
Incoherent 27 DIS 10.4% (226) 13% (13) 7.7% (82) 
Positive formal thought disorder 28 DIS 25.8% (558) 24.3% (268) 27.3% (290) 
Inappropriate affect 34 DIS 16.2% (351) 19.6% (216) 12.7% (135) 
Excessive activity 19 MAN 19.6% (426) 25.5% (283) 13.5% (143) 
Reckless activity 20 MAN 15.2% (330) 21% (233) 9.1% (97) 
Distractibility 21 MAN 37% (799) 47.4% (521) 26.3% (278) 
Reduced need for sleep 22 MAN 26.1% (565) 30.8% (340) 21.2% (225) 
Agitated activity 23 MAN 34.1% (740) 41.3% (457) 26.7% (283) 
Pressured speech 30 MAN 20.3% (440) 23% (255) 17.4% (185) 
Thoughts racing 31 MAN 21.6% (467) 33% (365) 9.7% (102) 
Elevated mood 35 MAN 18.1% (395) 20.6% (229) 15.5% (166) 
Irritable mood 36 MAN 39.4% (857) 47.7% (529) 30.7% (328) 
Increased self esteem 56 MAN 19.8% (432) 24.1% (267) 15.4% (165) 
Grandiose Delusions 57 MAN 17.4% (380) 23.3% (259) 11.3% (121) 
Slowed activity 24 DEP 16.1% (349) 23.6% (261) 8.3% (88) 
Loss of energy/tiredness 25 DEP 33.7% (729) 40.1% (444) 26.7% (285) 
Dysphoria 37 DEP 46.4% (1,009) 48.7% (540) 44% (469) 
Loss of pleasure 39 DEP 37.8% (815) 43.2% (477) 32% (338) 
Poor concentration 41 DEP 49.1% (1,061) 61% (676) 36.6% (385) 
Excessive self-reproach 42 DEP 19.4% (422) 25.8% (286) 12.8% (136) 
Suicidal ideation 43 DEP 27.9% (606) 34.2% (380) 21.3% (226) 
Initial insomnia 44 DEP 46.7% (1,005) 52.4% (576) 40.8% (429) 
Middle insomnia (broken sleep) 45 DEP 33.6% (723) 38.4% (423) 28.6% (300) 
Early morning waking 46 DEP 17.3% (372) 24.9% (274) 9.3% (98) 
Excessive sleep 47 DEP 10.6% (228) 15.2% (168) 5.7% (60) 
Poor appetite 48 DEP 34.6% (743) 37% (407) 32.1% (336) 
Weight Loss 49 DEP 22.1% (469) 29.3% (315) 14.8% (154) 
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Supplementary Tables S2.1 and S2.2 
Model fit statistics of unidimensional, multidimensional, bi-factor, and second-order models for 
different assessment methods 
 
Supplementary Table S2.1  
Item ratings based on face-to-face interviewa 
Sample size: 1,112  
Full information fit statisticsb 
 
LL AIC BIC SABIC 
A - Unidimensional Model -29965 60126 60618 60306 
B - Multidimensional Model (five uncorrelated factors) -28070 56335 56826 56515 
C - Multidimensional Model (five correlated factors) -27894 56004 56546 56202 
D - Bifactor Model (one general factor and five specific 
uncorrelated factors) -27597 55489 56226 55759 
E - Hierarchical Model (five first-order specific correlated 
factors and one second order general factor) -27995 56197 56713 56386 
LL, log-likelihood; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; SABIC 
Sample-size Adjusted Bayesian Information Criterion 
a. Only items with a valid frequency of ‘present’ ≥10% were analysed  
b. A difference of 10 in AIC, BIC and SABIC is considered important. Lower values indicate a 
statistically better model fit 
 
Supplementary Table S2.2 
Item ratings based on case note reviewa 
Sample size: 1,070  
Full information fit statisticsb 
 LL AIC BIC SABIC 
A - Unidimensional Model -23708 47595 48037 47755 
B - Multidimensional Model (five uncorrelated factors) -22239 44656 45099 44816 
C - Multidimensional Model (five correlated factors) -22159 44515 45008 44693 
D - Bifactor Model (one general factor and five specific 
uncorrelated factors) -21668 43594 44236 43826 
E - Hierarchical Model (five first-order specific correlated 
factors and one second order general factor) -22227 44640 45103 44808 
LL, log-likelihood; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; SABIC 
Sample-size Adjusted Bayesian Information Criterion 
a. Only items with a valid frequency of ‘present’ ≥10% were analysed  
b. A difference of 10 in AIC, BIC and SABIC is considered important. Lower values indicate a 
statistically better model fit 
 
 
Supplementary Table S3 




r (95% CI)b 
General 0.84 (0.82 to 0.84) 
Positive 0.9 (0.89 to 0.91) 
Negative 0.96 (0.96) 
Disorganization 0.93 (0.92 to 0.93) 
Mania 0.85 (0.84 to 0.86) 
Depression 0.96 (0.96 to 0.97) 
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a. OPCRIT simplified scores for each symptom dimension were obtained by the sum of the item 
weighted by the sign of the factor loading and divided by the number of valid items in each 
observation 
b. All p values <0.001 
 
 
Supplementary Table S4 
Latent factor scores by ICD-10 diagnosisa 
 General B (95% CI) 
Positive 
B (95% CI) 
Negative 
B (95% CI) 
Disorganization 
B (95% CI) 
Mania 
B (95% CI) 
Depression 
B (95% CI) 
ICD-10 




(-1 to -0.73) 
0.94*** 
(0.78 to 1.1) 
0.55*** 
(0.39 to 0.71) 
-0.08 













(0.71 to 1.03) 
0.7*** 
(0.39 to 1.01) 
 
-0.4** 
(-0.68 to -0.11) 
-1.14*** 
(-1.4 to -0.88) 
0.91*** 








(0.20 to 0.58) 
0.65*** 
(0.46 to 0.85) 
-0.45*** 











(-1 to -0.78) 
0.37*** 
(0.22 to 0.53) 
0.49*** 
(0.33 to 0.65) 
-0.22** 
(-0.37 to -0.11) 
-1.14*** 
-1.4 to -0.88) 
0.27*** 
(0.14 to 0.41) 
a. The analyses were controlled for gender, age, ethnicity, country, and type of assessment method 
(interview v. case records) 
 
 
Supplementary Table S5 
Latent factor scores by urbanicity within countrya,b 
 General B (95% CI) 
Positive 
B (95% CI) 
Negative 
B (95% CI) 
Disorganization 
B (95% CI) 
Mania 
B (95% CI) 
Depression 
B (95% CI) 




(-0.02 to 0.5) 
0.46** 
(0.11 to 0.8) 
0.36* 
(0.08 to 0.63) 
-0.2 
(-0.51 to 0.1) 
0.09 
(-0.22 to 0.4) 
0.14 
(-0.13 to 0.43) 
Amsterdam 




















(-0.37 to 0.17) 
Palermo 











(-0.09 to 0.27) 
-0.03 





















(-0.11 to 1.32) 
0.44 
(-0.14 to 1) 
-0.25 






















(-0.25 to 0.19) 
a. Brazil excluded from this analysis as only a single setting was part of the EU-GEI study 
b. The analyses were controlled for age, gender, ethnicity, diagnosis, and type of assessment 
(interview vs. case records) 




Supplementary Figure S1 
Path diagrams of the five theory-based models of psychopathologya 
 
                  Model A          Model B              Model C 
  
 
                                    Model D                  Model E
  
     
(▭) Observed symptoms (OPCRIT items); (Ö) Unobserved variables (latent factors); (") item loading 
on latent factors; (e) item error variance; G, general psychosis factor; Specific symptom factors: DEP, 
Depression; MAN, Mania; DIS, Disorganization; NEG, Negative; POS, Positive. OPCRIT item 
numbers are showed in Tables S1; for simplicity, only three items for each latent factor are presented 
in the diagrams. 
a. Explanatory note: Model A: unidimensional model with one unique general factor; Model B: 
multidimensional model with five uncorrelated specific factors; Model C: multidimensional model with 
five correlated specific factors; Model D: bifactor model with one general factor and five uncorrelated 
specific factors; Model E: hierarchical model with five correlated first-order specific factors and one 













Supplementary Figure S2 





a. Explanatory note: Predicted symptom dimension scores by ICD-based diagnostic categories. The 
continuous symptom dimension scores were computed using the function ‘FSCORES’ in Mplus 

























Supplementary Figures S3.1 and S3.2 
Diagnostic classification accuracy of general and specific symptom dimensions compared with a 
classification by chance 
 
Supplementary figure S3.1a,c 
 
 
Supplementary figure S3.2b,c 
 
 
Explanatory note 1: Figure S3.1 shows the density distribution (y-axis) of the subjects classified in the 
correct RDC diagnosis (x-axis) on the basis of general and specific symptom dimensions scores. 
Classification accuracy for subjects with psychopathology rating based on face-to-face interview (95% 
CI 0.54-0.63), and based on the case note review (95% CI 0.56-0.65), is compared with a 
classification by chance (95% 0.32-0.41). 
Explanatory note 2: Figure S3.2 shows the density distribution (y-axis) of the subjects allocated in the 
correct RDC diagnosis (x-axis) in United Kingdom (UK), the Netherland (NL), Spain (ES), France 
(FR), Italy (IT), and Brazil (BR). Density peaks to the right of the plot indicates a better accuracy. 
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Classification of subjects based on general and specific symptom dimensions scores was more 
accurate than a classification by chance in all the countries. 
Explanatory note 3: Multinomial ROC analysis was composed of two steps. Firstly, we ran B=100 
bootstrapped multinomial regression models, predicting RDC-based diagnoses on each of the six 
dimension scores in a random set of patients. For each model, the quota of the subjects who were 
correctly classified was determined and annotated. In a second step, we ran B=100 bootstrapped 
multinomial regression models in each random set of patients, but this time after shuffling RDC 
diagnoses prior to modelling (under the null hypothesis that symptom dimension scores had no 
prediction power). Based on kernel density estimation, we therefore obtained 1) the density 
distribution of the patients correctly allocated into the diagnostic categories based on general and 
specific symptom dimensions scores (actual diagnosis); and 2) the density distribution of the patients 
allocated into the diagnostic categories by chance (random diagnosis). Based on the difference of the 
two distributions, we may inform on the ability of general and specific symptom dimensions to 





































Chapter 5: Study 2  
 
The current paper focuses on the variation in symptom dimensions according to 
different patterns of cannabis use. The study aimed to examine whether use of 
cannabis was associated with a particular psychopathology pattern at FEP. The 
existence of a cannabis-associated symptom profile raises the question whether 
these parameters should be considered in the clinical decision-making process. 
Indeed, although cannabis use is the most preventable risk factor for psychosis, 
specific secondary prevention strategies are barely used in early intervention 
services. Table 2 reports the summary of aims and hypotheses for study 2. 
 
Table 2. Summary of aims and hypothesis for study 2 
Aims Hypothesis Grounds of the hypothesis Analytic approach 





at FEP and 
cannabis use 
The extent of lifetime 
exposure to cannabis 
is associated with 
more positive 
symptomatology at 
FEP in a dose-
response fashion 
Daily cannabis use and in 
use of high-potency 
cannabis partly explain the 
variation of psychosis 
incidence across Europe 
(Di Forti et al., 2019a). 
Experimental studies show 
that cannabis use 
exacerbates positive 






are more common in 
those who never tried 
cannabis 
Psychosis associated with 
cannabis use is 
characterised by a less 
degree of 
neurodevelopmental 
impairment (Cannon et al., 
2002a, Murray et al., 
2017b) 
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To identify latent 
factors of 
psychosis in the 
general 
population 
A bifactor solution 
accounts for the 
variance-covariance 






showing a continuous 
distribution of subclinical 
psychotic symptoms in the 
general population (van Os 



















current cannabis use 
but not with the 
lifetime extent of 
cannabis use 
Cannabis use has short-
term psychotropic effects 
in the majority of people 

































5.1 Daily use of high-potency cannabis is associated with more positive 
symptoms in first-episode psychosis patients: the EU-GEI case–control 
study 
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Abstract 
Background: Daily use of high potency cannabis has been reported to carry a high 
risk for psychotic disorder. However, the evidence is mixed on whether any pattern 
of cannabis use is associated with a particular symptomatology in first episode 
psychosis (FEP) patients. 
Method: We analysed data from 901 patients and 1235 controls recruited across six 
countries, as part of the European Network of National Schizophrenia Networks 
Studying Gene-Environment Interactions (EU-GEI) study. We used item response 
modelling to estimate two bifactor models, which included general and specific 
dimensions of psychotic symptoms in patients and psychotic experiences in controls. 
The associations between these dimensions and cannabis use were evaluated using 
linear mixed effects models analyses. 
Results: In patients, there was a linear relationship between the positive symptom 
dimension and the extent of lifetime exposure to cannabis, with daily users of high 
potency cannabis having the highest score (B=0.35; 95%CI 0.14 to 0.56). Moreover, 
negative symptoms were more common among patients who never used cannabis 
compared with those with any pattern of use (B=-0.22; 95%CI -0.37 to -0.07). In 
controls, psychotic experiences were associated with current use of cannabis but not 
with the extent of lifetime use. Neither patients nor controls presented differences in 
depressive dimension related to cannabis use. 
Conclusions: Our findings provide the first large scale evidence that first episode 
psychotic patients with a history of daily use of high potency cannabis present with 
more positive and less negative symptoms than those who never used cannabis or 
used low potency types. 
 
Keywords 






There is compelling evidence suggesting that cannabis use is associated with 
psychotic disorders (Marconi et al., 2016). However, it is unclear whether cannabis 
use is a ‘modifier’ factor for psychotic disorders, which affects symptom presentation. 
The existence of a pattern of psychotic symptomatology particularly associated with 
cannabis has been described in several case series (Walter Bromberg, 1934, Talbott 
and Teague, 1969, Spencer, 1971, Bernhardson and Gunne, 1972, Chopra and 
Smith, 1974). Nevertheless, case and cohort studies have found mixed results as to 
whether (Negrete et al., 1986, Peralta and Cuesta, 1992, Bersani et al., 2002, Green 
et al., 2004, Grech et al., 2005, Addington and Addington, 2007, Foti et al., 2010, 
Ringen et al., 2016, Seddon et al., 2016)  or not (Thornicroft et al., 1992, Stirling et al., 
2005, Dubertret et al., 2006, Boydell et al., 2007, van Dijk et al., 2012, Tosato et al., 
2013, Barrowclough et al., 2015) psychotic patients using cannabis present with more 
positive symptoms than those not using cannabis. Moreover, there is mixed evidence 
of any relationship between cannabis use and negative symptoms in psychosis. Some 
reports suggest fewer negative symptoms in psychotic patients that use cannabis 
(Peralta and Cuesta, 1992, Bersani et al., 2002, Green et al., 2004), which is 
consistent with having enough social skills to obtain the substance (Murray et al., 
2017). However, this association has not been confirmed in other studies (Grech et 
al., 2005, Seddon et al., 2016) and others even reported a positive association (Ringen 
et al., 2016). 
These inconsistencies might be explained by differences in study design and methods. 
For example, only a few findings were based on first episode psychosis (FEP) patients 
(Grech et al., 2005, Addington and Addington, 2007, Tosato et al., 2013, Seddon et 
al., 2016), which minimize selection and recall bias, and the confounding effect of 
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antipsychotic drugs on symptoms. In addition, a metanalysis of longitudinal studies 
concluded that most results lacked sufficient power to detect an effect of cannabis on 
symptoms, or inadequately controlled for potential confounders (Zammit et al., 2008). 
Furthermore, although a few studies included information on frequency of use, all 
failed to obtain detailed information on the lifetime pattern of cannabis use, especially 
on the type and strength of cannabis used. Of note, potent cannabis varieties, with 
high concentrations of Delta-9-Tetrahydrocannabinol (Δ9-THC), have been 
associated with the most harm to mental health (Di Forti et al., 2015, Freeman et al., 
2018) and, in recent years, these potent types have become more available worldwide 
(ElSohly et al., 2016, Potter et al., 2018, Freeman et al., 2019). Finally, no studies 
have used factor analysis of observed symptoms to evaluate to what extent cannabis 
use is a factor influencing the clinical heterogeneity of psychosis. 
On the other hand, in the general population there are consistent findings regarding 
the association between cannabis use and psychotic experiences (Ragazzi et al., 
2018). However, most studies had limited geographical coverage and the examined 
population was scarcely representative of the population at risk of psychosis (Ragazzi 
et al., 2018). 
In this study, we set out to clarify the association between detailed patterns of cannabis 
use and transdiagnostic symptom dimensions in a large multinational FEP sample. In 
addition, we examine the association between detailed patterns of cannabis use and 
subclinical symptom dimensions in a large sample of controls representative of the 
population at risk in each catchment area. 
Specifically, we sought to test the hypotheses that: (1) positive psychotic symptoms 
are more common among FEP patients with more frequent lifetime use of cannabis 
and greater exposure to use of high potency varieties; (2) positive psychotic 
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experiences are more common in population controls with a recent use of cannabis, 
who would be more resilient to the long-term effects of cannabis; (3) negative 
symptoms are more common among those patients who have never used cannabis. 
 
Methods 
Study design and participants 
This analysis is based on the incidence and case-control study work package of the 
EUropean network of national schizophrenia networks studying Gene-Environment 
Interactions (EU-GEI). 
FEP individuals were identified between 2010 and 2015 across six countries to 
examine incidence rates of schizophrenia and other psychotic disorders (Jongsma et 
al., 2018), and symptomatology at psychosis onset (Quattrone et al., 2019). For 
examining risk factors, we sought to perform an extensive assessment on 
approximately 1,000 FEP patients and 1,000 population-based controls during the 
same time period. 
Patients were included in the case-control study if they met the following criteria during 
the recruitment period: (a) aged between 18 and 64 years; (b) presentation with a 
clinical diagnosis for an untreated FEP, even if longstanding [International Statistical 
Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) 
codes F20-F33]; (c) resident within the catchment area. Exclusion criteria were: (a) 
previous contact with psychiatric services for psychosis; (b) psychotic symptoms 
originating from an identified organic condition; and (c) transient psychotic symptoms 
resulting from acute intoxication (ICD-10: F1x.5).  
The recruitment of controls followed a mixture of random and quota sampling methods, 
in order to achieve the best possible representativeness in age, sex, and ethnicity of 
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the population living in each catchment area. The identification process varied by site 
and was based on locally available sampling frames, including mostly the use of lists 
of all postal addresses and general practitioners’ lists from randomly selected 
surgeries. When these resources were not fully available, internet and newspapers 
advertising were used to fill quotas. Exclusion criteria for controls were: (a) diagnosis 
of a psychotic disorder; (b) ever having been treated for psychotic symptoms. 
We analysed data from eleven catchment areas, including urban and less urban 
populations (i.e. Southeast London, Cambridgeshire and Peterborough (England); 
central Amsterdam, Gouda and Voorhout (the Netherlands); Bologna municipality, city 
of Palermo (Italy); Paris [Val-de-Marne], Puy-de-Dôme (France); Madrid [Vallecas], 
Barcelona (Spain); and Ribeirão Preto (Brazil). Further information on the case-control 
sample and the recruitment strategies is included in the supplementary material. 
Measures 
Data on age, sex, and ethnicity were collected using a modified version of the Medical 
Research Council Sociodemographic Schedule (Mallett, 1997). The OPerational 
CRITeria (OPCRIT) system (McGuffin et al., 1991) was used by centrally trained 
investigators, whose reliability was assessed before and throughout the study (k=0.7), 
to assess psychopathology in the first four weeks after the onset and generate 
research-based diagnoses based on different diagnostic classification systems. The 
Community Assessment of Psychic Experiences (CAPE) (Stefanis et al., 2002) was 
administered to controls to self-report their psychotic experiences. The reliability of the 
CAPE is good for all the languages spoken in the countries forming part of the EU-
GEI study (http://cape42.homestead.com). 
A modified version of the Cannabis Experience Questionnaire (CEQEU-GEI) (Di Forti et 
al., 2009) was used by investigators to collect extensive information on the patterns of 
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use of cannabis and other drugs. We used six measures of cannabis use 
(Supplementary Table S2), including a variable measuring specific patterns of 
cannabis exposure by combining the frequency of use with the potency of cannabis. 
As illustrated in the supplementary material, the cannabis potency variable was based 
on the data published in the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) (European Monitoring Centre for Drugs and Drug Addiction, 2013, Di Forti 
et al., 2019). 
We selected confounders based on their possible association with cannabis use 
and/or symptom dimensions. These included: sex; age; ethnicity; use of stimulants, 
hallucinogens, ketamine, cocaine, crack, and novel psychoactive substances; current 
use of cigarettes (smoking 10 cigarettes or more per day=1), and current use of alcohol 
(drinking 10 alcohol units or more per week=1).  
Statistical analysis 
Dimensions of psychotic symptoms in patients and psychotic experiences in 
controls 
Data from OPCRIT and CAPE were analysed using multidimensional item response 
modelling in Mplus, version 7.4 (Muthén and Muthén, 2012), to estimate two bifactor 
models, based on the associations among observer ratings of psychotic symptoms in 
patients and self-ratings of psychotic experiences in controls. This methodology is 
described in full in our EU-GEI paper on symptom dimensions in FEP patients 
(Quattrone et al., 2019), and it was likewise applied to psychotic experiences in 
population controls. Briefly, CAPE items were dichotomized as 0 ‘absent’ or 1 
‘present’. In order to ensure sufficient covariance coverage for item response 
modelling, we used items with a valid frequency of ‘present’ ≥10% in our sample, and 
we excluded items with low correlation values (<.3) based on the examination of the 
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item correlation matrix. As in the previous analysis in patients, the bifactor solution 
was compared with other solutions (i.e., unidimensional, multidimensional, and 
hierarchical models) using Log-Likelihood (LL), Akaike Information Criterion (AIC), 
Bayesian Information Criterion (BIC), and Sample-size Adjusted BIC (SABIC) as 
model fit statistics. Path diagrams that illustrate these models are presented in 
Supplementary Figure S1. Reliability and strength indices such as McDonald’s omega 
(ω) (Rodriguez et al., 2016), omega hierarchical (ωH) (Rodriguez et al., 2016), and 
index H (Hancock and Mueller, 2001), were computed to determine: 1) the proportion 
of common variance accounted by general and specific symptom dimensions; 2) the 
proportion of reliable variance accounted by the general dimension not unduly affected 
by the specific dimensions; 3) the proportion of reliable variance accounted for by each 
specific dimension not unduly affected by the general and all the other specific 
dimensions; 4) the overall reliability and replicability of the bifactor construct of 
psychosis-like experiences. Finally, we generated factor scores for one general 
psychotic experience dimension and three specific dimensions of positive, negative, 
and depressive psychotic experiences. 
For patients, we used the previously generated factor scores for one general 
psychosis dimension and five specific dimensions of positive, negative, disorganised, 
manic, and depressive symptoms (Quattrone et al., 2019).  
Symptom dimensions and cannabis use 
We evaluated the relationship between psychotic symptom dimensions in patients, or 
psychotic experience dimensions in controls, and cannabis use using linear mixed 
effects models in STATA14 (StataCorp, 2015). We specifically modelled symptom 
dimension scores as a function of each of the six measures of cannabis use. We then 
evaluated the combined effect of frequency of use and potency of cannabis. To 
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account for the non-independence of symptom profiles of subjects assessed within 
the same country (for example, due to cultural similarities), and for the potential within-
site correlation (for example, due to context factors), we fitted a three-level mixed 
model, where the random effect encompassed two levels of random intercepts: one 
due to the countries, and another due to the sites within the countries. Finally, we used 
the Benjamini-Hochberg (B-H) procedure to reduce the false discovery rate, which we 




We analysed data from 901 FEP patients and 1,235 controls. The main socio-
demographic characteristics and history of substance misuse of patients and controls 
are presented in Supplementary Table S1. Supplementary Tables S3 and S5 show 
the sample prevalence of psychotic experiences in controls and of psychotic 
symptoms in patients. 
Bifactor model of psychotic experiences in controls 
Supplementary Table S4 shows that, as in our previous analysis of the OPCRIT items 
(Quattrone et al., 2019), the bifactor model provided the best fit for the CAPE items, 
as illustrated by AIC, BIC and SABIC substantially lower compared with competing 
models. This solution explained 60% of the unique variance. In addition, Figure 1 
shows that, within the bifactor model, the explained variance was due to individual 
differences mostly on the general psychotic experience dimension. This is illustrated 
by the relative omega coefficient, which, for example, showed that 85% of the reliable 
variance was due to the general dimension when partitioning out the variability in 
scores due to the specific dimensions. Moreover, factor loadings of moderate to high 
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magnitude were observed for most items on the general psychotic experience 
dimension, whereas factor loadings of a smaller magnitude were observed for the 
specific dimensions (Figure 1). Consistently, the index H, which is a measure of the 
construct reliability and replicability across studies (Hancock and Mueller, 2001), was 
very high for the general dimension (0.92), moderate for positive (0.78) and negative 
(0.71) dimensions and lower for the depressive dimension (0.41).  
 
Symptom dimensions in patients by pattern of cannabis use  
Models’ results are presented in Table 1.1 which shows that: 
1) There were no differences in the distribution of positive symptoms according to early 
age at first use (=<15 years old), nor, after B-H correction, according to ever or current 
use of cannabis. However, positive symptoms were more common among patients 
who spent more than 20 euros per week on cannabis (B=0.3; 95%CI 0.11 to 0.48; 
p=0.001). 
2) Fewer negative symptoms were observed among those patients who used 
cannabis at least once compared with those who never tried (B=-0.22; 95%CI -0.37 to 
-0.07; p=0.004). Early age at first use and current use of cannabis was not associated 
with negative symptomatology. 
3) Manic symptoms were more frequent among patients who had ever used cannabis 
(B=0.22; 95%CI 0.08 to 0.36; p=0.002). 
4) There were no differences in the distribution of the scores on the depressive, 





Psychotic experience dimensions in population controls by patterns of 
cannabis use 
Models’ results are presented in Table 1.2, which shows that: 
1) There were no differences in the distribution of positive psychotic experiences 
according to ever use of cannabis or early age at first use (=<15 years old). However, 
positive psychotic experiences were more commonly reported by subjects who 
currently used cannabis (B=0.33; 95%CI 0.15 to 0.51; p<0.001) and who spent more 
than 20 euros per week on cannabis (B=0.39; 95%CI 0.09 to 0.69; p=0.011).  
2) There were no differences in the distribution of the depressive and negative 
experiences in population controls according to cannabis use. 
 
Symptom dimensions by frequency of use and potency of cannabis 
The independent effects of frequency of use and potency of cannabis is reported in 
Supplementary Tables S6.1 and S6.2, and Supplementary Figure S2, showing that, 
only in patients, positive symptoms were more common in those who used cannabis 
on a daily basis and exposed to high potency varieties  
Testing the combined ‘type-frequency’ variable in patients, we found evidence of a 
linear relationship between the positive symptom dimension and the extent of 
exposure to cannabis, with daily users of high potency cannabis showing the highest 
score (B=0.35; 95%CI 0.14 to 0.56; p=0.001). Therefore, we introduced a contrast 
operator and plotted the exposure-response relationship for positive symptoms 
(Figure 2), by comparing the predictive margins of the adjusted mean of each group 
against the grand adjusted mean of all groups. Figure 2 shows that the adjusted mean 
for daily users of high potency cannabis was 0.2 units greater than the grand adjusted 
mean. Moreover, the adjusted means for the groups who never or rarely used 
cannabis were respectively 0.16 or 0.18 units lower than the grand adjusted mean. 
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A negative relationship between the negative symptom dimension score and patterns 
of cannabis use was also observed in patients. Figure 3 shows that patients with 
psychosis who never used cannabis had more negative symptoms either compared 




This is the first multinational study analysing data on the potency of the cannabis used 
by FEP patients to investigate a dose effect relationship between cannabis use and 
dimensions of symptoms, and also its effect on dimensions of psychotic experiences 
in population controls. We provide the first evidence that: 1) in patients, a positive 
correlation exists between the extent of premorbid cannabis use and the score on the 
positive symptom dimension, with daily users of high potency cannabis showing the 
most positive symptoms at FEP; 2) psychotic experiences in non-clinical populations 
are associated with current use of cannabis but are independent of the extent of 
lifetime exposure to cannabis; 3) negative symptoms at FEP are more common in 
patients who have never tried cannabis; 4) depressive symptoms are independent of 
any pattern of use of cannabis.  
Limitations 
Our findings must be considered in the context of two main limitations. First, individual 
data on patterns of cannabis use are not validated with biological samples. However, 
biological tests are not considered the gold standard method for such a validation 
(Large et al., 2012) and would not allow one to ascertain the extent of cannabis use 
over the years (Taylor et al., 2017). Moreover, studies combining self-report and 
laboratory data support the reliability of subjects in reporting the type of cannabis they 
use (Wolford et al., 1999, Freeman et al., 2014). Second, we did not take into account 
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the cannabidiol (CBD) contribution to the potency variable, as official data on its 
content in the different cannabis varieties were not available in most study sites; CBD 
might counterbalance Δ9-THC effects and minimise both psychotic experiences 
(Schubart et al., 2011) and symptoms (McGuire et al., 2018).  
Comparison with previous research 
We extend previous research on cannabis and psychotic symptoms to a multinational 
sample confirming the association between cannabis use and positive symptoms of  
FEP (Ringen et al., 2016, Seddon et al., 2016). Our results are in line with Schoeler et 
al. (2016), who carefully scrutinised the literature on the effect of continuation of 
cannabis use after FEP, concluding that this would be associated with a more severe 
positive symptomatology (Schoeler et al., 2016). That said, any comparison with 
previous research is limited by the lack of information on frequency and potency in all 
the previous studies along with subjects’ exposure to more potent varieties of cannabis 
in recent years (Potter et al., 2018). In this respect, we firstly provide some evidence 
that cannabis affects positive symptoms in a dose response manner, further 
supporting the converging epidemiological and experimental evidence that the use of 
cannabis with high content of Δ9-THC has a more detrimental effect than other 
varieties (Di Forti et al., 2009, Morrison et al., 2009, Freeman et al., 2018). 
We also report evidence in a multinational FEP sample of an association between 
lifetime cannabis use and fewer negative symptoms, the latter often considered as a 
marker of greater neurodevelopmental impairment in psychotic subjects. Two opposite 
interpretations should be discussed.  
First, some authors have suggested that people with a psychotic disorder might use 
cannabis as an attempt to self-medicate negative symptoms, and thus the observed 
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reduction in negative symptomatology would be an epiphenomenon due to the 
cannabis intake itself (Peralta and Cuesta, 1992).  
Second, psychotic disorders may be characterized by less neurodevelopmental 
features when associated with cannabis use (Ruiz-Veguilla et al., 2012, Ferraro et al., 
2013, Murray et al., 2017, Ferraro et al., 2019), hence FEP patients who do not initiate 
to use cannabis would have more negative symptoms.  
The lack of a dose dependency in our study appears to speak against the first and in 
favour of the second possibility, as the difference holds between those who never 
obtained cannabis and those who may have used it only once. Moreover, negative 
symptoms would reduce the social and instrumental skills that were necessary to 
obtain illegally cannabis and sustain its use in all the countries included in the study, 
except Holland.  
Last, we report that the cumulative exposure to cannabis does not impact on psychotic 
experiences in controls. One could of course argue that the largest proportion of 
subjects with the harmful pattern of cannabis use were patients. However, further 
research is needed to look into plausible mechanisms of resilience to the 
psychotogenic effect of cannabis as observed in our controls, who report psychotic 
experiences if current users but do not seem to accumulate a risk over life time 
cannabis use and develop psychotic disorders.  Indeed, future studies should aim to: 
1) investigate if and how genetic factors, plausibly regulating the endocannabinoid and 
dopamine systems, pose a small subset of cannabis users at high risk of developing 
a psychotic disorders with particular symptomatology; 2) clarify over the course of the 
disorder whether or not differences in symptomatology between current and former 
cannabis users may be related to residual cannabis effects. 
Implications 
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The novelty of our study is based on our examination of data on lifetime frequency of 
cannabis use and on the type of the cannabis used; high potency types are increasing 
worldwide. For instance, a recent potency study revealed that in London, the high 
potency type of cannabis called skunk has now taken up 96% of the street market 
(Potter et al., 2018). The EMCDDA has described a European cannabis market 
characterised by potent varieties (European Monitoring Centre for Drugs and Drug 
Addiction, 2013) Iike those present in Amsterdam coffee shops that can reach up to 
39% of THC. Indeed, as daily use, and use of high potency cannabis, have been 
associated both with greatest risk to develop psychotic disorders and to high rates of 
psychotic disorders across Europe (Di Forti et al., 2019), here we show that in FEP 
patients daily use of high potency cannabis drives a high score on the positive 
symptom dimension. Further research should aim to determine biological mechanisms 
underlying how cannabis impacts on different clinical manifestations of psychosis. 
Meanwhile, translating current findings into clinical practice, symptom dimension 
scores can be used to stratify patients and develop secondary prevention schemes for 
cannabis-associated psychosis.  
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Figure 1. Bifactor model of psychotic experiences in controls 
 
 
(£) Observed variables (No. of CAPE items); () Unobserved variables (latent factors); (") standardized item loading estimation onto latent factors; G, general 
psychosis-like factor; Specific psychotic experiences factors: DEP, Depression; NEG, Negative; POS, Positive. Reliability and strenght estimates: H=construct 
reliability index; ω= McDonald omega; ωH=hierarchical omega; ω/ωH= Relative omega.  
Explanatory note: McDonald‘s ω is an estimate of the proportion of the common variance accounted by general and specific symptom dimensions.(Rodriguez 
et al., 2016). Relative omega (ω/ωh) is the amount of reliable variance explained in the observed scores attributable to a) the general factor independently from 
the specific symptom dimensions, and 2) each specific symptom dimension independently from the general factor. 
H is an index of the quality of the measurement model based on the set of CAPE items for each dimension.(Hancock and Mueller, 2001) Indices can range 
from 0 to 1, with values closer to 1 indicating a better construct reliability and replicability across studies. 
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Figure 2. Positive symptom dimension in cases by patterns of cannabis use. 
 
Figure 2 shows the contrasts of the positive symptom dimension predicted mean of each group of 
patterns of use of cannabis against the predicted grand mean of all groups (represented by the red 
line). The positive value for the contrast of the daily use of high potency cannabis indicates more positive 
symptomatology in this group. On the other hand, negative values for the contrasts of the first two 
groups indicates less positive symptomatology when there is less exposure to cannabis. These 
differences are statistically significant, as indicated by 95% confidence intervals that do not overlap with 
zero. The model was a random intercept model which allowed symptoms to vary across countries and 
sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed 
















Figure 3. Negative symptom dimension in cases by patterns of cannabis use. 
 
Figure 3 shows the contrasts of the negative symptom dimension predicted mean of each group of 
patterns of use of cannabis against the grand adjusted predicted mean (represented by the red line). 
Subjects who had never used cannabis presented with more negative symptoms compared to the whole 
sample. The model was a random intercept model which allowed symptoms to vary across countries 







Table 1.1 Symptom dimensions in FEP patients by measures of cannabis usea 
Symptom dimension Ever used cannabis 
B (95% CI) 
Current use of 
cannabis 
B (95% CI) 
Age at first use of 
cannabis 
B (95% CI) 
Money used for 
cannabis 
B (95% CI) 
Positive 0.16* 
(0 to 0.31) 
0.21* 
(0.04 to 0.37) 
0.05 
(-0.13 to 0.22) 
0.3** 
(0.11 to 0.48) 
Negative -0.22** 
(-0.37 to -0.07) 
-0.09 
(-0.26 to 0.07) 
0.07 
(-0.09 to 0.22) 
0.07 
(-0.12 to 0.25) 
Depressive -0.08 
(-0.24 to 0.08) 
-0.08 
(-0.22 to 0.06) 
-0.09 
(-0.23 to 0.05) 
-0.11 
(-0.29 to 0.06) 
Disorganization -0.01 
(-0.24 to 0.03) 
0.01 
(-0.05 to 0.26) 
0.11 
(-0.06 to 0.28) 
0.1 
(-0.17 to 0.19) 
Manic 0.22** 
(0.08 to 0.36) 
0.12 
(-0.02 to 0.27) 
-0.09 
(-0.25 to 0.07) 
0.05 
(-0.11 to 0.22) 
General factor 0.05 
(-0.06 to 0.17) 
0.02 
(-0.1 to 0.14) 
-0.06 
(-0.09 to 0.22) 
0.03 
(-0.11 to 0.17) 
aAll models were adjusted for age, sex, ethnicity, use of other recreational/illicit substances, and 
diagnosis. Models were random-intercept models that included two random effects to allow 
symptomatology to vary across countries and across sites within countries but assumed that individual-
level exposure to cannabis had a fixed effect across the entire sample. 
Significance: * p < 0.05, ** p < 0.01, *** p < 0.001; associations that survived after Benjamini-Hochberg 
correction are showed in bold. 
 
 





B (95% CI) 
Current use of 
cannabis 
B (95% CI) 
Age at first use 
of cannabis 
B (95% CI) 
Money used for 
cannabis 
B (95% CI) 
Positive 0.05 
(-0.06 to 0.17) 
0.33*** 
(0.15 to 0.51) 
0.08 
(-0.11 to 0.25) 
0.39* 
(0.09 to 0.69) 
Negative  0.11 
(-0.01 to 0.24) 
0.16 
(-0.03 to 0.36) 
-0.11 
(-0.29 to 0.07) 
-0.12 
(-0.2 to 0.44) 
Depressive 0.09 
(-0.03 to 0.21) 
0.01 
(-0.19 to 0.20) 
-0.02 
(-0.21 to 0.16) 
-0.02 
(-0.3 to 0.35) 
General factor 0.04 
(-0.08 to 0.17) 
0.13 
(-0.07 to 0.33) 
0.08 
(-0.11 to 0.22) 
0.15 
(-0.18 to 0.48) 
aAll models were adjusted for age, sex, ethnicity, and use of other recreational/illicit substances. Models 
were random-intercept models that included two random effects to allow symptomatology to vary across 
countries and across sites within countries but assumed that individual-level exposure to cannabis had 
a fixed effect across the entire sample. 
Significance: * p < 0.05, ** p < 0.01, *** p < 0.001; associations that survived after Benjamini-Hochberg 









Supplementary Table S1. Socio-demographic characteristics and history of substance misuse 





Age (mean; SD) 30.8 (10.5) 36.1 (13.3) 
Sex (male %; N) 61.9 (558) 47 (581) 
 
Self-reported Ethnicity   
White (%; N) 59.05 (532) 75.22 (929) 
Black 18.65 (168) 9.55 (118) 
Mixed 11.54 (104) 9.15 (113) 
Asian 3.55 (32) 2.67 (33) 
North African 4.66 (42) 1.86 (23) 
Others 2.55 (23) 1.54 (19) 
 
Ever used cannabis   
Yes (%; N) 64.93 (585) 46.48 (574) 
Missing 1.44 (13) 1.05 (13) 
   
Current use of cannabis    
Yes (%; N) 21.64 (195) 10.61 (131) 
Missing 1.78 (16) 1.05 (13) 
   
Age at first use of cannabis   
Never Used (%; N) 33.63 (303) 52.47 (648) 
<=15 year old 27.75 (250) 13.52 (167) 
     16 year old and older 35.74 (322) 32.96 (407) 
Missing 2.89 (26) 1.05 (13) 
   
Money used for cannabis (weekly)   
From 0 to 20 euro 76.47 (689) 92.3 (1,140) 
More than 20 euro 16.1 (145) 3.16 (39) 
Missing 7.44 (67) 4.53 (56) 
   
Lifetime frequency of use   
     Never use 56.83 (512) 52.47 (648) 
     Less than daily 11.54 (104) 39.68 (490) 
     Daily 28.86 (260) 6.72 (83) 
     Missing 2.77 (25) 1.13 (14) 
   
Type of cannabis   
Never used 33.63 (303) 55.57 (648) 
Less than 10% THC 26.64 (240) 23.89 (295) 
More than 10% THC 32.63 (294) 18.06 (223) 






















   
Current tobacco use   
>10 cigarettes x day (%; N) 28.71 (262) 10.85 (134) 
Missing 3.77 (34) 1.94 (24) 
   
Current use of other drugs   
Stimulants (%; N) 




  1.05 (13) 
Hallucinogens 











Novel Psychoactive Substances 






      Missing 
2.67 (25) 
    1.6 (15) 
2 (0.16) 
    1.05 (13) 
Cocaine 
     Missing 
14.94 (140) 
    1.81 (17) 
5.83 (72) 
     1.13 (14) 
   
Current alcohol overuse   
Drinks =>10 units per week (%; N) 
      Missing 
10.88 (98) 
   11.4(103) 
12.47 (154) 
    3.24(40) 
   
Diagnosis   
Schizophrenia (%;N) 13.2 (282)  
Schizoaffective disorders 17.84 (381)  
Bipolar Disorders 2.48 (53)  
Psychotic Depression 1.92 (41)  
Unspecified Psychosis 6.74 (144)  
   
 
Supplementary table S2. Cannabis measures in the EU-GEI study 
 
Lifetime cannabis use 0=never used 1=Yes  
Currently using 
cannabis 
0=no use at the time of 
recruitment in the study 
and over the previous 4 
weeks 
1=Yes  
Age at first use of cannabis 0=started at age 16 years or 
older 
1=started at 
age 15 years 
or younger 
 
Lifetime frequency of use 0=never used 1=used less 
than daily 
2=used daily 
Money spent weekly on 
cannabis 
0=never used or spent 20 
EURO or less per week 











1Explanatory note: The potency variable was defined by a cut off of 10% of the THC concentration 
expected in the different varieties of cannabis in each catchment area, based on government and 
national data examined by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
(European Monitoring Centre for Drugs and Drug Addiction, 2013, Di Forti et al., 2019). 
Cannabis varieties classified as low potency (THC<10%) were: hash/resin from UK and Italy, imported 
herbal cannabis from UK, Italy, Spain and France, Brazilian marijuana and hash and the Dutch 
Geimporteerde Wiet.  
Cannabis varieties classified as high-potency (THC>10%) were: UK home-grown skunk/sensimilla UK 
Super Skunk, Italian home-grown skunk/sensimilla, Italian Super Skunk, the Dutch Nederwiet, 
Nederhasj and geimporteerde hasj, the Spanish and French Hashish (from Morocco), Spanish home-
grown sensimilla, French home-grown skunk/sensimilla/super-skunk and Brazilian skunk.
 
 













Do you ever feel as if people seem to drop hints about you or say things with a double 
meaning? 
2 POS 50.9% (629) 
Do you ever feel as if things in magazines or on TV were written especially for you? 5 POS 17.6% (217) 
Do you ever feel as if some people are not what they seem to be? 6 POS 74.7% (923) 
Do you ever feel as if you are being persecuted in some way? 7 POS 18.9% (233) 
Do you ever feel as if there is a conspiracy against you? 10 POS 12.4% (153) 
Do you ever feel as if you are destined to be someone very important? 11 POS 30.6% (378) 
Do you ever feel that you are a very special or unusual person? 13 POS 35.5% (438) 
Do you ever think that people can communicate telepathically? 15 POS 25.6% (316) 
Do you ever feel as if electrical devices such as computers can influence the way you think? 17 POS 11.2% (138) 
Do you belief in the power of witchcraft, voodoo or the occult? 20 POS 27.3% (337) 
Do you ever feel that people look at you oddly because of your appearance? 22 POS 34.2% (422) 
Do you ever feel as if the thoughts in your head are being taken away from you? 24 POS 3.9% (48) 
Do you ever feel as if the thoughts in your head are not your own? 26 POS 7.3% (90) 
Have your thoughts ever been so vivid that you were worried other people would hear them? 28 POS 10.6% (131) 
Do you ever hear your own thoughts being echoed back to you? 30 POS 9.1% (112) 
Do you ever feel as if you are under the control of some force or power other than yourself? 31 POS 5.3% (66) 
Do you ever hear voices when you are alone? 33 POS 6.8% (84) 
Do you ever hear voices talking to each other when you are alone? 34 POS 1.9% (23) 
Do you ever feel that you are not a very animated person? 3 NEG 44.8% (553) 
Do you ever feel that you are not much of a talker when you are conversing with other people? 4 NEG 51.8% (640) 
Do you ever feel that you experience few or no emotions at important events? 8 NEG 38.1% (470) 
Do you ever feel that you have no interest to be with other people? 16 NEG 50.2% (620) 
Do you ever feel that you are lacking in motivation to do things? 18 NEG 67.2% (830) 
Do you ever feel that you are lacking in energy? 21 NEG 70.9% (876) 
Do you ever feel that your mind is empty? 23 NEG 24.6% (304) 
Do you ever feel that you are spending all your days doing nothing? 25 NEG 42.6% (526) 
Do you ever feel that your feelings are lacking in intensity? 27 NEG 26.2% (323) 
Do you ever feel that you are lacking in spontaneity? 29 NEG 39.6% (489) 
Do you ever feel that your emotions are blunted? 32 NEG 31% (383) 
Do you ever feel that you are neglecting your appearance or personal hygiene? 35 NEG 27.3% (337) 
Do you ever feel that you can never get things done? 36 NEG 55.1% (680) 
Do you ever feel that you have only few hobbies or interests? 37 NEG 36.4% (450) 
Do you ever feel sad? 1 DEP 93.7% (1,157) 
Do you ever feel pessimistic about everything? 9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        DEP 48.8% (603)
Do you ever feel as if there is no future for you? 12 DEP 27.5% (340) 
Do you ever feel as if you do not want to live anymore? 14 DEP 24.9% (308) 
Do you ever cry about nothing? 19 DEP 34.9% (431) 
Do you ever feel guilty? 38 DEP 73.4% (907) 
Do you ever feel like a failure? 39 DEP 48.1% (594) 





Supplementary Figure S1 


















     
Explanatory note: (▭) Observed symptoms (CAPE items); (Ö) Unobserved variables (latent 
factors); (") item loading on latent factors; (e) item error variance. CAPE item numbers are 
showed in Tables S1; for simplicity, only three items for each latent factor are presented in the 
diagrams. 
Explanatory note:  Model A: unidimensional model with one unique general factor; Model B: 
multidimensional model with three uncorrelated specific factors; Model C: multidimensional model 
with three correlated specific factors; Model D: bifactor model with one general factor and three 
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uncorrelated specific factors; Model E: hierarchical model with three correlated first-order specific 
factors and one general second-order factor. 
As showed in the main text and in Table 1, the bifactor model for the CAPE (Model D) best 
reflected the dimensional structure of psychosis in population controls when compared with the 
other models. This is consistent with our previous findings on the bifactor model for the OPCRIT in 
patients (Quattrone et al., 2019). The bifactor model allows examining the variance due to each 
dimension whilst partitioning out the variance due to the common item effect of the whole 
symptomatology. Thus, in this study, we performed the best possible evaluation of the impact of 





















Supplementary Table S4. Model fit statistics of unidimensional, multidimensional, 
bifactor, second-order models for psychotic experiences and for psychotic symptoms 
 
CAPE (CONTROLS)   
Full information fit statisticsa  
LL AIC BIC SABIC 
A - Unidimensional Model -23638 47397 47715 47524 
B - Multidimensional Model (three uncorrelated 
factors) -23844 47808 48126 47936 
C - Multidimensional Model (three correlated 
factors) -23341 46808 47142 46942 
D - Bifactor Model (one general factor and three 
specific uncorrelated factors) -23139 46458 46935 46649 
E - Hierarchical Model (three first-order specific 
correlated factors and one second order 
general factor) 
-23341 46807 47135 46938 
 
OPCRIT (PATIENTS) (Quattrone et al., 2019)  
Full information fit statisticsa  
LL AIC BIC SABIC 
A - Unidimensional Model -29965 60126 60618 60306 
B - Multidimensional Model (five uncorrelated 
factors) -28070 56335 56826 56515 
C - Multidimensional Model (five correlated 
factors) -27894 56004 56546 56202 
D - Bifactor Model (one general factor and five 
specific uncorrelated factors) -27597 55489 56226 55759 
E - Hierarchical Model (five first-order specific 
correlated factors and one second order 
general factor) 
-27995 56197 56713 56386 
 
LL, log-likelihood; AIC, Akaike Information Criterion; BIC, Bayesian Information 
Criterion; SABIC Sample-size Adjusted Bayesian Information Criterion 
A difference of 10 in AIC, BIC and SABIC is considered important. Lower values 





Supplementary Table S5. Prevalence of OPCRIT symptoms in patients (Quattrone et 
al., 2019) 
OPCRIT ITEM Item no. Factor Valid frequency  
Persecutory Delusions 54 POS 71.6% (794) 
Well organised delusions 55 POS 41.6% (458) 
Delusions of influence 58 POS 24.1% (267) 




Widespread Delusions 60 POS 42.4% (437) 
Delusions of passivity 61 POS 15.2% (168) 
Primary delusional perception 62 POS 26.2% (286) 
Other primary delusions 63 POS 19.4% (213) 
Delusions & hallucinations last for one week 64 POS 47.9% (495) 
Persecutory delusions & hallucinations 65 POS 30.1% (311) 
Thought insertion 66 POS 16.4% (180) 
Thought broadcast 68 POS 15.5% (171) 
Third person auditory hallucinations 73 POS 29.3% (322) 
Running commentary voices 74 POS 24.1% (266) 
Abusive/accusatory/persecutory voices 75 POS 31.8% (329) 
Other (non-affective) auditory hallucinations 76 POS 23.3% (264) 
Non-affective hallucination in any modality 77 POS 26.7% (294) 
Negative formal thought disorder 29 NEG 19% (209) 
Restricted affect 32 NEG 36.4% (404) 
Blunted affect 33 NEG 21.9% (243) 
Bizarre behaviour 17 DIS 44.9% (496) 
Speech difficult to understand 26 DIS 20.9% (230) 
Incoherent 27 DIS 13% (13) 
Positive formal thought disorder 28 DIS 24.3% (268) 
Inappropriate affect 34 DIS 19.6% (216) 
Excessive activity 19 MAN 25.5% (283) 
Reckless activity 20 MAN 21% (233) 
Distractibility 21 MAN 47.4% (521) 
Reduced need for sleep 22 MAN 30.8% (340) 
Agitated activity 23 MAN 41.3% (457) 
Pressured speech 30 MAN 23% (255) 
Thoughts racing 31 MAN 33% (365) 
Elevated mood 35 MAN 20.6% (229) 
Irritable mood 36 MAN 47.7% (529) 
Increased self esteem 56 MAN 24.1% (267) 
Grandiose Delusions 57 MAN 23.3% (259) 
Slowed activity 24 DEP 23.6% (261) 
Loss of energy/tiredness 25 DEP 40.1% (444) 
Dysphoria 37 DEP 48.7% (540) 
Loss of pleasure 39 DEP 43.2% (477) 
Poor concentration 41 DEP 61% (676) 
Excessive self-reproach 42 DEP 25.8% (286) 
Suicidal ideation 43 DEP 34.2% (380) 
Initial insomnia 44 DEP 52.4% (576) 
Middle insomnia (broken sleep) 45 DEP 38.4% (423) 
Early morning waking 46 DEP 24.9% (274) 
Excessive sleep 47 DEP 15.2% (168) 
Poor appetite 48 DEP 37% (407) 
Weight Loss 49 DEP 29.3% (315) 
 
Supplementary Table S6.1. Symptom dimensions in patients by frequency of use and potency of cannabisa 
Model Lifetime frequency of use 
B (95% CI) 
Potency of cannabis 
B (95% CI) 
Less than daily 
(v. never used) 
Daily 
(v. never used) 
low potency 
(v. no use) 
high potency 




(-0.21 to 0.22) 
0.23** 
(0.07 to 0.39) 
0.09 
(-0.12 to 0.28) 
0.22** 




(-0.29 to 0.15) 
-0.09 
(-0.26 to 0.09) 
-0.24** 
(-0.41 to -0.06) 
-0.2* 




(-0.31 to 0.06) 
-0.1 
(-0.24 to 0.04) 
-0.13 
(-0.28 to 0.03) 
-0.13 




(0.05 to 0.47) 
0.11 
(-0.04 to 0.27) 
-0.02 
(-0.19 to 0.15) 
0.13 




(-0.17 to 0.22) 
0.13 
(-0.02 to 0.28) 
0.23** 
(0.06 to 0.39) 
0.27** 




(0.01 to 0.33) 
0.12* 
(0.01 to 0.25) 
0.06 
(-0.07 to 0.19) 
0.02 
 (-0.12 to 0.17) 
 
aAll models were adjusted for age, sex, ethnicity, current use of other recreational/illicit substances, and diagnosis. Models were 
random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within 
countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample. 


















Supplementary Table S6.2. Psychotic experience dimensions in controls by frequency of use and potency of cannabisa 
Model Lifetime frequency of use 
B (95% CI) 
Potency of cannabis 
B (95% CI) 
Less than daily 
(v. never used) 
Daily use 
(v. rare and never use) 
Low Potency 
v. no use 
High potency 




(-0.08 to 0.16) 
0.17 
(-0.05 to 0.38) 
0.08 
(-0.06 to 0.22) 
0.03 




(-0.02 to 0.24) 
0.14 
(-0.09 to 0.38) 
0.09 
(-0.05 to 0.24)  
0.12 




(-0.05 to 0.2) 
0.17 
(-0.08 to 0.4) 
0.08 
(-0.07 to 0.23) 
0.05 




(-0.1 to 0.16) 
0.13 
(-0.11 to 0.37) 
0.08 
(-0.07 to 0.23) 
-0.02 
(-0.19 to 0.15) 
 
aAll models were adjusted for age, sex, ethnicity, current use of other recreational/illicit substances. Models were random-intercept 
models that included two random effects to allow symptomatology to vary across countries and across sites within countries but 
assumed that individual-level exposure to cannabis had a fixed effect across the entire sample. 














Chapter 6: Study 3 
 
This paper uses genetic epidemiology and cannabis use data to examine the latent 
structure of psychosis. The study aimed to calculate PRSs for schizophrenia, bipolar 
disorder, and combined schizophrenia-bipolar disorder and to determine whether the 
variants conferring psychosis risk were also associated with the different expression 
of psychosis. Furthermore, the study aimed to examine whether the previously 
reported associations between cannabis use and the positive dimensions, in both 
FEP patients and controls, held when taking into account SZ-PRS. Overall, 
establishing coherence between symptom dimensions and genetic and 
environmental risk factors would confer validity to symptom dimensions as 
alternative phenotypes in the field of psychosis. Table 3 reports the summary of aims 
and hypotheses for study 3. 
 
Table 3. Summary of aims and hypothesis for study 3 
Aims Hypothesis Grounds for the hypothesis Analytic approach 
To examine the 
genetic population 






















in PRSice  
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To examine the 
relationship between 
latent factors of 
psychosis at FEP and 
PRS 
SZ PRS is 
associated with 
more negative 
symptoms at FEP 
Heritability studies show that 
negative symptoms are the most 







SZ PRS is 
associated with 
more positive 
symptoms at FEP 
SZ-PRS composite score also 
includes dopaminergic risk 
variants (Schizophrenia Working 
Group of the Psychiatric 
Genomics Consortium, 2014), 
the final common pathway 
towards experiencing positive 
symptoms (Edwards et al., 2016) 
BP PRS is 
associated with 
more manic 
symptoms at FEP 
BP-PRS would confer a modifier-
effect towards manic 
presentation at FEP (Bipolar 
Disorder Schizophrenia Working 
Group of the Psychiatric 
Genomics Consortium and 
Schizophrenia Working Group of 
the Psychiatric Genomics 
Consortium, 2018)  
To examine the 
relationship between 
latent factors of 
psychosis in the 
general population 
and PRS 





Genetic risk factors contribute to 
the continuity of psychotic 
experiences in the general 







use is associated 
with more psychotic 
symptoms and 
experiences when 











Both genes and 
environmental factors 










6.1 Schizophrenia polygenic risk score and cannabis use modify 
psychosis expression in first episode psychosis patients and population 
controls  
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Diagnostic categories within the psychosis spectrum are widely used in clinical 
practice, however psychosis may occur on a continuum. Therefore, we explored 
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whether the continuous distribution of psychotic symptoms across categories is a 
function of genetic as well as environmental risk factors, such as polygenic risk score 
(PRS) and cannabis use. 
Methods 
As part of the EU-GEI study, we genotyped first episode psychosis patients (FEP) 
and population controls, for whom transdiagnostic dimensions of psychotic 
symptoms or experiences were generated using item response bi-factor modelling. 
Linear regression was used, separately in patients and controls, to test the 
associations between these dimensions and schizophrenia (SZ) PRS, as well as the 
combined effect of SZ-PRS and cannabis use on the positive symptom/experience 
dimensions.  
Results 
SZ-PRS was associated with negative (B=0.18; 95%CI 0.03 to 0.34) and positive 
(B=0.19; 95%CI 0.03 to 0.36) symptom dimensions in 617 FEP, and with all the 
psychotic experience dimensions in 979 controls. The putative effect of SZ-PRS on 
either symptom or experience dimensions was of a small magnitude. Cannabis use 
was additionally associated with the positive dimensions both in FEP (B=0.31; 
95%CI 0.11 to 0.52) and in controls (B=0.26; 95%CI 0.06 to 0.46), independently 
from SZ-PRS. 
Conclusions 
We report two validators to the latent dimensional structure of psychosis. SZ risk 
variants and cannabis use independently map onto specific dimensions, contributing 
to variation across the psychosis continuum. Findings support the hypothesis that 
psychotic experiences have similar biological substrates as clinical disorders.  
 
Introduction 
Psychotic disorders are syndromes caused by multiple genetic and 
socioenvironmental factors (1). However, the current classification system is based 
on a ‘natural history approach’ rather than on a ‘natural classification’ (2). 
Specifically, diagnostic categories of non-affective (e.g., schizophrenia, 
schizoaffective disorders) and affective (e.g., bipolar disorder, psychotic depression) 
psychosis were developed from observed similarities and dissimilarities of signs and 
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symptoms over time, without considering biological or socio-environmental factors 
(3). Hence, the question of whether current diagnostic categories are the most valid 
phenotypes for research is still debated, due to the following methodological 
limitations. 
 
First, psychotic disorders are commonly studied as binary phenotypes (e.g., 
diagnosis yes/no), although psychotic symptoms follow a continuous distribution (4). 
Furthermore, some authorities claim that the introduction of operationalised 
classification systems in the 1970s led to the ‘death of phenomenology’ driving 
biological psychiatry to focus on the presence/absence of a diagnosis whilst 
overlooking the complex expression of psychotic phenomena (5).  
Moreover, Kraepelin’s paradigm (i.e., the neat distinction between non-affective and 
affective psychosis) has been challenged (6), though not yet replaced (3). As a 
consequence, the high comorbidity indices among psychotic disorders (7), as well as 
their high genetic correlation (8), may be an artefact of our own diagnostic 
conceptualization.  
 
To address these limitations, the use an approach based on symptom dimensions 
has been proposed (9). Consistent with this methodology, we reported that 
transdiagnostic psychopathology at first episode psychosis (FEP) can be 
represented by a general psychosis factor (G), and five specific dimensions of 
positive (POS), negative (NEG), disorganization (DIS), manic (MAN), and depressive 
(DEP) symptoms (10). Similarly, a model composed of general and specific 
experience dimensions has been proposed to measure subclinical psychosis in the 
general population (11, 12). These conceptualizations statistically reflect a ‘bi-factor 
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model’, where the general and specific dimensions account, respectively, for the 
unidimensional and multidimensional nature of the latent psychosis construct (13, 
14). We have previously advocated that such structures should be validated by the 
degree to which biological and environmental factors cohere with general and 
specific symptom dimensions (10). Indeed, according to the coherence theory of 
truth, psychiatric constructs can be approximated as true if they are well connected 
and integrated into our accumulated scientific evidence (15). 
  
Thus, we recently found evidence that cannabis-associated psychopathology at 
psychosis onset is characterised by high POS scores and low NEG scores (16). 
In relation to biological factors, symptom dimensions have been investigated in 
family, twin and adoption studies (17-22), overall showing that NEG or DIS 
symptoms had higher familial aggregation than other symptom dimensions. 
In recent years the availability of summary statistics from large genome-wide 
association studies (GWAS) across psychiatric phenotypes has allowed researchers 
to test in independent samples how the genetic liability to a disorder predicts any 
other traits (23). Genetic liability is commonly summarised into a polygenic risk score 
(PRS) (24), however, only a few studies to date have investigated the relation 
between SZ-PRS and psychotic symptom dimensions (25). In patients, an 
association between SZ-PRS and NEG (or DIS) symptoms was found in several SZ 
studies (26-28) and in Psychiatric Genomics Consortium (PGC) large mega-
analyses (29, 30). However, other studies have not found the same pattern of 
associations (31, 32), and only one study reported that SZ-PRS correlated with POS 
symptoms (28). Interestingly, in the general population an association was observed 
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between SZ-PRS and either NEG (12, 33) or POS psychotic experiences (34-36); 
however, negative findings have also been reported (37). 
 
The inconsistency across studies could be explained by differences in study design, 
methods, and GWAS power. Of note, only one small study examined a FEP sample 
(38), in which confounding effects of antipsychotic drugs on symptoms are minimised 
and a common comparable time point in the course of illness is used. In addition, 
most studies have not performed factor analysis of observed symptoms to measure 
and validate latent constructs. Finally, no studies have applied summary statistics 
from recent PGC GWAS investigating similarities and dissimilarities between SZ and 
BP (29). 
 
We have previously reported findings from bi-factor models of 1) psychotic 
symptoms in a multinational FEP sample (10) and 2) psychotic experiences in 
controls representative of the population at risk in each catchment area (11). In the 
current study, we aimed to investigate the association between these phenotypes 
and genetic loading for SZ and BP, as summarised by i) SZ-PRS, ii) BP-PRS, iii) 
combined SZ & BP- PRS. We further explored whether the previously reported 
association of cannabis use with the POS dimensions (16) holds when taking into 
account SZ-PRS.  
Based on an a priori synopsis, we hypothesized that SZ-PRS would be positively 
associated with the NEG dimension in FEP patients, and with the POS dimensions in 
both FEP patients and the general population. Furthermore, we hypothesized a 
cumulative effect of cannabis use on POS dimensions independent of SZ-PRS. 
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Finally, we expected in FEP, an association between BP-PRS and the MAN 
symptom dimension, and between the combined SZ & BP- PRS and the G factor. 
 
Methods and Materials 
Sample design and procedures 
FEP patients and population controls were recruited as part of the EUropean 
network of national schizophrenia networks studying Gene-Environment Interactions 
(EU-GEI). FEP patients were identified between 2010 and 2015 across six countries 
to examine incidence rates of psychotic disorders and patterns of symptomatology 
(10, 39). For examining biological and environmental risk factors, DNA samples were 
collected, and an extensive face-to-face assessment was conducted on 1,130 FEP 
and 1,497 controls, broadly representative of the population living in each catchment 
area by age, sex and ethnic group. All participants provided informed, written 
consent. Ethical approval was provided from local research ethics committees in 
each catchment area: South London and Maudsley and Institute of Psychiatry 
Research Ethics Committee; National Research Ethics Service Committee East of 
England–East Cambridge; Medisch-Ethische Toetsingscommissie van het 
Academisch Centrum te Amsterdam; Comité Ético de Investigación Clínica Hospital 
Gregorio Marañón; Comité Ético de Investigación Clínica del Hospital Clinic de 
Barcelona; Comité Ético de Investigación Clínica del Hospital Clinic Universitari de 
Valencia; Comité Ética de la Investigación Clínica del Principado de Asturias; Comité 
Ético de Investigación Clínica de Galicia; Comité Ético de Investigación Clínica del 
Hospital Virgen de la Luz de Cuenca; Comité de Protéction des Personnes–CPP Île 
de France IX; Comitato Etico Policlinico S Orsola Malpighi; Comitato Etico Azienda 
Ospedaleria Universitaria di Verona; Comitato Etico Palermo 1, Azienda Ospedaliera 
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Policlinico “Paolo Giaccone”; and Research Ethics Committee of the clinical Hospital 
of Ribeirão Preto Medical School, University of São Paulo, Brazil.  More information 
on recruitment strategies is available in earlier EU-GEI incidence and case-control 
papers (39, 40).  
 
Measures 
Data on age, sex, and ethnicity were collected using a modified version of the 
Medical Research Council Sociodemographic Schedule (41). 
The OPerational CRITeria (OPCRIT) system (42) was used by centrally trained 
investigators, whose reliability was assessed before and throughout the study 
(k=0.7), to assess psychopathology experienced in the first four weeks after FEP 
and define research-based diagnoses. Moreover, psychopathology assessment 
included the use of the Schedule for Deficit Syndrome (SDS) (43) to evaluate NEG 
symptoms, which are not extensively covered by the OPCRIT.  
The Community Assessment of Psychic Experiences (CAPE) (44) was administered 
to population controls to report their positive, negative, and depressive psychotic 
experiences. 
A modified version of the Cannabis Experience Questionnaire (CEQEU-GEI) (45) was 
used to collect extensive information on patterns of cannabis use.  
 
Dimensions of psychotic symptoms and experiences 
 
Data from OPCRIT and CAPE were analysed using item response modelling in 
Mplus, version 7.4, to estimate two bifactor models of psychopathology, based on 
the associations among observer ratings of psychotic symptoms in patients or self-
rating of psychotic experiences in controls (Supplementary Figures S1 and S2). This 
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methodology is described in full in earlier EU-GEI papers on transdiagnostic 
dimensions (10, 11). Briefly, OPCRIT and CAPE items were dichotomized as 0 
‘absent’ or 1 ‘present’, and two different bi-factor models were estimated for patients 
and controls. Bi-factor solutions were compared with three competitive solutions (i.e., 
unidimensional, multidimensional, hierarchical models of psychosis) using, as model 
fit statistics, Log-Likelihood (LL), Akaike Information Criterion (AIC), Bayesian 
Information Criterion (BIC), and Sample-size Adjusted BIC (SABIC). McDonald’s 
omega (ω) (46), omega hierarchical (ωH) (46), and index H (47), were used as 
reliability and strength indices.  
Data from SDS were analysed in Mplus, version 7.4, following the same procedure 
as described above. We did not estimate a bi-factor model for SDS due to lack of 
rationale for a G factor of negative symptoms. Instead, based on the structure of the 
NEG construct (48) and previous factor analysis studies on SDS (49), we estimated 
a multidimensional model of NEG symptoms composed of the two specific 
dimensions of 1) ‘avolition’ and 2) (lack of) ‘emotional expressivity’. We considered 
‘emotional expressivity’ as the most genuine phenotypic expression of primary 
negative symptoms for subsequent analysis, as the behavioural manifestation of 
‘avolition’ may partly overlap with depressive symptoms in a FEP sample. SDS was 
not administered in one of the study sites, Verona, which was therefore not included 
in the analysis of NEG symptoms. 
 
Genotype procedure 
The EU-GEI case-control sample was genotyped at the MRC Centre for 
Neuropsychiatric Genetics and Genomics in Cardiff (UK) using a custom Illumina 
HumanCoreExome-24 BeadChip genotyping array covering 570,038 genetic 
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variants. Imputation was performed in the Michigan Imputation Server, using the 
Haplotype Reference Consortium reference panel, with Eagle software for estimating 
haplotype phase, and Minimac3 for genotype imputation (50-52). The imputed best-
guess genotype was used for the present analysis.  
 
Population stratification and polygenic risk score calculation 
We performed a two-step procedure to account for the multi-ethnic nature of the 
sample (reported in full in the supplementary material), by excluding populations in 
our sample of very different ancestry from external GWAS data. Briefly, as a first 
step, we identified in our sample ancestry clusters of individuals through iterative 
pruning of principal component analysis (ipPCA) of single nucleotide polymorphisms 
(SNPs), and we tested for each cluster whether PRS discriminated cases from 
controls. As a second step, we merged these clusters (based on whether PRS had 
discriminative value), removed long-range genome regions with complex linkage 
disequilibrium (LD) patterns, recalculated main Principal Components (PCs), and 
finally constructed main PRSs using PRSice (53). Specifically, individuals’ risk 
variants were weighted by the log(odds ratio), where the odds ratio was extracted 
from the latest summary statistics of SZ and BP PGC mega-analyses (29, 54, 55), 
which did not include any EU-GEI sample. Logistic regression was then applied to 
predict case status from SZ- and BP-PRS, after covarying for 10 PCs, sex, age, and 
primary diagnosis. Nagelkerke's R2 was used as a measure of the difference in 
variance between the full-model versus a model with the covariates alone, at the 
SNPs p-value threshold (PT)=0.05 (selected a priori as it maximised the explained 
variance in case status in the PGC studies (54, 55)). 
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Relationship between symptom dimensions, polygenic risk scores, and cannabis use 
We tested for associations between PRSs and the scores on transdiagnostic 
dimensions of psychotic symptoms/experiences, separately in FEP and controls, 
using linear regression. 
Specifically, in FEP we tested for association between all symptom dimensions and 
the three PRSs. In controls, we tested for association between all psychotic 
experience dimensions and SZ-PRS; we did not test BP-related PRSs since 
(hypo)manic experiences were not rated in our controls. 
Moreover, we used predicted values of SZ-PRS after regression of case/control 
status, to illustrate the continuous distribution of SZ-PRS in our sample according to 
quartiles of positive psychotic experience and symptoms.  
To examine the combined associations of cannabis use and SZ-PRS with POS 
dimensions, we selected the two variables on pattern of cannabis use previously 
associated with POS (11), i.e., ‘lifetime daily use’ in patients and ‘current use’ in 
controls. We first checked for correlation with SZ-PRS, and subsequently we added 
the two cannabis terms to the models. 
All analyses were adjusted for sex, gender, 10 ancestry principal components, study 
site, and diagnostic category. Given the high number of outcomes (six dimensions in 
patients, four in controls) and predictors (PRSs and cannabis use), and the number 
of hypotheses (four in patients, one in controls), we controlled the false discovery 
rate using the Benjamini and Hochberg procedure (56), tolerating a 10% false 
discovery rate (q=0.10). Furthermore, as a sensitivity measure, in PRSice we tested 
whether the main effect of PRSs on dimensions held at other PT and ran a 
permutation analysis to further control the familywise error rate, by repeating the 
PRSice procedure shuffling the phenotype 5,000 times to obtain an empirical 
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distribution of the p-value at the best PT. Finally, we used AVENGEME (Additive 
Variance Explained and Number of Genetic Effects Method of Estimation) to further 
evaluate the consistency of the effect directions across different PT and compute the 
genetic covariance (σ12) between our symptom dimensions and the PGC GWAS 
data (57).  
 
Results 
Main PCs and PRS computation 
Population stratification findings are presented in the supplement material. Based on 
the case-control discriminative value of SZ- and BP-PRS in each population cluster, 
we merged 1,596 individuals (617 FEP and 979 population controls) for SZ-PRS 
analyses, and 505 FEP for BP-PRS analysis only. The ability of SZ and BP PRSs to 
distinguish cases from controls in the main sample is presented in Figure 1, showing 
that at PT=0.05, SZ-PRS accounted for a Nagelkerke's R2 of 0.09 (p=6.9x10-26); and 
BP-PRS for a Nagelkerke's R2 of 0.02 (p=5x10-6). 
 
Psychotic symptom dimensions by PRS in patients 
Findings on symptom dimensions in cases by SZ-, BP-, and SZ & BP- PRSs at 
PT=0.05 are shown in Table 1 and Figure 1. As expected in PRS cross-trait 
predictions (23), the magnitude of the SNPs effect was small for all the associations 
detected. Specifically, SZ-PRS was associated with a high score for both the positive 
(B=0.19, 95% CI 0.03 to 0.35; Nagelkerke's R2 =0.009, p=0.019) and negative 
(B=0.18, 95% CI 0.03 to 0.33; Nagelkerke's R2 =0.01, p=0.021) symptom 
dimensions. Moreover, we found no nominal association between  BP-PRS and the 
MAN symptom dimension (B=0.09, 95% CI -0.01 to 0.19; Nagelkerke's R2 =0.008, 
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p=0.055); and between SZ & BP- PRS and the G factor (B=0.06, 95%CI -0.05 to 
0.16; p=0.158). 
Sensitivity analysis showed that the pattern of associations between SZ-PRS with 
either POS or NEG symptom dimensions was consistently observed across all PT 
and remained relevant even after permutation analysis (Figure S7 – supplement, 
showing empirical p-values of 0.007 for POS; and of 0.055 for NEG). Furthermore, a 
positive genetic covariance was observed between both NEG and PGC SZ GWAS 
[σ12=0.56 (95%CI 0.39 to 0.76)] and POS and PGC SZ GWAS [σ12=0.51 (95%CI 
0.35 to 0.69)].  
Finally, the violin plots presented in Figure 2 illustrate the kernel distribution of 
predicted value of SZ-PRS across individual quartiles of positive psychotic 
symptoms. 
 
Psychotic experience dimensions by SZ-PRS in controls 
A positive association between SZ-PRS with a higher score at all psychotic 
experience dimensions was found (Table 2). Sensitivity analysis showed that the 
association between SZ-PRS with POS psychotic experiences was consistent 
across different PT and remained relevant after permutation analysis (Figure S8 – 
supplement, showing an empirical P-value = 0.003). The kernel distribution of 
predicted value of SZ-PRS according to individual quartiles of psychotic experiences 
in controls is reported in Figure 3. 
 
POS symptom dimensions by PRS and cannabis use in patients and controls 
Daily cannabis use (B=0.31; 95%CI 0.11 to 0.52; p=0.002) and SZ-PRS (B=0.22; 
95%CI 0.04 to 0.39; p=0.014) were independently associated with POS symptoms in 
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patients, and this joint model improved fit over a model with SZ-PRS alone (LR 
chi2(1)=6.10, p = 0.01).  
Similar results were found for POS psychotic experiences in controls, with main 
effects of current use of cannabis (B=0.26, 95%CI 0.06 to 0.46; p=0.011) and SZ-
PRS (B=0.13, 95%CI 0.02 to 0.25; p=0.022) (Figure 4), and with an improvement of 




This is the first study to investigate the combined effect of SZ-PRS and cannabis use 
on psychosis dimensions. We found that these two factors, independently from each 
other, are associated with more clinical and sub-clinical POS symptoms in both FEP 
patients and controls. Moreover, we found a relationship between SZ-PRS and more 
NEG symptoms and experiences. Finally, we did not find in our sample an 
association between BP-PRS and MAN symptoms; or between the combined SZ & 
BP- PRS and the G factor.  
Our findings provide first evidence that in patients and controls, the latent structure of 
psychosis, as generated using a statistically guided approach, is valid and coheres 
with both SZ risk variants and cannabis use. However, any further interpretation on 
the applicability of these findings should take into account the small magnitude of all 
the detected associations. 
 
Comparison with previous research  
Our findings extend those from previous research on the validity of psychosis 
symptom dimensions by ascertaining their coherence with genetic factors and 
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cannabis use. First, under the hypothesis that psychosis symptom presentation is 
partly a function of SZ genetic liability, we reported an association between SZ-PRS 
and both POS and NEG symptom dimensions. This in line with a meta-analysis 
suggesting that different SZ risk loci impact on SZ clinical heterogeneity, e.g. genes 
related to immune system might be overrepresented for NEG, and genes related to 
addiction and dopamine-synapses might be overrepresented for POS (58).  
Familial co-aggregation of NEG symptoms was reported in the Danish adoption 
study (19), in the Roscommon family study (59), in the Maudsley twin series studies 
(18). Genome-wide suggestive linkages with an effect on NEG symptoms have also 
been reported, although without reaching a significance threshold (60, 61). GWAS 
and PRS examinations provide good evidence of a polygenic signal for NEG (26-30). 
Altogether, these studies provide converging evidence that NEG has substantive 
heritability at least partly due to cumulative schizophrenia risk loci. The DIS 
dimension has also been reported as having high heritability in some studies (20), 
but we found no evidence of its association with SZ-PRS in our FEP sample, and we 
could not examine this latent construct in our controls. Speculatively, it is possible 
that DIS symptom differ in their lifetime v. FEP prevalence, or that genetic loci 
influencing DIS are different from those carrying SZ risk (20). 
 
Second, our results on the relationship between SZ-PRS and POS are intriguing but 
less consistent with previous literature. Possible familial co-aggregation of POS 
symptoms was rarely reported (62, 63). However, a previous study observed that BP 
patients with higher SZ-PRS presented with more mood-incongruent POS symptoms 
(64), which suggests SZ-PRS has a POS modifier effect. Nevertheless, this was not 
confirmed by meta-analysis of PGC and GPC samples (30, 65). We may consider in 
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interpreting our data, that the EU-GEI sample included FEP patients only, hence 
symptomatology rating was not confounded by antipsychotic treatment; whereas 
PGC and GPC samples are most chronic schizophrenia samples, where the 
enduring antipsychotic treatment can attenuate POS symptoms and increase NEG 
symptoms  (i.e., secondary NEG symptoms). Moreover, various environmental 
factors impacting at different levels on dopaminergic activity makes it difficult to 
disentangle the risk variants contribution to POS symptoms over the course of SZ.  
From this perspective, we extend previous evidence that use of cannabis is 
associated with more POS symptomatology at FEP (11, 66), clarifying that this 
association is independent from SZ genetic risk loading.  
 
Third, unlike our hypothesis and larger studies (29, 67), we did not report an 
association between BP-PRS and MAN. This may suggest that our sample is too 




Fourth, we replicated in our controls the same patterns of associations as in cases 
between SZ-PRS and dimensions, but in the form of sub-clinical psychosis. Further, 
we provide novel evidence that SZ-PRS and current cannabis use are both 
associated with more POS psychotic experiences. It has been debated whether sub-
clinical psychotic symptoms have an etiological overlap with full-blown psychosis. 
Our findings support the evidence that SZ-PRS correlates with psychotic 
experiences (35), which in adults may be reflecting similarities with biological SZ risk 
factors (35). Moreover, a few SNPs reaching genome-wide significance have been 
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recently identified for psychotic experiences, for example in CNR2, coding for the 
cannabinoid receptor type 2 (68). This suggests that further studies are needed to 
clarify the relationship between patterns of cannabis use and sets of genes 
potentially enhancing its psychotropic effects (69). 
 
Finally, to our knowledge this is the first study examining SZ & BP- PRS and G factor 
in psychotic disorders, under the hypothesis they have a positive correlation. We 
report a negative finding which may be explained by G not properly reflecting general 
psychopathology in our FEP sample. On other hand, the G factor of psychotic 
experiences in controls well correlated with SZ genetic liability. 
 
Limitations 
The following limitations suggest exercising caution when interpreting our findings. 
1) We performed extensive work for defining the fine-scale population structure in a 
multi-ethnic sample. Certainly, having a sample of individuals from a single 
homogenous population would have improved the quality of the analysis, however 
our study has the advantage of being more representative of the real clinical 
practice. Most important, we included as far as possible population clusters not 
located in Europe but still suitable for PRS analyses, which is in line with a more 
general aim of not contributing to healthy disparities (70). 
2) Regarding symptom ratings in patients, we used symptom dimensions from two 
different scales, i.e. NEG from SDS, and the other symptom dimensions from 
OPCRIT. In the EU-GEI study, negative symptoms were rated through the 
administration of SDS; moreover, exploratory factor analyses of OPCRIT in other 
samples showed that a hybrid DIS/NEG dimension was often obtained rather than 
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discrete NEG and DIS dimensions (30, 71). Of note, our preliminary analysis of 
SZ-PRS and NEG using OPCRIT showed no nominal association (72), due, 
possibly, to the scarce item covariance coverage, acknowledged as a limitation in 
our earlier paper on symptom dimensions (10). 
3) Regarding the bifactor solutions, G may be difficult to interpret and possibly 
overfits the data (73). Nevertheless, in our model, G improves the measurement 
of specific dimensions by making their score not unduly affected by the all-item 
covariance (10). Moreover, based on the strength of item factor loadings in our 
sample, G could be interpreted: 1) in patients, as combined manic-delusional 
symptomatology (10); 2) in controls, as a combined measure of all types of 
psychotic experiences (11). 
4) We did not validate self-reported information on current use of cannabis with 
biological samples. However, this method does not allow ascertaining lifetime 
patterns of cannabis use (40) and is not considered a gold standard method (74). 
Moreover, it has been shown that self-report information on cannabis use is 
consistent with laboratory data (75). 
5) We did not use a PRS based on GWAS of symptom dimensions, as this is 
currently unavailable. It is noteworthy that, genes conferring risk to a disorder 
(‘risk genes’) may not overlap with genes modifying symptom presentation 
(‘modifier genes’) (76), although it is hypothesised that there are genes with a 
mixed effect (58). Thus, our study answers the question whether the genetic 
liability for psychotic disorder explains variance of some phenotypic traits, without 
accounting for other possible genetic sources of that variance (i.e., the 




Most clinical and research psychiatrists still embrace Kraepelin’s nosology in the field 
of psychosis, despite the fact that for a century concerns have been raised related to 
the absence of converging validators to distinguish non-affective and affective 
psychotic disorders (77). We report two classes of external validators of 
transdiagnostic symptom dimensions, such as SZ-PRS and cannabis use. It should 
be born in mind that pharmacological and psychological interventions, as well as 
cannabis cessation and all secondary prevention strategies target particular 
symptoms more than the general diagnosis. Hence, our findings support the concept 
of a psychosis continuum 
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Table 1. Symptom dimension scores by PRSs in cases 
 
Generala 
B (95% CI) 
Positivea 
B (95% CI) 
Negativeb 
B (95% CI) 
Disorganizationa 
B (95% CI) 
Maniaa 
B (95% CI) 
Depressiona 




(-0.09 to 0.18) 
p=0.528 
0.19 
(0.03 to 0.35) 
p=0.021*† 
0.16 
(0.1 to 0.3) 
p=0.019*† 
-0.01 
(-0.16 to 0.14) 
p=0.928 
0.06 
(-0.07 to 0.2) 
p=0.378 
-0.06 
(-0.2 to 0.07) 
p=0.350 
BP PRS 0.06 0.05 -0.005 0.01 0.09 -0.01 
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model (-0.03 to 0.15) 
p=0.175 
(-0.06 to 0.17) 
p=0.341 
(-0.09 to 0.08) 
p=0.915 
(-0.1 to 0.1) 
p=0.976 
(-0.01 to 0.19) 
p=0.055 
(-0.1 to 0.08) 
p=0.938 
Explanatory note. B, Unstandardized regression coefficient; CI, confidence interval. Covariates in 
multiple models were sex, age, ten ancestry PCs, and categorical diagnosis. 
a. Symptom dimension scores from OPCRIT factor analysis. 
b. Symptom dimension scores from SDS factor analysis. 
Associations nominally significant after permutation analysis are showed in bold 
*P-values nominally significant after Benjamini-Hochberg procedure at FDR threshold = 0.1 
(†Benjamini-Hochberg P-value: 0.056) 
 
 
Table 2. Psychotic experience dimension scores by SZ-PRS in controls 
Explanatory note. B, Unstandardized regression coefficient; CI, confidence interval. Covariates in 
multiple models were sex, age, and ten ancestry PCs. 
a. Psychotic experience dimension scores from CAPE factor analysis 
Associations nominally significant after permutation analysis are showed in bold 
*P-values nominally significant after Benjamini-Hochberg procedure at FDR threshold = 0.1 





















B (95% CI) 
Positivea 
B (95% CI) 
Negativea 
B (95% CI) 
Depressiona 




(0.02 to 0.24) 
p=0.003*†† 
0.14† 
(0.03 to 0.26) 
p=0.016*† 
0.18†† 
(0.05 to 0.3) 
p=0.005*† 
0.15† 
(0.03 to 0.27) 
p=0.012*†† 
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Figure 1 - SZ-PRS and BP-PRS by FEP-control status 
The bar plot shows the variance in case-control status (y-axis) explained by SZ-PRS 

















Figure 2 - SZ- PRS, BP- PRS, and SZ & BP- PRS by symptom dimensions in 
FEP 
The bar plot shows the variance (y-axis, Nagelkerke's R2) explained by the different 


















Figure 3 – Distribution of SZ-PRS according to quantiles of psychosis in the general population and separately in FEP patients  
The violin plots show the distribution of SZ-PRS in the EU-GEI sample by individuals classified according to their score at POS experience dimension and 
symptom dimensions, separately in population controls (left side) and FEP patients (right side) at different quantiles.  
In controls: (1) 0-25% psychotic experiences; (2) 25-75% psychotic experiences; and (3) 75-100% psychotic experiences.  
In FEP: (4) 0-25% psychotic symptoms; (5) 25-75% psychotic symptoms; and (6) 75-100% psychotic symptoms.  
Explanatory note: Interquartile range, 95% confidence interval, median and mean are illustrated within the bars. On each side of the bars is represented a 
kernel density estimation to show the distribution shape of the data. 
Dots indicate current cannabis use in controls and daily cannabis use in patients (red=no; green=yes) 
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Figure 4 – POS dimensions by SZ-PRS and cannabis use in controls 
The graph presents the predicted POS symptom dimension scores at two different covariate values 
(cannabis use yes/no), holding SZ-PRS at 25th, 50th, and 75th percentiles. Predicted values were 















6.2 Study 3, supplementary material  
 
TABLE S1 















 Mean (SD) 32.8 (11.7) 34.4 (12.3) t(2,2623)=2.8; p<0.005 
 
Gender 
 Male 292 (46.3) 932 (46.7) χ2(1)=0.03; p=0.85 
 
Self-reported Ethnicity 
 White 420 (66.6) 1,473 (73.8) χ2(5)=13.5; p<0.05 
 Black 92 (14.6) 212 (10.6)  
 Mixed 62 (9.8) 164 (8.2)  
 Asian 18 (2.9) 50 (2.5)  
 North African 21 (3.3) 55 (2.8)  
 Other 18 (2.8) 41 (2.1)  
Research Domain Criteria Diagnosis (case only sample) 





18 (5.9) 32 (4)  








48 (17.65) 131 (16.2)  







TABLE S2  
Sociodemographic and clinical differences between individuals providing buccal or blood sample1 
Case-control genotyped 











 Mean (SD) 34.7 (12.4) 32.5 (11.4) t(2,1992)=2.8; p<0.005 
 
Gender 
 Male 152 (53.7) 912 (51) χ2(1)=0.74; p=0.38 
 
Self-reported Ethnicity 
 White 420 (66.6) 1,473 (73.8) χ2(5)=13.5; p<0.05 
 Black 92 (14.6) 212 (10.6)  
 Mixed 62 (9.8) 164 (8.2)  
 Asian 18 (2.9) 50 (2.5)  
 North African 21 (3.3) 55 (2.8)  
 Other 18 (2.8) 41 (2.1)  
Research Domain Criteria Diagnosis (case only sample) 





1 (0.9) 31 (4.5)  








12 (10.3) 119 (17.2)  














Figure S2 - Bifactor model of psychotic experiences in population controls  
based on CAPE items (2) 
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Explanatory note: Multidimensional model of negative symptoms 
SDS was administered in all EU-GEI study sites with the exception of Verona, which 
was therefore excluded from SDS factor analysis and subsequent analysis on PRSs 
and negative symptoms. Item response modelling showed that the six SDS items had 
strong factor loading into the social avolition and lack of emotional expressivity 
dimensions. This is illustrated by the high reliability index H (Figure S3) (3). We 
therefore retained the multidimensional model of SDS for the present analysis, using 
the score at the emotional expressivity dimension as a measure of NEG symptoms in 
FEP patients.  
 
Figure S3 – Multidimensional model of primary negative symptoms at FEP 
based on SDS items 
 
(£) Observed variables (SDS items); () Unobserved variables (latent factors); (") 
standardized item loading estimation onto latent factors; soc, avolition factor (e.g., 
active social withdrawal); exp, emotional expressivity factor. SDS items: CI, curbing 
of interests; DSP, diminished sense of purpose; DSD, diminished social drive; RA, 
restricted affect; DER, diminished emotional range; PS, poverty of speech. 
H=construct reliability index; H is an index of the quality of the measurement model 
based on the loading of SDS items into each dimension (3). Indices can range from 









Explanatory note: Population structure and PRSs calculation 
Supplementary methods 
We applied a two-step procedure to account for the multi-ethnic structure of the EU-
GEI sample, as follows: 
1) Determination of the fine population structure using iterative pruning 
Unsupervised clustering based on iterative pruning of single nucleotide 
polymorphisms (SNPs) was used in R, using the ‘IPCAPS’ package (4), to capture 
the fine-scale population structure. This method involves repetitive splits based on 
multivariate Gaussian mixture modelling of principal components (PCs). Unlike 
admixture profiling procedures, we did not make assumptions on the population 
ancestry in our sample, so the algorithm freely assigned individuals to population on 
nested datasets until no further population substructure was identified, by regulating 
the fixation index (FST) at 0.008, which is the common measure of the genetic 
distance between populations (4).  
1b) Computation of cluster-specific principal components and PRSs 
Genotype pre-processing steps were repeated for each identified population cluster, 
based on the assumption that allele frequencies vary across populations. 
Specifically, using plink 1.9, in each sub-population we excluded SNPs with minor 
allele frequency (MAF) <0.05%, Hardy Weinberg Equilibrium p<10-6, missingness 
>2%, and subjects with heterozygosity Fhet >0.14 or <-0.11 or relatedness >0.1. 
Within each population cluster, we built ancestry principal components and SZ and 
BP PRSs, with the aim to examine the predictive value of cluster-specific PRS and 
identify the suitable main sample for subsequent analysis.  
2) Computation of main principal components and PRSs across populations 
For constructing main PCs in the final sample, we pre-processed SNPs by using 
clumping which retains the ‘index’ SNP for each linkage disequilibrium (LD) region 
(i.e., the SNP with the highest MAF), using the R packages ‘bigsnpr’ and ‘bigstatsr’ 
(5). Further, LD pattern differs by population, due to biological events such as, for 
example, inversion polymorphism (6). Thus, to ensure that main PCs did not capture 
mostly the variance due to differences in long-range genome regions with complex 
LD patterns, we ran an iterative algorithm to identify and remove these regions within 
our sample, using the (5). 
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Finally, we repeated the PRSice procedure in the main sample and constructed SZ-
PRS, BP-PRS, SZ & BP- PRS, and SZ v. BP- PRS, using PGC GWAS as training 
sets (7-9).  
Given that, in this sample, controls are representative of the general population and 
they are not matched with cases, two sensitivity analyses were performed to verify 
that case-control PRS prediction was not affected by differences in case-control 
ancestry distribution. First cases and controls were plotted in the PCA 
multidimensional space, within and across population nodes, in order to exclude 
systematic differences in their distribution at the visual inspection. Second, controls 
were formally matched with cases by sex and age-range within population nodes, in 




Sample and Genotype Quality Control (QC) 
We recruited 1,130 FEP case participants and 1,497 control participants, who were 
assessed face-to-face. We successfully genotyped 72.7% of FEP (N=822, source of 
sample: 85.6% blood and 14.4% saliva) and 78.4% of controls (N=1,174, source of 
sample: 84.7% blood and 15.3% saliva). After imputation, 8,277,535 variants with 
info score > 0.6 were identified. Genotyped individuals were more likely to be older 
and of a white ethnicity than those not genotyped. Buccal sample collection was 
used more frequently in older individuals or in those of a black/mixed ethnicity (Table 





Iterative pruning led to the identification of three first-degree nodes (nodes 1-3; 
Figure S4). Node1 had three second-degree sub-nodes (A, B, C), comprising White-
British individuals recruited in the UK and Dutch individuals recruited in Holland (A); 
Spanish individuals recruited in Spain (B), and Italian individuals recruited in Italy 
(C). 
From node no.2 originated two main sub-nodes (sub-node D and E). Sub-node D 
was composed of White Brazilian ethnicity, with a smaller representation of Brown 
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Brazilian ethnicity, recruited in Brazil; whereas sub-node E was composed of 
individuals of Arab/Maghreb ethnicity recruited especially in France. As sub-node E 
was relatively small, we merged it with sub-node D. 
From node no.3 two second-degree sub-nodes (sub-node F and G) originated. Sub-
node F was most composed of Asian and South American individuals recruited 
across different countries, and Surinamese individuals recruited in Holland.  Sub-
node F was composed mainly of Black African, Black Caribbean, and Brown or Black 
Brazilian individuals, most recruited in the UK or Brazil.  
At PT=0.05, SZ-PRS was associated with case status in 5 out of 6 population 
clusters (sub-nodes A-F), explaining up to 13% of the variance (in sub-node D). 
Moreover, BP-PRS was associated with case status in 3 out of 6 population clusters 
(sub-nodes A, B, D), explaining consistently less variance than SZ-PRS. 
 
Sensitivity analyses excluded that the ancestry distribution of cases and controls in 
this sample could have a substantial impact on PRS prediction.  
More specifically, first, there were no observable systematic differences in the case-
control distribution in the PCA ancestry multidimensional spaces (Figure S5).  
Second, SZ-PRS case-control prediction in the final matched sample, composed of 
=521 pairs of cases and controls (N=179 from sub-node A; N= 113 from sub-node B; 
N=106 from sub-node C; and N=123 from sub-node D), accounted for a 
Nagelkerke's R2 of 0.094 (p=8.4x10-17) at the fixed Pt-threshold of 0.05. These 
results were similar to the main analysis in 621 cases and 982 unmatched controls 
(Nagelkerke's R2 = 0.09; p=6.9x10-26), at the same fixed Pt-threshold of 0.05. 
 
Main PCs and PRS computation 
Based on the case-control discriminative value of SZ- and BP-PRS, we merged 
1,677 individuals clustered in nodes from A-E in SZ-PRS analysis; and we further 
excluded nodes C and E in BP-PRS analysis. 
Five long-range LD regions on chromosome 6 (from 29155749 to 30578335; from 
31386313 to 31978687; from 32804798 to 33460609; from 33841361 to 34455330; 
from 35377301 to 36288879) and one long-range LD region on chromosome 8 (from 
15773120 to 19548644), were identified in the main sample and removed for 
computing the main PCs. 
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Figure S4 – Identified population subgroups and related SZ-PRS and BP-PRS 
For each population cluster (aka node), three plots are presented. Plots A to F show three ancestry principal components for each 
individual coloured by their self-reported ethnicity. Plots A1 to F1, and A2 to F2, show the variance in case-control status (y-axis) 
explained by SZ-PRS and BP-PRS respectively, at different PT (x-axis). The gradient of colour of the bars represent the significance of 
the association (i.e. the redder, the more significant the association is); a fixed PT =0.05 was however a priori selected. All the 
abbreviation is reported at the end of the supplementary material. 
A) NODE no.1 Sub-node A (most represented population: 40% White-Dutch (WD) recruited 
in Holland; 38% White-British (WB) recruited in UK; 11% White-French (WF) recruited in 
France)    
 
A1) SZ-PRS, at Pt=0.05: Nagelkerke's R2=0.076; p=4.1x10-8  A2) BP-PRS, at Pt=0.05: Nagelkerke's R2=0.043; p=2.4x10-
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B) Sub-node B (most represented population: 84% White-Spanish (WS) recruited in Spain; 
8% White-French (WF) recruited in France; 2% White-Brazilian (WB) recruited in Brazil) 
 















































































































































































































































































































































































































































































































































C) Sub-node C (most represented population: 77% White-Italian WI)  recruited in Italy; 11% 
White-Brazilian (WBR) recruited in Brazil; 3% White-French (WF)  recruited in France) 
 
C1) SZ-PRS - at Pt=0.05, Nagelkerke's  R2=0.052; p=2.3x10-4  C2) BP-PRS - at Pt=0.05, Nagelkerke's R2=0.01; p=0.105 
 
 











































































































































































































































































































































































D) Sub-node D (most represented population: 49% White-Brazilian recruited in Brazil; 16% 
Brown-Brazilian recruited in Brazil; 7% Arab/Maghreb recruited in France) 
 




































































































































































































































































































































































































































































































































































































































































































































































































































































































E) Node E (most represented population Asian recruited in UK or Holland, Indian recruited in 
UK, American and South Americans recruited in Spain, Surinamese recruited in Holland, 
mixed White-Black Caribbean recruited in UK) 
 
 







































































































































































































































































































































































































































































































Node F (most represented population Black African and Black Caribbean recruited in the UK) 
 
SZ-PRS - at Pt=0.05, R2=NS   BP-PRS - at Pt=0.05, R2=NS 









































































































































































































































































































































Figure S5 – Cases and controls distribution across population subgroups 
The plots show no observable systematic differences in the PCA ancestry 
distribution between cases and controls in population sub-nodes of interest (i.e., 
‘sub-node A’, mostly composed of British and Dutch individuals; ‘sub-node B’, mostly 
composed of Spanish individuals; ‘sub-node C’, mostly composed of Italian 
individuals; ‘sub-node D’, mostly composed of Brasilian individuals) and in the final 
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Figure S7 – SZ-PRS and BP-PRS in the final sample at different Pt-thresholds 
 
SZ-PRS         BP-PRS 
  
Explanatory note: The plots shows the variance in case-control status (y-axis) explained by SZ-PRS at different PT (max no. of variants after clumping 
at PT=1: 106,508; no. of variants at predefined PT=0.05: 26,281); and by BP-PRS at different PT  (max no. of risk variants after clumping at PT=1: 88,084; no. 
of risk variants at predefined PT=0.05:18,092) 
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Figure S8 – SZ-PRS by POS and NEG in patients and controls 
The plots show the variance in POS / NEG symptom / experience dimension scores (y-axis) explained by SZ-PRS at different PT  (max no. of risk variants after clumping at PT=1: 
106,508; no. of risk variants at predefined PT=0.05: 26,281). All the associations remained significant after permutation analysis. 
 























Freq. Percent Cum. 
BA (Black African) 5 0.88 0.88 
JE 1 0.18 1.06 
OE 48 8.50 9.56 
OT 2 0.35 9.91 
SA 1 0.18 10.09 
WB 211 37.35 47.43 
WD 225 39.82 87.26 
WF 61 10.80 98.05 
WIR 10 1.77 99.82 
WS 1 0.18 100.00 






Freq. Percent Cum. 
AR 1 0.30 0.30 
OE 9 2.73 3.03 
SA 2 0.61 3.64 
WB 1 0.30 3.94 
WBR 12 3.64 7.58 
WF 26 7.88 15.45 
WPO 2 0.61 16.06 
WS 277 83.94 100.00 










Freq. Percent Cum. 
AM 1 0.29 0.29 
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AR 1 0.29 0.58 
BA 1 0.29 0.88 
OE 25 7.31 8.19 
WB 6 1.75 9.94 
WBR 39 11.40 21.35 
WD 1 0.29 21.64 
WF 7 2.05 23.68 
WI 261 76.32 100.00 







Freq. Percent Cum. 
AM 1 0.27 0.27 
AR 50 13.33 13.60 
AS 12 3.20 16.80 
BA 5 1.33 18.13 
BB 12 3.20 21.33 
BBR 58 15.47 36.80 
BC 2 0.53 37.33 
OE 13 3.47 40.80 
OT 7 1.87 42.67 
SA 11 2.93 45.60 
WB 2 0.53 46.13 
WBR 187 49.87 96.00 
WD 3 0.80 96.80 
WF 3 0.80 97.60 
WI 3 0.80 98.40 
WS 5 1.33 99.73 
YB 1 0.27 100.00 









BA Black African 
BB Black Brazilian 
BBR Brown Brazilian 
BC Black Caribbean 
JE Jewish - Other European 
OE Other European 
OT Other Mixed 
SA South American 
WB White British 
WBR White Brazilian 
WD White Dutch  
WF White French 
WI White Italian 
WIR White Irish 
WPO White Portugal 
WS White Spanish 
YB Yellow Brazilian 
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Chapter 7: General Discussion 
 
7.1 Summary of the aims 
The overall aim of this thesis was to examine the latent structure of psychopathology 
at FEP, and the relationship of derived transdiagnostic symptom dimensions with 
biological and environmental factors. 
The first part of this thesis has examined different models of psychopathology 
pertaining to the psychosis spectrum. The first hypothesis explores whether one 
general factor contains traits shared among categories of non-affective and affective 
psychotic disorders, and five specific dimensions contain distinctive traits across 
these categories (Chapter 4). This structure is statistically reflected through the 
bifactor model of psychopathology, which challenges the unsatisfactory traditional 
distinction between categories of non-affective and affective psychosis. Only a few 
studies have proposed a bifactor solution to solve dimensionality issues in 
psychosis, and no studies to date have constructed this model at the onset of 
psychosis, where symptoms are less likely to be confounded by prolonged 
treatments and social stigma. Hence, I have applied bifactor modelling to psychosis 
symptoms using a multi-site incidence sample of FEP patients; moreover, I have 
replicated the bifactor structure of psychopathology in controls representative of the 
population at risk for psychosis in each study site (Chapter 5). I have evaluated the 
psychometric properties of the bifactor model, including reliability and strength 
indices, and compared the bifactor model with competitive unidimensional and 
multidimensional solutions. 
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However, the validity of the bifactor solution cannot rely on psychometric data only. 
The plausibility of alternative phenotypes in psychosis should be tested by its 
coherence with external factors, in the context of a falsifiable integrated theory  
(Kendler, 2015). Thus, the second part of this thesis aimed to examine the 
relationship of the bifactor latent psychopathology structure with external factors. The 
general assumption was that the continuous distribution of symptoms reflected the 
gradient of neurodevelopmental impairment in psychosis and the exposure to 
socioenvironmental risk factors such as use of cannabis. I have investigated these 
aspects in different studies (Chapters 4, 5, and 6), under the hypothesis that 
individuals may follow different pathways to psychosis, depending on the source and 
timing of neurodevelopmental aberrances (Murray et al., 2017a). 
In addition to validating the latent factors of psychopathology, the third part of this 
thesis has disentangled the relationship between cannabis use and psychotic 
symptoms, with the aim to inform clinical practice and research in this field (Chapter 
5). The recent increase in accessibility of high-potency cannabis in Europe (Freeman 
et al., 2019) demonstrates the importance of this investigation and in particular the 
need to develop strategies that prevent cannabis use. Given that daily use of high 
potency cannabis has been associated with a higher incidence of psychotic 
disorders across Europe (Di Forti et al., 2019a), I have hypothesised that this pattern 
of use would further be associated with the highest positive symptom dimension 
score. Moreover, I have hypothesised that the symptom dimension profile in 
cannabis-associated psychosis would reflect the lack of an early 
neurodevelopmental impairment, given that the use of cannabis may impact on a 
late stage of brain maturation, i.e. during adolescence (Bloomfield et al., 2016). In 
particular, the existence of a specific cannabis-associated psychopathology, differing 
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from other forms of psychosis, would be suggestive of a cannabis-specific 
pathogenic trajectory, and it would reinforce the evidence that cannabis use is a 
component cause of psychosis (Murray and Di Forti, 2016). Moreover, these findings 
would serve as the basis for developing personalised treatment and care algorithms 
for clinicians. 
The fourth part of this thesis has further validated the latent structure of psychosis 
using genetic data (Chapter 6). The study aimed to determine whether common 
genetic variants conferring psychosis risk were also acting as ‘modifier’ factors of 
psychosis expression. In the literature, studies using larger samples reported that 
SZ-PRS indexed negative symptomatology in chronic schizophrenia samples 
(Fanous et al., 2012, Bipolar Disorder Schizophrenia Working Group of the 
Psychiatric Genomics Consortium and Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2018, Jonas et al., 2019). However, the novelty of 
my study is the use of a bifactor model examining psychopathology in FEP patients, 
as well as recruiting controls representative of the population living in the boroughs 
where all new cases of psychosis were identified in the time-period of the study.  
The use of a FEP sample is crucial for examining ‘primary’ negative symptoms 
(Peralta et al., 2000), given that, in subsequent stages of the disorder, the pattern of 
symptoms can be more severely confounded by non-genetic factors, such as 
enduring antipsychotic treatment (Kirschner et al., 2017) and the loss of social status 
that may result from the stigma of a psychosis diagnosis (Birchwood et al., 2007). 
Finally, my study has served to examine for the first time the combined effect of 
cannabis use and SZ-PRS on symptom dimensions, under the hypothesis that these 
are two independent factors affecting symptom presentation. 
 
 193 
7.2 Key findings 
 
Psychopathology structure at FEP 
In Chapter 4, I showed that a bifactor model, composed of one general factor and 
five specific dimensions of positive, negative, disorganisation, manic, and depressive 
symptoms, best represents psychopathology at FEP when compared with 
competitive theory-based models. These results challenge, from a psychometric 
perspective, the neat Kraepelin dichotomy between non-affective and affective 
psychotic disorders. Specifically, they indicate that the formation of specific 
dimensions is justified in addition to the general factor, and vice versa, across 
diagnostic categories.  
Furthermore, in Chapter 5, I replicated the bifactor structure of psychopathology in 
population controls, whereby psychotic experiences were best represented by one 
general factor and three specific dimensions.  
Altogether, these results are in line with the notion that the psychotic symptom 
distribution follows a continuum in the general population (van Os et al., 2009) as 
well as in patients across diagnostic categories of psychotic disorders (Allardyce et 
al., 2007b). 
 
Symptom dimensions by demographic and context factors 
My results in Chapter 4 show that demographic and context factors map onto the 
general and specific symptom dimensions. Transdiagnostic negative symptoms at 
FEP were more expressed in men and associated with an earlier age at psychosis 
onset; according to a neurodevelopmental model of psychosis, negative symptoms, 
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being male, and having an early age at onset are all suggestive of early 
neurodevelopmental impairment in psychosis (Castle and Murray, 1991).  
Transdiagnostic positive symptoms at FEP were more expressed in ethnic 
minorities, coherent with the literature showing, in these groups, higher incidence of 
subclinical and frank psychosis (Sharpley et al., 2001, Fearon et al., 2006, van Os et 
al., 2009). 
Transdiagnostic depressive symptoms at FEP were more expressed in women and 
associated with a late age at onset, which is consistent with what is known about 
neurodevelopmental-related gender differences in psychosis (Castle and Murray, 
1991, Abel et al., 2010). 
Finally, the urban environment was associated with a higher score on the general 
psychosis factor, consistently with the notion that the urban context may involve 
exposure to various risk factors and result in heterogenous psychopathology 
outcomes (van Os et al., 2002b). 
Overall, these findings can be interpreted according to a developmental risk model of 
psychosis, where an early neurodevelopmental pathway indexed by prominent 
negative symptoms can be discerned from an affective pathway(Murray et al., 2004). 
Moreover, a risk pathway involving substance use is presented in the following 
paragraph. 
 
Symptom dimensions by cannabis use 
Study 2 established a dose response relationship between the score at the positive 
symptom dimension at FEP and the extent of lifetime exposure to cannabis; 
moreover, it showed a higher score at the negative symptom dimension at FEP in 
individuals who never tried cannabis (Chapter 5). The existence of a particular 
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symptom profile of cannabis-associated psychosis is coherent with the hypothesis of 
a disease trajectory characterised by less early neurodevelopmental impairment, 
since the use of high potency cannabis might produce disturbances in a late stage of 
neurodevelopment, in adolescence (Di Forti et al., 2014, Murray et al., 2017b). 
The study also showed that in controls, the positive psychotic experience dimension 
was associated with a recent use but not with the extent of lifetime use of cannabis. 
This is in line with evidence suggesting that individuals vary in their susceptibility to 
long-lasting effects of cannabis (Hurd et al., 2019).  
 
Symptom dimensions by polygenic risk scores 
Findings from study 3 indicated in patients that SZ-PRS was associated with higher 
scores on both the positive and negative symptom dimensions (Chapter 6).  
As introduced earlier, the association between SZ-PRS and the negative symptom 
dimension was previously shown in larger studies of chronic patients (Fanous et al., 
2012, Ruderfer et al., 2014, Bipolar Disorder Schizophrenia Working Group of the 
Psychiatric Genomics Consortium and Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2018, Jonas et al., 2019), whereas the 
association between SZ-PRS and the positive symptom dimensions is novel and 
warrants cautiousness in its interpretation. Indeed, a limitation of previous studies is 
that positive symptoms may be attenuated, and negative symptoms may deteriorate 
through the prolonged use of antipsychotics. Hence, although pending replication in 
larger FEP samples, my findings show 1) an association between SZ-PRS and the 
positive symptom dimension at FEP, and that 2) the association between SZ-PRS 
and the negative symptoms holds even when the evaluation is restricted to primary 
as opposed to secondary negative symptoms. This observation is coherent with twin 
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and adoption studies showing that negative symptoms are the most heritable 
schizophrenia trait (Cardno et al., 2008). Furthermore, contrary to the initial 
hypothesis, study 3 has reported no evidence that a general psychosis factor at FEP 
indexes a common genetic propensity to develop schizophrenia and bipolar disorder, 
which suggests further research is needed to validate the use of a general factors as 
a phenotype in psychotic disorders, for example examining a larger set of pleiotropic 
genes (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2019). 
Finally, my findings show that SZ-PRS is associated with either general and positive, 
negative, and depressive psychotic experience dimensions in population controls, 
which is consistent with the notion of a continuum of psychosis in the general 
population (van Os et al., 2009), and with the evidence of the genetic correlation of 
psychotic experiences with multiple psychiatric disorders (Legge et al., 2019b). 
 
7.3 Wider implications 
 
7.3.1 Should we use symptom dimensions or categorical diagnoses? 
 
Psychometric findings from the bifactor model of psychopathology provide new 
insights into symptom distribution in the general population (Chapter 5) and in FEP 
patients (Chapter 4), regardless of diagnostic categories. 
Nevertheless, in clinical practice, setting categorical boundaries is instrumental in 
reducing clinical complexity and using disease-specific guidelines. Should we then 
discard the use of diagnostic categories in the field of psychosis, based on the lack 
of convergence of validators in clearly distinguishing non-affective from affective 
psychosis? Answering this question requires a brief digression into the field of 
epistemology. The categorisation approach in psychiatry is deductive, i.e. it follows a 
top-down logic in that we try to confirm a general theoretical construct (diagnosis) 
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based on a series of converging elements presented by the patient. Indeed, the use 
of the current nosological systems allows patients to be treated according to 
guidelines that reflect the evidence from studies based on these diagnoses. Given 
that, Eric Turkheimer introduced the adverbs ‘meaningful but arbitrary’ (MBA) to best 
describe the utility without validity of nosology constructs (Turkheimer et al., 2008). 
In fact, a diagnosis of psychotic disorders involves two MBA distinctions: the first 
operates between ‘normality’ and the psychotic disorder, and the second between 
different classes of psychotic disorders. 
Alternative to the categorisation approach is the symptom-based approach which is 
inductive in its exploratory stage. However, the statistical process of identifying latent 
factors (based on the joint co-variation of observed symptoms) is only apparently a 
data-driven process. A few MBA actions occur in any factor analysis and involve, for 
example, the decision to establish the joints within the multidimensional space. 
Indeed, any software addresses this indeterminacy problem by imposing a ‘simple 
structure’ (Thurstone, 1940), which allows each item to load highly onto no more 
than one factor. Moreover, the multidimensional space can be rotated in different 
ways to create a variety of simple structures, ranging from uncorrelated latent factors 
(e.g. orthogonal rotations) or correlated factors at different degrees and orders (e.g. 
oblique rotations). Leaving the multidimensional space undetermined would 
otherwise make data hardly interpretable, at least in the case of classic 
psychopathology. An example of a multidimensional structure without a simple 
structure is the Guttman’s intelligence radex (Guttman, 1954), where stimuli are 
plotted unrotated in circular dimensions. However, Guttman aimed to demonstrate 
that similarities in intelligence could be represented by a unique general intelligence 
factor, without being interested in setting joints within that space (Kendler et al., 
 198 
2017). Interestingly, Guttman’s ‘G’ (i.e. ‘General') factor of intelligence encouraged 
research into a general factor of psychopathology, as presented in the next 
paragraph.  
In summary, psychometric findings from Chapter 4 of my thesis do not answer the 
question whether research into psychosis should be conducted using symptom 
dimensions or diagnostic categories. Indeed, both dimensions and categories are 
instrumental, hence choosing one of the two should primarily depend on individual 
research purposes (Zachar and Kendler, 2017). Rather, my findings are relevant as 
they re-affirm two points. First, even if continuously distributed symptom dimensions 
are more flexible constructs than rigid diagnostic categories, this approach carries a 
degree of indeterminacy - therefore any taxon interpretation should be avoided when 
based on symptoms only. Indeed, a factor analysis of symptoms is nothing more 
than an instrumental MBA operation that organises the multivariate space of 
psychopathology according to a psychometric model. Indeed, a debate in the 
philosophy of science concerns the fact that latent factors, as well as diagnostic 
categories, are instrumental constructs that do not exist in nature (Kendler, 2015). 
Hence, latent factors should be validated investigating the common causes 
associated with the co-variation of certain sub-groups of data (Kendler, 2015). 
Secondly, for symptom dimensions to serve as useful and valid psychosis 
phenotypes, it is necessary that their association with external factors is coherent 
with a solid theoretical framework, for example, an integrated developmental risk 





7.3.2 The research into a general factor of psychopathology 
 
The application of bifactor modelling in an incidence psychosis sample (Chapter 4), 
allowed the emergence of a general factor unifying manic and delusional items at 
FEP, challenging Kraepelin’s dichotomy. Moreover, a general factor emerged in 
population controls, encompassing a more heterogenous series of items, including 
positive, negative, and depressive psychotic experiences. Although the use of 
different scales and methods for rating psychotic symptoms and experiences do not 
allow a direct comparison, the qualitative differences in the general factor between 
FEP and controls were expected (Caspi et al., 2014), under the notion that 
psychopathology expression would be less specific in the general population than in 
patients (Caspi and Moffitt, 2018, Legge et al., 2019b). 
My findings from the bifactor models question the existence of a general factor in 
psychosis (Lahey et al., 2012, Reininghaus et al., 2016, Caspi and Moffitt, 2018). 
Attempts to identify a ‘G’ (‘General’ - aka ‘P’, ‘Psychopathology’) factor, summarising 
a parsimonious structure of general psychopathology, have been carried out since 
Guttman’s notion of a G factor of intelligence (Guttman, 1954). However, it was only 
at the end of the 1990s that this research was extended to general community 
samples, leading to the identification of two underlying latent factors, such as an 
internalised dimension of mood and anxiety symptoms and an externalised 
dimension of substance use and antisocial behaviour (Krueger et al., 1998); an 
additional third dimension of thought disturbances further emerged when psychotic 
symptoms were included in these models (Markon and Krueger, 2006, Markon, 
2010, Kotov et al., 2011, Wright et al., 2013). In the Dunedin study, Caspi et al 
interpreted a general factor as an individual’s propensity to develop different forms of 
psychopathology (Caspi et al., 2014), and a similar interpretation was given by the 
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Hierarchical Taxonomy Of Psychopathology (HiTOP) group (Kotov et al., 2017). In 
the field of psychosis, a general factor was proposed to encompass a shared 
susceptibility encompassing enduring non-affective and affective psychotic disorders 
(Reininghaus et al., 2013, Reininghaus et al., 2016), and my findings extend this 
conceptualization to an incidence FEP sample, where the G factor statistically 
accounted for the co-variation of manic and delusional symptoms. On the other 
hand, the contribution of negative, depressive, and disorganization items was 
minimal. Hence, in my FEP sample, G would represent a common presentation in 
schizophrenia and bipolar disorder (using current diagnostic system language), 
however, its validity as a phenotype indexing a common genetic propensity to these 
two disorders is not confirmed by my findings. 
 
7.3.3 Do symptom dimensions index neurodevelopmental impairment in 
psychosis? 
 
The specific symptom dimensions at FEP emerged as key elements for scoring inter-
individual differences due to sociodemographic determinants, cannabis use, and 
polygenic risk scores. A question concerning these findings is whether patients may 
be stratified according to neurodevelopmental trajectories. In particular, the source 
and timing of disruptions over the neurodevelopmental process may produce 
heterogenous phenotypes that do not overlap with traditional diagnostic categories, 
and these abnormalities may be indexed by transdiagnostic symptom dimensions, 
i.e. using a ‘symptom-developmental approach’. My findings show that prominent 
negative symptomatology is more common in men, in those not using cannabis, 
having an earlier age at onset and high SZ-PRS. Although, I did not directly 
investigate early abnormalities in neural networks and deficits in neuro and social 
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cognition, according to a developmental risk model of psychosis, children carrying 
early abnormalities in neural networks (due to genetics and/or medical events) may 
experience deficits in neuro- and social cognition and take on a trajectory of 
scholastic and social difficulties, resulting often in social isolation and deficits in 
emotional expression (Cannon et al., 2002a). These difficulties, which may attract 
further adverse events such as bullying, are indeed identified as primary negative 
symptoms at FEP. Altered cognitive schema may further exacerbate paranoid 
interpretations of otherwise neutral stimuli and trigger an early psychosis onset 
(Howes and Murray, 2014).  
My findings also show that prominent positive symptoms are more common in ethnic 
minorities and in those using cannabis, following a dose-response relationship, and 
they are also associated with high SZ-PRS. Overall, these characteristics may be 
associated with a late impairment in the neurodevelopmental timeline (childhood – 
adolescence), where disadvantageous familial or social context and use of drugs 
may trigger psychosis in those with a good premorbid functioning (Murray et al., 
2004). 
 
7.3.4 What can we learn from cannabis-associated psychopathology at FEP? 
 
My findings reported in Chapter 5 indicate that different patterns of cannabis use 
contribute to explaining symptom dimension variation at FEP. This study is novel as 
it takes into account the potency of cannabis which has increased worldwide.  
As previously mentioned, my findings can be interpreted according to the theory that 
cannabis-associated psychosis follows a different neurodevelopmental trajectory 
compared with psychotic disorders not associated with cannabis use. Patients who 
use cannabis tend to have reduced negative symptoms, which allow them to get illicit 
 202 
substances or to be part of a peer group that uses them. Furthermore, there is 
evidence that cannabis-associated psychosis has other characteristics that, as a 
whole, are strongly indicative of less early neurodevelopmental impairment, such as 
better premorbid functioning (Ferraro et al., 2013), less neurological signs (Ruiz-
Veguilla et al., 2012), and better neuropsychological functioning (Yucel et al., 2012). 
The interpretation that cannabis-associated developmental impairment may occur in 
a late stage of brain maturation is consistent with evidence from epidemiological, 
neuroimaging, and neurochemical examinations. These studies show that the effects 
of cannabis on the brain and risk of psychosis are higher if the exposure to cannabis 
occurs in adolescence (Bossong and Niesink, 2010). For example, the Dunedin 
study showed that individuals were at higher risk of cannabis-associated psychosis if 
their age of cannabis initiation was under 15 (Arseneault et al., 2002), and these 
findings were replicated in the GAP study (Di Forti et al., 2014). Similarly, some 
neuroimaging studies have claimed to find more global reduction in grey matter 
volume (Wilson et al., 2000) as well as alterations in white matter (Zalesky et al., 
2012, Orr et al., 2016) in individuals who started using cannabis in adolescence. 
Finally, positron emission tomography reports suggest that early initiation to 
cannabis use is correlated with lower dopamine synthesis capacity in the striatum 
(Urban et al., 2012). Interestingly, low dopamine synthesis capacity is a 
characteristic that has been often reported in cannabis-associated psychosis (Urban 
et al., 2012, Mizrahi et al., 2013, Thompson et al., 2013, Bloomfield et al., 2014), as 
opposed to the pattern of a high dopamine synthesis in the striatum which is 
commonly seen in idiopathic schizophrenia (McCutcheon et al., 2020). In cannabis-
associated psychosis, it remains unclear whether the low release of pre-synaptic 
dopamine precedes cannabis use or it is a consequence of the regular use of 
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cannabis. It has been hypothesised that cannabis-associated dopaminergic 
abnormalities could be post-synaptic rather than pre-synaptic (Murray et al., 2014),  
The possibility of different neurodevelopmental pathways resulting in different 
dopamine abnormalities is relevant for interpreting my findings on the relationship 
between use of cannabis and the positive dimensions of psychotic symptoms and 
experiences. While in patients and controls, the positive dimensions were associated 
with current use of cannabis, coherently with what is known about the short-term 
psychotropic effects of Δ9-THC (Hindley et al., 2020), only in patients were positive 
symptoms associated with the extent of lifetime exposure to cannabis, following a 
dose-response pattern. This finding suggests that patients may be vulnerable to 
long-term effects of cannabis, perhaps elicited through a dysfunctional 
endocannabinoid system during adolescence (Bossong and Niesink, 2010), as 
demonstrated in animal models (Pistis et al., 2004). In particular, the 
endocannabinoid system and exogenous cannabinoids may be involved in all steps 
of brain maturation, since this process is genetically determined, epigenetically 
driven, and environmentally influenced (Tau and Peterson, 2010). The 
endocannabinoid system has been widely reported as dysfunctional in psychosis 
(Volk and Lewis, 2016, Minichino et al., 2019), and this may result in dysregulation of 
various neurodevelopmental processes, including synaptogenesis and neural 
pruning during adolescence and short- and long-term plasticity processes 
(Basavarajappa et al., 2009).  
 
7.3.4 Secondary prevention of cannabis-associated psychosis 
 
Whether or not symptom presentation in cannabis-associated psychosis reflects a 
late developmental impairment in psychosis, symptom dimensions may be a 
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candidate target for secondary prevention strategies in cannabis-associated 
psychosis (Chapter 5). Currently, individuals presenting with cannabis-associated 
FEP usually receive the same treatment as patients with ‘idiopathic’ schizophrenia, 
despite differences clearly existing in the clinical presentation of these two groups. 
The absence of specific guidelines is a matter of urgency, considering that in South 
London, up to 21%, of new cases of psychosis can be attributed to daily use of 
cannabis, and up to 30% to the use of high-potency varieties (Di Forti et al., 2019a). 
Moreover, approximately 35% of patients presenting with a cannabis-induced 
psychosis have a later transition to a diagnosis of schizophrenia (Murrie et al., 2019). 
Since cannabis use is a preventable risk factor for the onset and a worse course of 
psychosis, it is urgent to develop treatment strategies based on the stratification of 
patients at FEP according to their symptom profile and patterns of cannabis use. 
These strategies should take into account that cannabis users keep having the most 
prominent positive symptomatology if they do not discontinue the use of cannabis 
after FEP (Schoeler et al., 2016a). Moreover, cannabis cessation or reduction 
strategies should take into account that FEP patients using cannabis are often young 
and have good premorbid functioning. Using the most appropriate form of 
communication and treatment, this sub-group of patients may be receptive to the 
dissemination of credible and persuasive information on the detrimental effects of 
cannabis on mental health (Englund et al., 2017, McClure et al., 2019). Finally, the 
findings reported in my thesis support the caution that governments and policy 
makers should take before legalising cannabis for recreational use. There is a risk of 
cannabis use increasing in countries following such legalising policies (Melchior et 
al., 2019, Murray and Hall, 2020), which may widely increase the distribution of 
positive psychotic symptomatology, both in cases and in the general population. 
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Finally, psychological interventions, which may be based on motivational 
enhancement therapy, family therapy, and contingency management could be 
offered, as recently recommended by the WHO (World Health Organization, 2020), 
and high-quality trials should be conducted to evaluate the effects of these 
interventions (Hunt et al., 2019).   
 
7.3.5 Towards personalised medicine? 
 
In clinical practice, the identification of key features at FEP may be critical for 
improving the prediction of a long-term illness prognosis and tailoring personalised 
treatment from the beginning of the disease. From a research perspective, studies 
using predictive analysis at an individual-level are emerging in addition to the classic 
group-based studies (Hahn et al., 2017). Although the classic group-based studies 
allow us to identify treatments that are effective for the average patient, they may 
jeopardise relevant information for smaller sub-group of patients. Hence, from a 
clinical perspective, it is crucial to integrate parameters from different modalities of 
investigation regardless of diagnostic categories, ranging from symptom dimensions 
to socio-environmental and biological determinants. In Figure 1, two possible clinical 
scenarios are described where a developmental-symptom approach may be useful 
to formulate clinical impressions, potentially guiding future research into personalised 
medicine (Figure 1). Indeed, biological parameters such as SZ-PRS may be useful in 
the future for formulating clinical impressions and informing clinical decisions.  
 
However, general limitations should be considered in integrating PRS analysis into a 
symptom-developmental approach. 
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1) Missing heritability. Currently, only 22% of variance in SZ is explained by 
common genetic variance, resulting in a high degree of missing heritability. 
Further study efforts examining larger GWAS, rare variants, environmental 
modifiers, and epigenetic effects are needed to make personalised medicine 
effective in real clinical practice. 
2) Lack of trans-ancestral studies. Currently, SZ GWAS is best powered for 
individuals of a European ancestry. This may require a researcher to restrict 
analysis to individuals of European ancestry, to better control population 
stratification. It is crucial to address this limitation as early as possible, 
conducting large SZ GWASs in different ethnic groups, to ensure that 
genetics does not increase disparities in the availability of care (Martin et al., 
2019). 
3) Lack of symptom dimension GWASs. This is a common criticism in PGC 
GWASs, which lack clinical depth. The PGC highlighted that this was an 
intentional choice at the beginning of the Consortium activities, when it was 
agreed that diagnostic categories were the most appropriate phenotype 
characterization that would lead to the essential large sample size (Sullivan et 
al., 2018), including for schizophrenia (Ripke et al., 2013). However, now that 
a plateau has been reached on novel identified loci in relation to the 
progressive increase of sample size, new study designs may allow deeper 
phenotypic characterization. 
4) Limited value in assisting with transition to psychosis, psychosis outcome, and 
pharmacotherapy. It has been proposed that SZ-PRS has the potential to 
improve the detection of at-risk individuals and their transition to psychosis 
(Oliver et al., 2019). However, it has been shown that this strategy currently 
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would only marginally improve psychosis risk prediction (Perkins et al., 2020). 
Moreover, in addition to SZ-PRS concerns, the use of the ultra-risk paradigm 
in clinical practice has been questioned as it would only intercept only a small 
proportion individuals destined to become actual FEP patients (Ajnakina et al., 
2017).   
Moreover, SZ-PRS, currently, has poor predictive value on treatment-
resistance (Legge et al., 2019a), even if it has been associated with a more 
severe course of the disease (Jonas et al., 2019).  Finally, response to 
pharmacological therapy is known to be polygenic, and these genes may be 
different from the risk genes for the disorder (Garcia-Gonzalez et al., 2017). 
An important finding in this field is the negative association between SZ-PRS 
and response to lithium (International Consortium on Lithium Genetics et al., 
2018). However, current pharmacogenetic testing for psychosis is still focused 
on single gene-drug interaction, with best level of evidence available for 
polymorphisms of CYP2D6 and risperidone pharmacokinetic (Kneller et al., 
2020), DRD2 and risperidone efficacy (Bousman, 2019), and MC4R and 
antipsychotic toxicity (Czerwensky et al., 2013). Concerns have been raised 
due to the lack of standardization on these pharmacogenetics tests, and some 
authors have recommended that at least CYP2D6, CYP2C19, HLA-A, and 
HLA-B should be included in all gene panels to be used in pharmacogenetic 
testing (Bousman et al., 2019).  
5) Finally, conducting a PRS examination might require sharing the results with 
patients. This process may generate anxiety in an already vulnerable group 
who are predisposed to paranoia and only a small pilot study to date has 
examined these aspects (Putt et al., 2020).  
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Fig. 2. Diagrams of two different neurodevelopmental pathways, that might be suggested by different observable symptom 
presentations at FEP 
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Explanatory note. In the first scenario, a patient would present with an onset of psychosis with prominent negative symptoms at 
FEP, poor premorbid functioning, and a high SZ-PRS. These factors would be suggestive of an early neurodevelopmental 
impairment; therefore, a careful investigation should be done in relation to psychiatric family history, the historical occurrence of 
pre- and peri-natal adverse events, and scholastic and premorbid functioning. Moreover, SZ-PRS and the other clinical 
characteristics, may help to detect individuals who are potentially CNV carriers, and suggest molecular diagnostics for recurrent 
structural genetic variants. This examination has already been proposed as a first line genetic test for patients with other 
neurodevelopmental conditions such as autism spectrum disorders, developmental delay, and intellectual disability (Schaefer et al., 
2013, O'Byrne et al., 2016). Finally, since primary negative symptoms are a therapeutic challenge, from a clinical research 
perspective, more specific clinical trials should include patients with the indices of early neurodevelopmental impairment, as 
opposed to evaluating all patients experiencing both primary and secondary negative symptoms. 
In a second scenario, a patient would present with a FEP with prominent positive symptoms, good premorbid functioning, and a 
history of daily use of high-potency cannabis. Here, information derived from SZ-PRS may be more unspecific, however in the 
future polygenic scores might be calculated with reference to specific biological pathways which may relate to the environmental 
risk factor, for example the endocannabinoid system. Meanwhile, environmental factors such as cannabis use may be preventable, 
and treatment strategies involving cannabis cessation measures should be applied, aiming to recover the pre-onset level of 
functioning and reduce the risk of a poor prognosis (Schoeler et al., 2016a).
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Chapter 8: Conclusive remarks and future directions 
Clinicians and researchers are undergoing a crisis of confidence in psychiatric 
nosology. In response to the crisis, the findings from this PhD indicate that the 
bifactor model of psychopathology is a valid instrument toward conducting high-
quality transdiagnostic research into psychosis. Cumulatively, these findings 
reinforce the case for integrating symptom dimension ratings into routine clinical 
practice, which would allow clinicians to formulate clinical impressions according to a 
developmental-symptom model, and to progressively develop personalised 
intervention schema. From this perspective, conditions such as cannabis-associated 
psychosis may benefit from developing specific secondary prevention strategies in 
early intervention services. Moreover, over the next years, the increasing predictive 
value of polygenic approaches may result in their application in clinical settings, 
further contributing to the paradigm shift from treating diagnoses toward treating the 
patient. 
 
A number of future research directions have arisen from the work presented within 
this thesis, which are as follows: 
 
Genetic variation of the endocannabinoid system and risk of first episode psychosis  
First of all, the identification of a particular cannabis-associated symptomatology at 
FEP may imply the existence of a specific pathway toward developing cannabis-
associated psychosis. However, the relationship between the use of exogenous 
cannabinoids and the polygenic variation of the endocannabinoids system with which 
they interact, has not been investigated yet. Hence, I have developed a pathway-
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specific polygenic score, which indexes the genetic susceptibility to schizophrenia 
due to endocannabinoid genes only (Quattrone et al., 2019).  
 
Epigenetic pattern of transdiagnostic symptom dimensions at first episode psychosis 
Secondly, symptom dimensions can be further validated with additional biological 
determinants, such as epigenome data. This will allow me to conduct the first 
epigenome-wide association study on symptom dimensions with genome-wide 
methylation data using the EPIC array on about 1,000 participants in the EU-GEI 
study.  
 
Longitudinal stability of transdiagnostic symptom dimensions and their relationship 
with psychosis outcome 
Thirdly, to further validate the bifactor structure, the longitudinal stability of the 
bifactor structure of psychopathology and its relationship with outcome measures 
should be evaluated. During my PhD, I have led a follow-up study of around 300 
FEP patients and 100 controls from the EU-GEI and the GAP sample, on average 
five years after their onset of psychosis, which will enable me to assess the stability 
of the bifactor structure psychopathology at follow up. 
 
Finally, I hope this thesis and its future developments will encourage consideration 
toward symptom dimensions in formulating clinical impressions and toward 
conducting more hypotheses-driven transdiagnostic research into psychosis. 
 
In summary, this PhD thesis has shown that symptom dimensions are valid and 
useful phenotypes in the field of psychosis. This work highlights that these 
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dimensions may be integrated with biological and socio-environmental risk 
determinants, allowing to examine relevant clinical questions. As genetics move from 
research to clinical application, these enhanced phenotypes have the potential to 
contribute to an accurate individual characterization. 
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